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Abstract 
Tryptophan hydroxylase (TPH) catalyzes the hydroxylation of tryptophan to L-5-hydroxytryptophan, which is 
the first and rate-limiting step in the biosynthesis of 5-hydroxytryptamine (serotonin). Serotonin acts as a 
hormone and neurotransmitter in a variety of tissues and is involved in a wide range of physiological 
functions. Dysregulation of the level of serotonin is associated with a variety of physiological and psychiatric 
disorders. TPH exists in two homologous isoforms; TPH1 and TPH2. Isoform 1 is primarily expressed in the 
peripheral tissues, while isoform 2 is mainly found in the central nervous system. As the rate-limiting 
enzymes in the synthesis of serotonin, TPH1 and TPH2 play vital roles in the serotonergic systems of the 
peripheral tissues and central nervous system, respectively. 
The active form of TPH contains iron(II) and catalyzes tryptophan hydroxylation utilizing 6R-L-erythro-
5,6,7,8-tetrahydrobiopterin (BH4) and molecular oxygen. The TPH isoforms are members of an enzyme 
subfamily of iron(II)-containing mono-oxygenases, referred to as the aromatic amino acid hydroxylases. The 
family also includes phenylalanine hydroxylase and tyrosine hydroxylase. These homologous enzymes all 
form homotetramers, in which each subunit comprises an N-terminal regulatory domain, a highly conserved 
catalytic domain, and a C-terminal tetramerization domain. 
In this dissertation, both human TPH isoforms were under investigation. Of the isoforms, TPH2 is less 
characterized in literature due to low purification quantities caused by its inherent instability and tendency to 
aggregate. To overcome this challenge, three variants of human TPH2 with deletion mutations of entire or 
parts of domains were expressed, purified, and examined. Removal of the C-terminal tetramerization domain 
resulted in TPH variants which could be purified in quantities sufficient for enzymatic characterization. 
However, this variant suffered from a high inactivation rate. Upon further removal of the N-terminal regulatory 
domain, a significant decrease in rate of inactivation was observed. This observation renders the regulatory 
domain the main source of instability. To overcome the inherent instability of the regulatory domain, 
differential scanning fluorimetry was used to identify stabilizing ligands. In absence of ligands the unfolding 
was continuous and polyphasic. However, in presence of tryptophan or phenylalanine the unfolding shifted to 
apparent two-state, indicative of increased thermostability and monodispersity. The shift in unfolding 
behavior was accompanied by a ligand concentration-dependant increase in transition temperature. This 
thermostabilizing effect was confirmed by a significant decrease in inactivation rate. Analytical gel filtration 
revealed that in the presence of the regulatory domain, the TPH2 variant resides in a monomer-dimer 
equilibrium. With the addition of phenylalanine a significantly shift towards dimer was observed explaining 
the ligand-induced increase in thermostability. These results led to the addition of phenyalanine in the 
purification buffer solutions which significantly increased the purification yields.  
Very little is known about the catalytic mechanism of TPH and most of the knowledge in literature stem from 
extrapolations of results obtained for the other members of the enzyme subfamily. In this dissertation, results 
are presented that demonstrate that the steady-state kinetic mechanism of the catalytic domain of human 
TPH1 follows a hybrid Ping Pong-ordered mechanism. In this mechanism, the reaction can either occur 
through a Ping Pong or a sequential mechanism depending on the concentration of tryptophan, and 
substrate inhibition occurs via competitive inhibition of BH4 binding. The kinetic study also revealed that the 
isoforms display very different kinetic properties despite their high sequence identity. One of the major 
differences is that TPH1 is substrate inhibited, while TPH2 is not. By scrutinizing the crystal structures of the 
isoforms, it was found that differences reside in the orientation of a loop lining the active site. Point mutations 
were conducted within this loop, and significant changes in the kinetic parameters of the mutant TPH1 
variants were observed. Molecular dynamics simulations revealed that the substrate inhibition mechanism 
occurs through a closure of the BH4 binding pocket upon tryptophan binding, and that the active site loop is 
involved in this mechanism by propagating structural changes from the tryptophan binding site to the BH4 
binding pocket.  
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Dansk resumé 
Tryptophanhydroxylase (TPH) katalyserer hydroxylering af tryptophan, hvorved L-5-hydroxytryptophan 
dannes. Dette er det første og hastighedsbestemmende trin i biosyntesen af 5-hydroxytryptamin (serotonin). 
Serotonin agerer som hormon og neurotransmitter i forskelligt væv og er involveret i en lang række 
fysiologiske funktioner. Forstyrrelser i serotoninbalancen er associeret med flere fysiske og psykiske 
sygdomme. TPH eksisterer som to isoformer; TPH1 og TPH2. Isoform 1 bliver primært udtrykt i det perifere 
væv, imens isoform 2 hovedsageligt udtrykkes i centralnervesystemet. Som de hastighedsbestemmende 
enzymer i syntesen af serotonin, spiller TPH1 og TPH2 vigtige roller i de serotonergiske systemer i 
henholdsvis det perifere væv og centralnervesystemet.  
Den aktive form af TPH indeholder jern(II) og katalyserer hydroxylering af tryptophan ved hjælp af 6R-L-
erythro-5,6,7,8-tetrahydrobiopterin (BH4) og molekylært ilt. TPH isoformerne er medlemmer af enzym 
underfamilien kaldet de aromatiske aminosyre hydroxylaser. Denne familie inkluderer også 
fenylalaninhydroxylase og tyrosinhydroxylase. Medlemmerne i denne familie er nært beslægtede og danner 
alle homotetramerer. Hver underenhed i tetrameren består af et N-terminalt regulatorisk domæne, et 
konserveret katalytisk domæne og et C-terminalt tetrameriseringsdomæne.   
I denne afhandling er begge humane TPH isoformer blevet undersøgt. Af de to isoformer er specielt TPH2 
en udfordring at oprense i mænger, der muliggør karakterisering. Der forefindes derfor færre undersøgelser 
af TPH2 i litteraturen. For at overkomme denne udfordring, blev tre TPH2 varianter med trunkeringer af hele 
eller dele af domæner udtrykt, oprenset og undersøgt. Trunkering af det C-terminale tetrameriserings-
domæne resulterede i en TPH2 variant, der kunne oprenses i mængder, der muliggjorde karakterisering af 
denne variant. Denne variant havde dog en meget høj inaktiveringshastighed. Inaktiveringshastigheden 
kunne sænkes markant ved yderligere at trunkere det N-terminale regulatoriske domæne. Dette viser, at det 
regulatoriske domæne er hovedoversagen til den ringe stabilitet. For at finde en løsning på dette problem, 
blev differential scanning fluorimetry benyttet til at identificere stabiliserende ligander. Uden ligander viste 
resultaterne, at proteinudfoldningen var kontinuerlig. Udfoldningen ændres dog til tilsyneladende to-stadie 
ved at tilsætte fenylalanin eller tryptophan. Dette indikerer øget termostabilitet og monodispersitet. Skiftet i 
udfoldning var ledsaget af en koncentrations-afhængig forøgelse af smeltetemperaturen. Denne 
termostabiliserende effekt blev bekræftet ved at iagttage, at inaktiveringshastigheden også blev sænket. 
Analytisk gelfiltrering viste sidenhen, at tilstedeværelsen af det regulatoriske domæne gør, at TPH varianten 
forefindes i en monomer-dimer ligevægt. Disse resultater viste også, at tilsætning af fenylalanin skifter denne 
ligevægt betragteligt mod dimer, hvilket kan forklare den observerede forøgelse af termostabiliteten. Disse 
resultater førte til, at fenylalanin blev tilsat i oprensningsopløsningen, hvilket resulterede i højere 
oprensningsudbytter.  
Man ved meget lidt om TPH’s katalytiske mekanisme. Den bliver derfor beskrevet med udgangspunkt i de 
resultater, man har opnået for de andre medlemmer af AAAH familien. I denne afhandling præsenteres 
resultater, der peger på, at det katalytiske domæne af TPH1 følger en Ping Pong-ordnet steady-state 
mekanisme. I denne mekanisme kan reaktionen enten forløbe via en Ping Pong eller sekventiel mekanisme 
afhængig af koncentrationen af tryptophan. Substratinhibering forekommer ved kompetitiv hæmning af BH4 
binding. Den kinetiske undersøgelse viste også, at isoformerne udviser meget forskellige kinetiske 
parametre på trods af deres høje sekvensidentitet. Én af de største forskelle er, at kun TPH1 udviser 
substratinhibering. Ved minutiøs gennemgang af isoformernes krystalstrukturer blev der fundet forskelle i et 
loop der ligger over det aktive site. Der blev foretaget punktmutationer i dette loop, og det viste sig at 
resultere i ændringer af de kinetiske parametre for TPH1. Molekylærdynamiske simuleringer afslørede, at 
inhiberingsmekanismen fungerer ved, at BH4 bindingslommen blokeres efter binding af tryptophan. Loopet er 
involveret i denne mekanisme ved at forlænge de strukturelle ændringer fra tryptophan’s bindingslomme til 
BH4’s bindingslomme.   
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Abbreviation list 
3CP  Human rhinovirus 3C protease 
3D  Three-dimensional 
4a-hydroxy-BH4  4a-carbinolamine tetrahydrobiopterin 
5-HT  5-hydroxytryptamin 
5-HTP  5-hydroxytryptophan 
6-MePH4  6-methyl-5,6,7,8-tetrahydropterin 
AA  Amino acid 
AAAH  Aromatic amino acid hydroxylases 
AADC  Aromatic amino acid decarboxylase 
ACT   Aspartate kinase, chorismate mutase, and TyrA  
ANS  8-anilino 1-naphthalenesulfonic acid  
AUC  Area under the curve  
BH2  7,8-dihydrobiopterin 
BH4  5,6,7,8-tetrahydrobiopterin 
BLAST  Basic Local Alignment Search Tool 
CaMKII  Ca2+/calmodulin-dependent protein kinase II 
CNS  Central nervous system 
DF  Dilution factor/degrees of freedom 
DMPH4  6,7-Dimethyl-5,6,7,8-tetrahydropterine 
DMSO  Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid 
DOPA  3,4-dihydroxyphenylalanine 
DSF  Differential scanning fluorimetry 
DTT  Dithiothreitol 
GTP  Guanosine triphosphate 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HPLC  High-performance liquid chromatography 
ITC  Isothermal titration calorimetry 
MBP  Maltose binding protein 
MD  Molecular dynamics  
NAD(P)H  Nicotinamide adenine dinucleotide phosphate 
NMR  Nuclear Magnetic Resonance 
OPLS  Optimized Potentials for Liquid Simulations 
PAH  Phenylalanine hydroxylase 
PDB  Protein Data Bank 
PKA  Protein kinase A 
PPW   Protein Preparation Wizard  
qBH2  Quinonoid dihydrobiopterin 
qPCR  Quantitative polymerase chain reaction 
RESPA  Reversible reference system propagator algorithms 
RMSD  Root-mean-square deviation 
SAXS  Small-angle X-ray scattering 
SDS-PAGE   Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEC-SAXS  Size exclusion chromatography small-angle X-ray scattering 
TEV  Tobacco Etch Virus 
TH  Tyrosine hydroxylase 
TIP3P  Transferable intermolecular potential 3 point 
TPH  Tryptophan hydroxylase 
TRIS  Tris(hydroxymethyl)aminomethane 
UV-Vis   Ultraviolet–visible 
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Dissertation introduction 
 
This dissertation concerns characterization of the enzyme tryptophan hydroxylase (TPH) which catalyzes the 
first and rate-limiting step in the biosynthesis of the neurotransmitter and hormone serotonin.[1,2] This step is 
catalyzed by two distinct tryptophan hydroxylase isoforms in the brain and peripheral tissues, respectively.[2-
4] The existence of two isoforms introduces the possibility of selectively targeting the serotonergic systems of 
the brain and peripheral tissues by e.g. isoform-specific modulators of activity.[5] This, however, requires 
thorough characterization of both isoforms on a molecular level. 
The overall aim of this project was to characterize the TPH isoforms to improve the current understanding of 
their structure-function relationships. So far, proper characterization of the isoforms has been hampered by 
insufficient purification yields caused by their notorious instability and tendency to aggregate.[6] This 
challenge has to be overcome to fully understand the intriguing functions of the TPH isoforms. The 
Metalloprotein Chemistry and Engineering Group at DTU has paved the way for TPH characterization by 
advancing the purification strategies of a variety of TPH variants.[7-9] Despite great efforts, TPH isoform 2 
variants comprising the regulatory domain still pose a challenge to purify. In this dissertation, special 
emphasis is on overcoming this challenge.  
Although the isoforms are expressed in different tissues, they are highly homologous. The isoforms share a 
high sequence identity, they both form complex homotetrameric structures, and are believed to follow the 
same reaction mechanism.[10-12] Despite these observations, it was discovered by former members of the 
Metalloprotein Chemistry and Engineering Group that the isoforms display very different kinetic 
parameters.[13] This is puzzling and the underlying mechanism of this observation is not understood. It was, 
therefore, set forth to thoroughly study the kinetic mechanism of TPH and to identify the structural origin of 
the different kinetic properties of the isoforms. 
To shed light on the characteristics of the TPH isoforms, an interdisciplinary approach has been conducted 
in which an array of experimental methods has been utilized in conjugation with computational techniques. 
As full-length TPH isoform 2 proves challenging to purify, an ensemble of variants with deletion mutations of 
either entire or parts of domains has been studied throughout this dissertation. In addition, variants with point 
mutations were also analyzed to identify the significance of single residues. The results presented in this 
dissertation improve the understanding of fragments of the complicated function of the TPH isoforms. 
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Outline of dissertation 
This dissertation is divided into eight chapters concerning different aspects of the structure and function of 
tryptophan hydroxylase. The first chapter provides a fundamental introduction to the enzyme and how it is 
involved in the synthesis of one of the most important hormone and neurotransmitters in human beings. 
Each of the following chapters concerns individual areas of tryptophan hydroxylase research and within each 
chapter a comprehensive introduction to the current TPH research area will be found.  
Chapters 2 through 4 concern the identification of ligands which influence the oligomeric state of TPH 
resulting in increased thermostabiliy. Results from these chapters have been pulished in FEBS Open Bio 
(Appendix A.1). Chapter 5 presents results obtrained from experiements conducted at Stanford University 
during a 3 month research stay. In chaptes 6 through 8, the steady-state and substrate inhibition 
mechanisms are investigated. Based on the results presented in these chapters a manuscript has been 
prepared and submitted (Appendix A.2). 
Throughout the dissertation, the chapters will gradually delve into the complicated molecular mechanisms 
exerted by tryptophan hydroxylase. The content of the chapters and how they narrow down from isolation of 
the full-length enzyme to studying specific residues of an active site loop is outlined in the following figure.  
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1 Introduction to tryptophan hydroxylase 
In this chapter, the importance of tryptophan hydroxylase (TPH) will be described and some key concepts 
about TPH will be introduced. This chapter will serve as brief introduction to some of the fundamental 
concepts, while more thorough introductions to the individual branches of the TPH theory are found in the 
relevant chapters.  
 
 
 
 
 
 
1.1 The aromatic amino acid hydroxylases 
Tryptophan hydroxylase (TPH) is a member of an enzyme subfamily of iron(II)-containing mono-oxygenases, 
referred to as the aromatic amino acid hydroxylases (AAAHs). Together with TPH, the family also comprise 
phenylalanine hydroxylase (PAH) and tyrosine hydroxylase (TH), which all originate from a common 
protein.[14] While PAH only exists in one form, TPH exists in two isoforms, and TH in four isoforms. In TH, 
the four isoforms only differ in the length of the N-terminus, which originates from alternative splicing of a 
single gene.[15] The isoforms of TPH are less conserved and are encoded by two different genes.[16]  
Common for the AAAHs, is that they catalyze the hydroxylation of their respective amino acid substrate 
utilizing iron(II), 6R-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4), and molecular oxygen.[17] All AAAHs are 
only active with ferrous iron in the active site.[18-20] Iron is bound in the active site by a common structural 
motif consisting of three endogenous protein ligands, referred to as the 2-His-1-carboxylate facial triad.[21] In 
the absence of amino acid substrate, the iron atom will also coordinate three water molecules, Figure 1.1 A. 
In the presence of substrate and co-substrate a rearrangement occurs in the AAAHs which results in 
dissociation of two water molecules from the iron, and the glutamic acid residue changes from a 
monodentate to bidentate ligand, Figure 1.1 B.[22-24]  
The homologous AAAHs all form homotetramers, in which each subunit comprise an N-terminal regulatory 
domain, a highly conserved catalytic domain, and a C-terminal tetramerization domain, Figure 1.1 C.[25] The 
sequence identity, structure, and function of the domains will be further discussed in chapter 4, 6, and 7. 
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Figure 1.1. Representation of the coordination of iron and the quaternary structure of the AAAHs. (A) Octahedral 
coordination of iron by the 2-His-1-carboxylate facial triad and three water molecules in the absence of 
substrates (PDB entry: 1PAH). (B) Trigonal bipyramidal coordination of iron in the presence of substrate and co-
substrate (PDB entry: 1KW0). Iron is shown in pink and water molecules are represented as red spheres. (C) 
Cartoon illustration of the tetrameric structure of full-length rat phenylalanine hydroxylase (PDB entry: 5FGJ). 
Regulatory domains are colored blue, catalytic domains are colored green, and tetramerization domains are 
colored yellow. 
1.1.1 AAAH catalyzed reactions 
TPH catalyzes the hydroxylation of tryptophan to L-5-hydroxytryptophan (5-HTP), which is the first step in the 
synthesis of 5-hydroxytryptamine (5-HT, serotonin), Figure 1.2.[26] Dysregulation of serotonin is associated 
with a variety of disorders, as discussed in a following section. PAH is a liver enzyme and catalyses the 
conversion of L-phenylalanine to L-tyrosine in the rate limiting step in phenylalanine catabolism.[27,28] Loss 
of PAH activity impairs catabolism of phenylalanine resulting in phenylketonuria which leads to intellectual 
disability and mental disorders.[29] TH is mainly expressed in the brain and catalyzes the hydroxylation of 
tyrosine to L-3,4-dihydroxyphenylalanine (L-dopa).[30] This is the rate limiting step in the synthesis of 
catecholamines such as dopamine, epinephrine, and norepinephrine, which are important neurotransmitters 
and hormones.[31]  
Because the AAAHs are very homologous and their substrates are similar, the enzymes are not fully specific 
towards their respective substrates. This is evident from studies of the catalytic domain of human and rabbit 
TPH1, where comparable Vmax/Km-values for phenylalanine and tryptophan as substrates have been 
found.[20,32] However, compared to tryptophan, hydroxylation of tyrosine is at least three orders of 
magnitude slower.[20] Similarly, TH is able to hydroxylate phenylalanine and tryptophan with Vmax/Km-values 
one and two order of magnitude lower than with tyrosine, respectively.[33,34] Compared to TPH and TH, 
PAH displays a higher degree of substrate specificity, as Vmax/Km-value for phenylalanine is three orders of 
magnitude greater than that for tryptophan, and tyrosine is not hydroxylated.[35]    
3 
 
NH3
+
O
O
-
NH3
+
O
O
-
OH
NH3
+
O
O
-
OH
NH3
+
O
O
-
OH
OH
N
H
O
NH3
+
O
-
N
H
O
NH3
+
O
-
OH
L-phenylalanine L-tyrosine
L-tyrosine L-dopa
L-tryptophan L-5-hydroxytryptophan
TPH
TH
PAH
 
Figure 1.2. The enzymatic reactions catalyzed by the AAAHs. PAH converts L-phenylalanine to L-tyrosine, TH 
converts L-tyrosine to L-3,4-dihydroxyphenylalanine (L-dopa), and TPH converts L-tryptophan to L-5-
hydroxytryptophan (5-HTP). 
1.2 The TPH isoforms 
Tryptophan hydroxylase exists in two homologous isoforms; TPH1 and TPH2 which consist of 444 and 490 
amino acid residues, respectively (Figure 1.3).[16] Isoform 1 is primarily expressed in the peripheral tissues, 
such as in enterochromaffin cells of the gastrointestinal tract and in the adrenal glands, while isoform 2 
primarily is found in serotonergic neurons in the central nervous system (CNS).[36,37]  
 
Figure 1.3. Number of amino acid residues in the regulatory (blue), catalytic (green), and tetramerization (yellow) 
domains of TPH1 and TPH2. 
The main differences between the two isoforms are found in the regulatory domain, where TPH2 have 
additional 46 residues in the N-terminus.[16] The extended N-terminus of TPH2 has been found to reduce 
expression level [38], decrease enzymatic activity [39], and posses an additional phosphorylation site [40]. 
1.2.1 TPH phosphorylation 
The isoforms have a common phosphorylation site at Ser58(TPH1)/Ser104(TPH2) which is phosphorylated 
by protein kinase A (PKA).[41,42] An additional phosphorylation site, Ser19, resides in the extended N-
terminus of TPH2. Ser19 has been found to be phophorylated by PKA and Ca2+/calmodulin dependent 
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protein kinase II (CaMKII).[38,43] Phosphorylation of TPH2 results in a modest increase in activity. Of the 
two phosphorylation sites in TPH2, Ser19 is the main site responsible for increased activity.[41]  
Besides increasing the activity, phosphorylation of Ser19 also acts as a 14-3-3 protein binding site.[41] 14-3-
3 proteins represent a family of proteins which are present in the majority of eukaryotic organisms, where 
they bind to a wide variety of phosphorylated proteins.[44] The binding of a 14-3-3 protein increase the 
activity and stability of phosphorylated TPH2.[41,45] In addition, binding of a 14-3-3 protein inhibits 
phosphatase-catalyzed dephosphorylation resulting in prolonged activation. 
1.3 Serotonin and related disorders 
Serotonin (5-hydroxytryptamine, 5-HT) acts as hormone and neurotransmitter in a variety of tissues and is 
involved in a wide range of physiological functions.[37,46,47] Serotonin is synthesized from L-tryptophan in 
two steps, Figure 1.4. The first step is the TPH catalyzed hydroxylation of L-tryptophan to L-5-
hydroxytryptophan (5-HTP).[17] The second step is decarboxylation of 5-HTP to serotonin catalyzed by 
aromatic amino acid decarboxylase (AADC).[48]. A detailed review of the reaction mechanism is presented 
in chapter 5. 
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Figure 1.4. The biosynthesis of serotonin from L-tryptophan. The conversion of L-tryptophan to 5-HTP is 
catalyzed by TPH and requires molecular oxygen and BH4 as co-substrates. The conversion of 5-HTP to 
serotonin is catalyzed by AADC. 
Serotonin exerts its function by acting on 15 different 5-HT receptors which are distributed throughout the 
entire human body.[49] In the peripheral tissues, the rate-limiting reaction in the synthesis of serotonin is 
mainly catalyzed by TPH1.[37] Here serotonin acts as a hormone to constrict large blood vessels and 
regulates platelet adhesion.[50,51] Serotonin is also found in the intestines where it is involved in e.g. 
gastrointestinal motility and homeostasis.[52,53] Dysregulation of peripheral serotonin level is involved in 
several conditions e.g. functional gastrointestinal disorders, lung fibrosis, carcinoid syndrome, and 
osteoporosis.[54-57] 
In the central nervous system, the rate-limiting step in the serotonin synthesis is primarily catalyzed by 
TPH2.[36] The synthesis is mainly in the dorsal raphe nuclei of the brain stem where it acts as a 
neurotransmitter.[58] Here, serotonin is involved in regulating centers of the brain that involve e.g. 
wakefulness, temperature regulation, blood-pressure regulation, aggressive and sexual behavior.[59,60] 
Several disorders have been reported to be related to dysfunction of the serotonin system in the CNS, such 
as depression, schizophrenia, autism, and ADHD.[61] 
As TPH is the rate-limiting step in the synthesis of serotonin, it is a potential target in treatments of the 
serotonin associated disorders.[52,62] The neurological disorders are associated with decreased levels of 
neuronal serotonin and the gastrointestinal disorders are associated with increased levels of serotonin.[63-
65] As the groups of disorders are oppositely influenced by serotonin, a TPH isoform-specific modulator is 
desirable to independently regulate the two isoforms.[66] This is evident from the substrate analogue p-
chlorophenylalanine, which has been used as a TPH1 inhibitor in treatment of carcinoid syndrome.[67,68] As 
p-chlorophenylalanine also inhibits TPH2, serotonin is depleted in the CNS resulting in severe side-effects 
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such as depression.[69-72] More recent inhibitors for TPH1 have been identified.[73,74] These inhibitors are 
not isoform-specific, as they also inhibit TPH2, but they do not cross the blood-brain barrier, and therefore 
only deplete 5-HT in the gastrointestinal tract.[63] Very recently compounds that selectively inhibit TPH1 over 
TPH2 have been identified.[75] These compounds bind in an inhibitory site that is located in the catalytic 
domain but is separated from the active site.  
With improved knowledge about the TPH isoforms, potential drugs which specifically stimulate TPH2 activity 
might be identified. These could provide an alternative to the modern antidepressants which inhibit serotonin 
reuptake. The reuptake inhibition is accompanied with several side-effect caused by the non-specific nature 
of this treatment.[76] 
1.4 Tetrahydrobiopterin 
6R-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4) is an important co-substrate in several enzymes of metabolic 
importance, including the AAAHs, alkylglycerol mono-oxygenase, and nitric oxide synthases.[77] BH4 is 
formed de novo from GTP in a sequence of three enzymatic steps.[77] The intracellular concentration of BH4 
in the brain has been found not to saturate TPH2 and is likely around or lower than Km,BH4 (~20 µM [40]).[78]  
In the reaction catalyzed by TPH, BH4 is converted to 4a-carbinolamine tetrahydrobiopterin (4a-hydroxy-
BH4), Figure 1.5.[79] The product 4a-hydroxy-BH4 is converted to quinonoid dihydrobiopterin (qBH2), either 
spontaneously or catalytically by pterin-4a-carbinolamine dehydratase.[80] BH4 is enzymatically regenerated 
from qBH2 by an NAD(P)H-dependent oxidoreductase.[81] If qBH2 is not regenerated, it will rearrange non-
enzymatically to form 7,8-dihydrobiopterin (BH2).[81] The role of BH4 in the hydroxylation of tryptophan is 
further described and discussed in chapter 5.  
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Figure 1.5.  Schematic illustration of the recycling of co-substrate BH4. Insert illustrates 6-methyl-5,6,7,8-
tetrahydropterin (6-MePH4)   
The natural co-substrate of the AAAHs is BH4 [82], however, earlier studies have used a co-substrate 
analogue 6-methyl-5,6,7,8-tetrahydropterin (6-MePH4), Figure 1.5 (insert). 
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2 Purification of tryptophan hydroxylase  
This chapter starts by introducing the background of TPH purification and how the purification strategy, 
utilized in this dissertation, has been optimized by previous students of the Metalloprotein Chemistry and 
Engineering Group at DTU. The optimized purification procedure is presented followed by a description of 
how the procedure has been applied to the different TPH variants. Results of purification of hTPH2 utilizing 
this procedure are subsequently presented. This is followed by a presentation and discussion of the 
purification yields obtained for the different TPH variants. 
 
 
 
 
 
 
 
2.1 Introduction and background 
For proper enzymatic characterization sufficient quantities of pure enzyme are required. Extraction from its 
original source is a tedious procedure and will often yield low quantities of the target enzyme. This is also the 
case for TPH, as it has been extracted only in low quantities from brain tissues [83-85] and purification or the 
extracts has resulted in low yields [86-89]. Recombinant expression of TPH1 from different mammalian 
species in E. coli has greatly increased the available quantities of active enzyme. Despite the increased 
quantities of TPH1, characterization has been hampered by its inherently poor stability.[90-93] Especially the 
N-terminal regulatory domain has been identified as the source of TPH instability and reduced solubility.[94] 
The quantity of stable enzyme was increased by recombinant expression of only the catalytic domain of 
TPH1 (cTPH1) in E. coli.[95] The amount of active TPH1 was increased ~10-fold compared to full-length. 
Furthermore, it was found that high ionic strength, in the form of 100 mM (NH4)2SO4, greatly increases 
purification yields. A rapid and more convenient procedure for achieving pure catalytic domain of TPH1 in 
high quantities has subsequently been described by Nielsen et al.[96] 
Purification strategies for full-length TPH have been optimized by expressing TPH variants as fusion protein, 
which enables very selective affinity chromatography. TPH1 has been expressed as a fusion protein with 
maltose binding protein [91,97], glutathione S-transferase [98], and Histidine-tag [99]. In all these cases, 
attempts to cleave the fusion protein and isolate active TPH1 were unsuccessful. In a study by McKinney et 
al.[100], fusion proteins of human TPH1 and TPH2 with 6xHis-MBP were expressed in E. coli and purified in 
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high yields. The fusion proteins were successfully cleaved with tobacco etch virus (TEV) protease. However, 
the purity of the cleaved TPH1 and TPH2 samples was low (50 and 80 % pure, respectively).  
In the Metalloprotein Chemistry and Engineering Group at DTU, a method for purification of chicken cTPH1 
and human cTPH2 expressed in E. coli was presented by M. S. Nielsen.[101] The procedure consists of two 
steps, anion exchange followed by gel filtration. J. Boesen optimized and applied this strategy successfully to 
human cTPH1.[102] J. Boesen furthermore fund that the regulatory domain of hTPH1 has a requirement for 
high ionic strength during purification.  
Ion-exchange is excluded because of the requirement of hTPH1 for high salt concentration. Therefore, L. T. 
Haahr developed a purification procedure for hTPH1, which, instead of ion-exchange, includes an affinity 
chromatographic step using a MBP fusion protein.[103] This purification strategy allows the use of 300 mM 
(NH4)2SO4, which has been found to stabilize the regulatory domain.[102] Successful cleavage of the fusion 
protein was achieved using human rhinovirus 3C protease (3CP). After cleavage, stable TPH was achieved 
which subsequently was further purified with additional affinity and gel filtration steps. This method was also 
applied successfully to purify the regulatory and catalytic domains of TPH1 (rchTPH1).[103] This method 
was, however, non-successful in relation to TPH2 variants containing the regulatory domain.[103]  
The purification strategy presented by L. T. Haahr includes two affinity purification steps and two gel filtration 
steps and has a duration of two days. The duration of the purification was significantly reduced, while the 
yield was increased, by performing on-column cleavage of the MBP-TPH fusion protein.[104] Using on-
column cleavage with MBP-3CP, the purification procedure is reduced to one affinity step and one gel 
filtration step. In my master’s project, this procedure was optimized to successfully purify rchTPH2 in 
quantities suitable for enzymatic characterization.[105] The purification yield was found to increase 
significantly when the 47 N-terminal residues were removed.[105]   
2.2 TPH variants and nomenclature 
Throughout this dissertation, abbreviation of the different TPH variants will be used. As will be described in 
section 2.3.2, all TPH variants are expressed as fusion proteins with MBP. Before MBP is cleaved from the 
target TPH variant, the variant will be referred to as MBP-TPH. In total, 14 human TPH variants were purified 
according to the procedures described in section 2.3. In Table 2.1, description, abbreviation, molecular 
weight, and extinction coefficient at 280 nm (calculated using ProtParam [107]) for each variant are listed. In 
the abbreviation, the first letter(s) refers to the domains which are included in the TPH variant; “r” refers to 
the regulatory domain, “c” refers to the catalytic domain, and if no letters are included the full-length variant is 
referred to. The letter(s) in italic refers to the species from which the protein sequence originates from; i.e. “h” 
refers to Homo sapiens (human). NΔ followed by a number refers to truncation of that number of residues 
from the N-terminus.  
2.3 Experimental procedures 
The purification strategy and conditions used in this study, is based on the purification procedure developed 
by L. T. Haahr [103] which has been optimized by previous members of the Metalloprotein Chemistry and 
Engineering Group. A flow diagram of the procedure is presented in Figure 2.1. 
2.3.1 Materials 
All used chemicals were of analytical grade, and all solutions were prepared using water from an 18.2 
MΩ·cm Milli-Q synthesis A10 Q-Gard system which was filtered through a 0.22 µm filter. Protein purification 
was performed on an ÄKTA purifier 100 from GE Healthcare. Utilized GE Healthcare column variants: 
HiLoad Superdex 200 26/60 pg, HiLoad Superdex 75 26/60 pg, and XK 16/20 column packed with 25 mL  
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Figure 2.1. Flow chart presenting the general purification procedure of the MBP-TPH variants. 
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Dextrin Sepharose High Performance media. During purifications, all TPH containing solutions were kept in 
ice water, except during the chromatographic steps, which were performed at room temperature. Protein 
solutions were concentrated using an Amicon ultrafiltration cell with an Ultracell PL-3 membrane. Protein 
concentrations were determined by measuring the absorbance at 280 nm on an ND-1000 NanoDrop 
Spectrophotometer from Saveen Werner.  
2.3.2 Cloning and expression of TPH variants 
The expression of the TPH variants was conducted by laboratory technicians and the following procedure 
was used. Full-length cDNA optimized for expression in E. coli was obtained from GenScript. All proteins 
were expressed as maltose binding protein fusion proteins from the pET26 expression vector in E. coli 
BL21(DE3) (Novagen) cells. The sequences of the proteins expressed are given in Appendix B. The 
recombinant fusion proteins contain a cleavage recognition site for human rhinovirus 3C protease [106]. The 
construct encoding the different protein variants was obtained by PCR. The primers used are listed in the 
supporting information of Appendix A.1. All DNA sequences were verified by sequencing (Eurofins). Proteins 
were expressed at 20°C for 14 h as previously described [96].  
2.3.3 Purification of chTPH1 variants 
E. coli cells from one or more 650 mL cultures were thawed from -80 °C and resuspended in buffer solution 
containing 20 mM TRIS/H2SO4, 100 mM (NH4)2SO4, pH 8.0, to a volume of 40 mL (per 650 mL cell culture). 
The resuspended cell culture was lysed by sonication for 3x30 seconds using a Satorius Labsonic at 80 % 
amplitude, while kept in ice water. The lysed sample was centrifuged at 4 °C and 18,000 x g for 20 minutes. 
The supernatant was decanted to another tube and centrifuged a second time at 4 °C and 18,000 x g for 20 
minutes, while the pellet was discarded. The supernatant was collected and filtered through a 0.45 μm filter.  
A volume of approximately 35 mL filtered supernatant was loaded with a flow-rate of 5 ml/min onto a Dextrin 
Sepharose column which was equilibrated with 5 column volumes of buffer solution. Following sample 
loading, an MBP-3CP solution was prepared by diluting MBP-3CP from stock with buffer solution to a 
concentration of 2.2 µM. 30 ml MBP-3CP solution was loaded onto the column with a flow-rate of 5 ml/min, 
and the column was incubated at room temperature for one hour. Once the flow (5 mL/min) was resumed, 10 
mL of the protein-containing eluate was collected. The collected solution, containing target protein, was 
filtered through a 0.45 μm filter prior to loading on a HiLoad Superdex 200 prep grade column, which had 
been equilibrated with 2 column volumes of buffer solution. The same buffer solution from the affinity 
chromatography step was used as mobile phase using a flow-rate of 2.5 mL/min, and UV-detected (280 nm) 
peaks, containing the target protein, were collected. The concentration of the collected protein was 
determined by UV-Vis absorption at 280 nm utilizing theoretical extinction coefficients obtained from Expasy 
[107]. The samples were either concentrated by ultrafiltration prior to freezing in liquid nitrogen, or if the 
concentration of target protein was high enough in the eluate, the ultrafiltration was bypassed, and the 
protein solution was frozen in liquid nitrogen and stored at -80 °C. 
2.3.4 Purification of rchTPH1 and hTPH1 
Purification of the rchTPH1 and hTPH1 was conducted with the same procedure as described for chTPH1, 
with the only difference being the buffer solution. These variants were purified in either 20 mM TRIS/H2SO4, 
300 mM (NH4)2SO4, pH 8.0 or 20 mM TRIS/H2SO4, 300 mM (NH4)2SO4, 3 mM L-phenylalanine, pH 8.0 
throughout the purification. 
2.3.5 Purification of chTPH2 variants 
Purification of the chTPH2 variants was conducted in 20 mM HEPES/NH4OH, 100 mM (NH4)2SO4, pH 7.0 
with the same procedure as described for chTPH1.  
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2.3.6 Purification of rchTPH2 
Purification of the rchTPH2 variants was conducted in 20 mM HEPES/NH4OH, 300 mM (NH4)2SO4, 3 mM L-
phenylalanine, pH 7.0 with the same procedure as described for chTPH1. As rchTPH2 could not be purified 
in the absence of L-phenylalanine, a method that uses two buffer solutions was used. The resuspension, 
lysis, and affinity chromatography step, was performed with a buffer containing 20 mM HEPES/NH4OH, 300 
mM (NH4)2SO4, 3 mM L-phenylalanien, pH 7.0 and the gel filtration was performed with a buffer containing 
20 mM HEPES/NH4OH, 300 mM (NH4)2SO4, pH 7.0. With this procedure the final purification product is 
assumed not to contain L-phenylalanine.   
2.3.7 Purification of NΔ47-rchTPH2 variants and hTPH2  
Purification of NΔ47-rchTPH2 variants and hTPH2 were conducted in either 20 mM HEPES/NH4OH, 300 mM 
(NH4)2SO4, pH 7.0 or 20 mM HEPES/NH4OH, 300 mM (NH4)2SO4, 3 mM L-phenylalanine, pH 7.0 with the 
same procedure as described for chTPH1.  
2.3.8 SDS-PAGE analysis 
Evaluation of molecular weights and purity was conducted by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE). Proteins were resolved on Mini-PROTEAN TGX gels (7.5 %) from Bio-Rad run 
at 100 V for 75 min with a protein standard from Bio-Rad (no. 161-0304). Gels were stained with Coomassie 
Blue G-250 to visualize the proteins.  
2.4 Introduction to TPH variants 
In total 14 variants have been produced to characterize TPH (Table 2.1). Because all TPH variants were 
purified as fusion proteins with MBP, they contain two additional residues in the N-terminus (Gly and Pro). 
These residues originate from the recognition and cleavage site of 3CP, Figure 2.1. The design of the 
Y125A-, Y125L-, Y125W-chTPH1, Y171A-, Y171W-chTPH2, loop-swap-chTPH1, and loop-swap-chTPH2 
variants is described in chapter 7. NΔ47-rchTPH2 will be described in the following section.  
2.4.1 Truncation of the N-terminus 
Full-length hTPH2 and rchTPH2 have proven to be challenging to purify in quantities sufficient for enzymatic 
characterization.[103,105] In pursuit of a hTPH2 variant with improved purification properties, attention was 
turned towards the crystal structure of phenylalanine hydroxylase. The structure of PAH from rat (PDB entry: 
1PHZ) lacks interpretable electron density in the 18 N-terminal residues, suggesting that the terminus is 
mobile.[108,109] The mobility of the N-terminus has also been confirmed by an NMR study.[110] The 
mobility of this region could cause instability and promote aggregation. The termini of rnPAH and hTPH2 
were aligned to identify a corresponding mobile region of hTPH2, Figure 2.2. 
Figure 2.2 shows that the first 47 residues of hTPH2 align with the mobile 18 residues of rnPAH, which 
indicates that these residues of hTPH2 are mobile. hTPH2 has an additional 46 residues in the N-terminus 
compared to hTPH1. Unlike hTPH2, hTPH1 has been purified with high yields which also suggests that the 
N-terminus of hTPH2 induce instability or insolubility. Therefore, a mutant variant lacking 47 residues in the 
N-terminus, NΔ47-rchTPH2, was expressed, purified, and characterized.  
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Table 2.1. Included domain, molecular weights, and theoretical extinction coefficients at 280 nm of the 
investigated TPH variants. 
Domain(s) Isoform Abbreviation 
Molecular 
weight (Da) 
Extinction coefficient at 
280 nm (M
-1
 cm
-1
) 
Catalytic TPH1 chTPH1 36,220 33,350 
Catalytic TPH1 Y125W-chTPH1 36,243 37,360 
Catalytic TPH1 Y125A-chTPH1 36,128 31,860 
Catalytic TPH1 Y125L-chTPH1 36,170 31,860 
Catalytic TPH1 
Loop-swap-
chTPH1 
36,250 33,350 
Catalytic and regulatory TPH1 rchTPH1 47,816 33,350 
Full-length TPH1 hTPH1 51,008 33,350 
Catalytic TPH2 chTPH2 36,339 39,310 
Catalytic and regulatory TPH2 rchTPH2 52,574 51,800 
Catalytic and regulatory TPH2 NΔ47-rchTPH2 47,434 44,810 
Full-length TPH2 hTPH2 56,080 53,290 
Catalytic TPH2 
Loop-swap-
chTPH2 
36,309 39,310 
Catalytic TPH2 Y171A-chTPH2 36,247 37,820 
Catalytic TPH2 Y171W-chTPH2 36,362 43,320 
 
 
Figure 2.2. Alignment of hTPH2 and rnPAH, using Clustal Omega (only the first 60 residues shown). "-" marks a 
gap in the primary structure. "*" marks conserved residues, ":" marks conservation of residues with highly 
similar properties and "." marks conservation of residues with slightly similar properties. The grey background 
in the sequence of rnPAH illustrates the highly mobile part of the N-terminal region, for which no crystal 
structure is available. The gray background in hTPH2 illustrates the corresponding region. 
2.5 Results of TPH purifications 
2.5.1 Purification of TPH variants 
All TPH variants were purified according to section 2.3. Purifications of chTPH1, rchTPH1, hTPH1, chTPH2, 
NΔ47-rchTPH2, and rchTPH2 resulted in chromatograms, yields, and purity similar to the ones obtained in 
previous theses or dissertations.[101-103,105] Several mutant versions were constructed for chTPH1 and 
chTPH2; Loop-swap-chTPH1, Y125A-chTPH1, Y125L-chTPH1, Y125W-chTPH, Loop-swap-chTPH2, 
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Y171A-chTPH2, and Y171W-chTPH2. The purpose of these mutations is described and discussed in 
chapter 7. All these mutant variants resulted in chromatograms very similar to the wild-type version (see 
Appendix C.2-10).  
2.5.2 Purification of hTPH2 
Full-length hTPH2 was purified in 20 mM HEPES/NH4OH, 300 mM (NH4)2SO4, 3 mM L-phenylalanine, pH 
7.0. After lysis, centrifugation, and filtration, 35 mL supernatant was loaded on a dextrin sepharose column.  
The chromatogram from the affinity chromatographic step of hTPH2 is shown in Figure 2.3.  
 
Figure 2.3. Chromatogram from affinity chromatography of hTPH2 using 20 mM HEPES/NH4OH, 300 mM 
(NH4)2SO4, 3 mM L-phenylalanine, pH 7.0 as mobile phase on a Dextrin Sepharose 16/12 column. The black line 
is the absorption at 280 nm. The red dashed line illustrates when MBP-3CP was loaded on the column. The 
green dashed line shows when the mobile phase was changed to elution buffer. The orange dashed lines 
indicate where samples for SDS-PAGE analysis were taken from P1 and P3. The black dashed line shows the 
collected protein from P2, which was also subjected to SDS-PAGE analysis. 
First the flow-through of unwanted proteins was eluted. The SDS-PAGE analysis in Figure 2.4 shows that 
MPB-hTPH2 binds the column very well, as only small amounts of MBP-hTPH2 is found in Peak 1 (P1).  
MPB-3CP was loaded and incubated for one hour. After the incubation period, P2 was eluted and collected. 
The SDS-PAGE analysis in Figure 2.4 shows that P2 contains hTPH2 with very low amounts of impurities. 
P3 contains MPB, MPB-3CP, and small amounts of MPB-hTPH2, which suggests incomplete cleavage. P2 
from the chromatogram in Figure 2.3 was collected (10 mL) for further purification.  
The 10 mL was loaded onto a gel filtration column resulting in two peaks eluting. Judged from the absence of 
a peak at the void volume (~108 mL) in the chromatogram in Figure 2.5, very small amounts of aggregate 
are formed. Two peaks are eluted at around 140 mL and 160 mL. The SDS-PAGE analysis shows that both 
peaks predominantly contain hTPH2. The elution volumes of P4 and P5 correspond to a higher ordered 
oligomer and tetramer, respectively.[103]  
The yield of this purification was 1.9 mg/L cell culture. As large quantities are found in the pellet (P in Figure 
2.4) after lysis and centrifugation, the low yield is probably accounted for by the low solubility of hTPH2.  
The purification of hTPH2 was also conducted in a buffer solution that did not contain L-phenylalanine. The 
resulting chromatograms of this purification are very similar to the ones obtained with L-phenylalanine. The 
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chromatograms can be found in Appendix C.1. In the absence of L-phenylalanine, a purification yield of 0.4 
mg/L cell culture was achieved. This yield is similar to the 0.6 mg/L cell culture obtained by L. T. Haahr using 
a 2 day off-column cleavage procedure.[103]  
 
Figure 2.4. SDS-PAGE result of collected peaks from purification of hTPH2 using a buffer solution containing 20 
mM HEPES/NH4OH, 300 mM (NH4)2SO4, 3 mM L-phenylalanine, pH 7.0. M: Molecular weight standard. R: 
Resuspension of cell culture (diluted 1:10). P: Resuspended pellet (diluted 1:10). S: Supernatant (diluted 1:10). 
P1: Flow-through of unwanted species (diluted 1:1). P2: Peak eluting after cleavage with MBP-3CP (diluted 1:1). 
P3: Peak from elution of MBP-bound species (diluted 1:1). P4 and P5: Peaks from gel filtration. 
 
 
Figure 2.5. Chromatogram from gel filtration on a Hiload 26/600 Superdex 200 column of the collected protein 
from affinity chromatography in the purification of hTPH2 using 20 mM HEPES/NH4OH, 300 mM (NH4)2SO4, 3 mM 
L-phenylalanine, pH 7.0. The black line is the absorption at 280 nm. The orange dashed line indicates where 
sample for SDS-PAGE analysis was taken from P4. The black dashed line shows the collected protein from P5, 
which was also subjected to SDS-PAGE analysis. 
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2.6 Purification yields 
The obtained purification yields differ significantly among the TPH variants. Some variants are purified in 
high yields while others are impossible to purify in quantities sufficient for enzymatic characterization. 
Tryptophan has been found to stabilize hTPH1 [97], but the presence of tryptophan complicates 
concentration determination and activity assays due to its absorption at 280 nm. For reasons described in 
chapter 3, phenylalanine was chosen as an alternative to tryptophan in the purification buffer solutions. In the 
following, Std and L-Phe buffers refer to buffer solutions without and with 3 mM L-phenylalanine, 
respectively.  
2.6.1 Purification of TPH2 variants 
Purification of chTPH2 and the three mutant variants in 20 mM HEPES/NH4OH, 100 mM (NH4)2SO4, pH 7.0 
resulted in yields between 10 and 16 mg/L cell culture. The purification yield of chTPH2 did not change 
significantly when 3 mM L-phenylalanine was added to the purification buffer solution, Figure 2.6.  
In the absence of L-phenylalanine, full-length hTPH2 was purified in very low quantities. Truncation of the C-
terminal tetramerization domain resulted in a variant, rchTPH2, which could not be isolated and concentrated 
in quantities suitable for characterization in Std buffer. Truncation of 47 residues in the N-terminus of the 
regulatory domain resulted in a variant, NΔ47-rchTPH2, which could be purified in quantities comparable to 
chTPH2.  
With 3 mM L-phenylalanine in the buffer solution, the purification yield of hTPH2 was increased 5-fold (only 
based on one purification of each). When rchTPH2 was purified with L-Phe buffer in the affinity 
chromatographic step and Std buffer in the gel filtration step, around 1 mg/L cell culture was achieved. This 
yield was increased 6-fold by using L-Phe buffer throughout the purification. The yield of NΔ47-rchTPH2 was 
increased 4-fold by purifying with L-Phe buffer compared to Std buffer. 
 
Figure 2.6. Average (±SD) yields obtained from purifications of the TPH2 variants (n=1-10). Red bars represent 
purifications using 20 mM HEPES/NH4OH, 100 or 300 mM (NH4)2SO4, pH 7.0 and green bars represent 
purifications using  20 mM HEPES/NH4OH, 100 or 300 mM (NH4)2SO4, 3 mM L-phenylalanine, pH 7.0 For data see 
Table D.1 in Appendix D.   
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The yields of variants containing the regulatory domain were increased significantly by introducing 3 mM L-
phenylalanine to the purification buffer solution. It was investigated whether this was caused by an increase 
in the solubility of the variants. The solubility of the fusion proteins MBP-chTPH2, MBP-rchTPH2 and MBP-
NΔ47-rchTPH2 were analyzed by SDS-PAGE of cells lysed in either Std or L-Phe buffer, Figure 2.7. The 
SDS-PAGE analysis shows that the solubility of rchTPH2 is rather low as great amounts are found in the 
insoluble fraction (P). In the absence of the regulatory domain, chTPH2, the solubility increases significantly 
as the majority of the protein is found in the soluble fraction (S). Truncation of the 47 N-terminal residues 
resulted in increased solubility, however, still inferior to only the catalytic domain.   
Addition of 3 mM phenylalanine to the buffer solution does not seem to have a profound effect on the 
solubility of any of the hTPH2 variants in Figure 2.7. Because the expression levels of the variants also seem 
equivalent, the profound differences in purification yield obtained in the absence and presence of 
phenylalanine do not seem to originate from a change in solubility.  
 
Figure 2.7. Solubility of hTPH2 variants. Comassie-blue stained SDS-PAGE gel (7.5 % acrylamide) from E.coli 
lysates showing total protein content in resuspension (R), pellet (P), and supernatant (S). A molecular weight 
marker with indicated weights is in the first lane. + L-Phe indicates the presence of 3 mM L-phenylalanine in the 
lysis buffer and - L-Phe indicates absence of L-phelynalanine. 
2.6.2 Purification of TPH1 variants 
All TPH1 variants comprising only the catalytic domain were purified in 20 mM TRIS/H2SO4, 100 mM 
(NH4)2SO4, pH 8.0 while variants also comprising the regulatory domain were purified in 20 mM TRIS/H2SO4, 
300 mM (NH4)2SO4, pH 8.0. Increased ionic strength was used for hTPH1 and rchTPH1 because J. Boesen 
found that these conditions stabilize the regulatory domain of TPH1.[102] Figure 2.8 shows that the yields of 
all the hTPH1 variants, besides Y125L-chTPH1, are similar and ranges between 19 and 26 mg/L cell culture. 
Unlike hTPH2, variants of TPH1 which contain the regulatory domain are purified in high yields. Furthermore, 
3 mM L-phenylalanine does not seem to have an effect on the purification yield of neither hTPH1 nor 
rchTPH1. 
19 
 
 
Figure 2.8. Average (±SD) yields obtained from purifications of the TPH1 variants (n=1-4). Red bars represent 
purifications using 20 mM TRIS/H2SO4, 100 or 300 mM (NH4)2SO4, pH 8.0 and green bars represent purifications 
using  20 mM TRIS/H2SO4, 300 mM (NH4)2SO4, 3 mM L-phenylalanine, pH 8.0 For data see Table D.1 in Appendix 
D.   
2.7 Discussion 
Characterization of both isoforms of TPH has been hampered by their inherent instability and solubility. 
Procedures enabling purification of quantities sufficient of enzymatic characterization of a variety of TPH 
variants has been developed by former student of the Metalloprotein Chemistry and Engineering Group at 
DTU.[101-103] The procedures are, however, not suitable for purifying hTPH2 variants containing the 
regulatory domain, as very low yields are obtained.[103] Even with the optimized procedure used in this 
dissertation, which only comprise one affinity chromatographic step, including on-column cleavage, followed 
by gel filtration, very low amounts were obtained.  
Truncation of 47 residues in the N-terminus resulted in a variant that could be purified in quantities 
comparable to chTPH2 which is sufficient for enzymatic characterization. In chapter 3, it is described that the 
thermostability of NΔ47-rchTPH2 and rchTPH2 are comparable. In this chapter, the SDS-PAGE analysis of 
MPB-NΔ47-rchTPH2 and MPB-rchTPH2, and MPB-chTPH2 revealed that the solubility is significantly 
decreased by the presence of the regulatory domain but increased upon truncations of the N-terminus. The 
solubility of these variants is anticipated to be lowered in the absence of the MBP fusion partner. Judging 
from the observed purification yields, the influence of the N-terminus on the solubility might be even greater 
in the absence of the MBP fusion partner. Furthermore, L-phenylalanine did not have an effect on the 
solubility of the MBP-hTPH2 variants. Whether this is the case after cleavage of the fusion protein is 
unknown.  
The presence of L-phenylalanine in the buffer solution significantly increased the purification yields of hTPH2 
variants containing the regulatory domain. The yield of chTPH2 was not increased, suggesting that L-
phenylalanine has an effect only on the regulatory domain. Like rchTPH2, addition of L-phenylalanine 
increased the yield of NΔ47-rchTPH2. This suggests that L-phenylalanine does not exert its effect on the N-
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terminus. The lower yield of chTPH2 compared to NΔ47-rchTPH2 purified in L-Phe buffer is caused by less 
efficient on-column cleavage of the fusion protein.[105] 
With the two-step purification procedure used in this dissertation, hTPH1 and rchTPH1 were purified with 
similar yields as previously obtained with the two day procedure (four-step procedure).[103] In contrast to the 
hTPH2 variants, L-phenylalanine had no influence on the purification yields of hTPH1 and rchTPH1, 
suggesting that the stabilizing effect is isoform specific. This is unexpected considering the high sequence 
identity of the isoforms. The role of L-phenylalanine is explored in chapter 3 and 4. 
2.8 Conclusion 
In this chapter, it is demonstrated how full-length human TPH2 can be purified to homogeneity using a 
simple and fast two step procedure. The same holds true for a variety of deletion mutation variants and 
variants with single or multiple point mutations. Limited purification quantities are still obtained from 
purification of TPH2 variants containing the regulatory domain. The quantities can, however, be significantly 
increased by addition of 3 mM L-phenylalanine to the purification buffers. With the two-step purification 
procedure and addition of L-phenylalanine, around 30 mg NΔ47-rchTPH2 is obtained per L cell culture. This 
quantity is sufficient for most experiments including crystallization attempts. 
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3 Stabilization of tryptophan hydroxylase 2 
Tryptophan hydroxylase isoform 2 is notoriously known to suffer from low stability. In this chapter an attempt 
to overcome this issue is presented. This chapter concerns the identification of stabilizing ligands by utilizing 
differential scanning fluorimetry (DSF). The methodology behind DSF will be introduced and previous results 
obtained for the AAAHs using DSF will be presented. 
DSF was used to investigate the effect of eight compounds on three TPH2 variants; chTPH2, rchTPH2, and 
NΔ47-rchTPH2. The experimental DSF procedure used to determine TPH transition temperatures is 
presented. The results obtained from the small scale ligand screen using DSF is presented and discussed. 
To investigate if the unfolding is accompanied by enzymatic inactivation, thermal inactivation measurements 
were conducted. The obtained results are presented and discussed. The majority of the results presented in 
this chapter have been published in FEBS Open Bio (Appendix A.1) 
 
 
 
 
 
 
 
3.1 Differential scanning fluorimetry 
In chapter 2 it was discussed how characterization of TPH2 has been hampered by insufficient purification 
yields due to its instability and tendency to aggregate. Increased purification yields might be achieved 
through increasing the thermostability of the notoriously instable TPH2. The stability of a protein determines 
the equilibrium between the native folded state and an ensemble of semi-folded and unfolded states.[111] 
Increased stability can therefore be achieved through stabilization of the native state.[111] It is known that 
the native state can be stabilized by binding of specific ligands, thereby reducing the proteins propensity to 
unfold and aggregate.[112]  
The increase in thermostability induced by a ligand can be quantified by measuring the change in unfolding 
temperature, Tm. The increase in Tm is proportional to the concentration of the ligand and the affinity of the 
ligand for the protein.[113] The change in Tm as a function of ligand concentration can be measured in a fast 
and high-throughput fashion by utilizing differential scanning fluorimetry.[114]   
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In DSF the thermal unfolding of a protein is monitored in the presence of a fluorescent dye.[114] The dyes 
used in DSF are highly fluorescent in a non-polar environment compared to in an aqueous solution. In this 
study, the dye SYPRO orange was used, Figure 3.1. In aqueous solution, the fluorescence of the 
hydrophobic moiety of SYPRO orange is quenched. When the temperature induced unfolding of the protein 
is initiated, hydrophobic patches from the core of the protein will be exposed. SYPRO orange will bind to 
these patches resulting in an increase in fluorescence.[114]  
 
Figure 3.1. Structure of SYPRO
®
 orange. 
In the case of a two-state unfolding of a protein, the plot of fluorescence intensity as a function of 
temperature will yield a sigmoidal curve. Initially, the intensity is low as SYPRO orange does not bind folded 
protein. After unfolding, the protein sample will eventually aggregate resulting in quenching of the 
intensity.[114] The transition temperature can be calculated by fitting a Boltzmann sigmoidal (eq. 1) to the 
unfolding curve, 
 
     
     
      
    
 
 
 (eq. 1) 
where LL and UL are the values of minimum and maximum intensities, respectively, and a denotes the slope 
of the curve at Tm.  
3.2 AAAH stability 
Differential scanning fluorimetry has been utilized in attempts to stabilize or identify potent ligands in all 
members of the AAAH family. Furthermore, DSF has been used to determine the change in stability 
introduced by point mutations.[115,116] 
The transition temperature of full length hPAH has been found to range from 47.5 – 49.5 °C.[115,116] 
Substrate phenylalanine (>1 mM) has been found to increase Tm with 3.4 and 2.7 °C in PAH from human 
and legionella pneumophila, respectively.[116,117] Tm of the regulatory domain of hPAH, however, was 
increased by 21.7 °C with 1 mM phenylalanine.[118] The regulatory domains of hTPH1 and hTH were not 
stabilized by tryptophan and tyrosine, respectively.[118] Similar to PAH, the transition temperature is 55.5 °C 
for hTPH2 and range from 45.2 – 51.8 °C for full length hTH.[119-121] 
DSF has been utilized to screen compound libraries in hPAH and hTH to identify compounds which increase 
Tm. Compounds were identified which increased Tm as much as 13.6 and 21.7 °C for hPAH and hTH, 
respectively.[115,121]  
3.3 Experimental procedures 
3.3.1 Differential scanning fluorimetry 
The unfolding of the TPH2 variants was recorded with an Agilent Technologies Stratagene MX3005 P RT-
PCR machine (λex = 465 nm, λem = 610 nm). The ligand screen was performed with total volume of 25 µL in 
96-well plates (polypropylene plates from Agilent Technologies). Each well was composed of protein at a 
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concentration of 1 µM, SYPRO orange at a concentration of 2X (diluted from SYPRO
® 
5000X stock from 
Sigma), and ligand (diluted in purification buffer) in a concentration range of 0.1 µM to 10 mM. Each plate 
contained control wells with the purification buffer with and without protein and ligand. Scans were carried 
out using a scan-rate of 1 °C/min, going from 20 °C to 95 °C. The thermograms were baseline corrected with 
MxPro QPCR Software and analyzed for transition temperatures with GraphPad Prism 6 utilizing a 
Boltzmann sigmoid fit (eq. 1). The obtained Tm-values as a function of substrate concentrations were fitted 
with eq. 2 [122], 
 
   
    
      
      (eq. 2) 
 
where Kd is the dissociation constant of the substrate, Tm,0 is transition temperature at zero concentration of 
ligand, and a is the maximal increase in Tm, where a + Tm,0 is Tm at saturating compound concentration 
(Tm,max).  
3.3.2 Heat induced inactivation 
The rate of inactivation at 30 °C was determined by heating the protein in aliquots of 1300 µL to 30 °C in a 
water bath. The denaturation was stopped at a certain time point by cooling the protein solution in ice water. 
The enzymatic activity was determined at different time points with a continuous fluorescence assay 
described in details in chapter 6. The obtained data was fitted with one-exponential decay curves, and the 
rate constants, k, were calculated using an exponential function, Et = E0e
-kt
, where E0 is the initial enzyme 
activity, and Et is the activity after time t at 30 °C. From the decay rate constants, half lives (t½) of the TPH 
samples were calculated using t½=ln(2)/k. 
3.4 DSF results 
The characterization of both isoforms of full length hTPH are very limited compared to that of PAH and TH. 
This is primarily caused, as described in chapter 2, by low purification yields of the TPH isoforms. Deletion of 
the regulatory domain significantly increases the purification yield [123], however the possibility to obtain 
knowledge about this domain is lost. The regulatory domains of all the AAAHs comprise a fold motif referred 
to as an ACT domain (see chapter 4). Such domains have been found to bind L-valine, L-serine, and L-
phenylalanine.[118,124,125] To analyze if similar binding of ligands occur in the ACT domain of TPH2, the 
transition temperature was analyzed in the presence of different amino acids or amino acid derivatives. The 
change in Tm of the TPH2 variants was analyzed with eight compounds; L-phenylalanine, L-tryptophan, L-
tyrosine, L-valine, L-serine, D-phenylalanine, 5-hydroxytryptophan (5-HTP), and 5-hydroxytryptamine (5-HT). 
All compounds were screened in a concentration range of 0.1µM-10mM except for L-Tyr which was 
screened from 0.1 µM-1.5 mM, due to limited solubility. 
3.4.1 DSF results of chTPH2 
Tm was determined for chTPH2 in purification buffer; 20 mM HEPES, 300 mM (NH4)2SO4, pH 7.0. 
Representative examples of the DSF results of chTPH2, in the presence of the highest tested concentrations 
of the ligands, are presented in Figure 3.2. The unfolding curves in Figure 3.2 show that chTPH2 has an 
almost ideal two-state unfolding behavior with a transition temperature of 42.7 ± 1.3 °C. 
Two-state unfolding was observed for all compounds except 5-HTP and 5-HT. These compounds appear to 
change the unfolding from two-state to continuous (see Figure 3.3 for example of continuous unfolding); 
hence, it was not possible to obtain a good fit with the eq. 1 and Tm-values were therefore not obtained for 
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these compounds. The remaining compounds did not have a significant effect on the unfolding behavior or 
Tm-value of chTPH2, Figure 3.2. 
 
Figure 3.2. Normalized and baseline corrected differential scanning fluorimetry curves - ligand screen on 
chTPH2 (enzyme concentration of 1 µM). Representative examples of the highest concentration of the 
compounds in the screen (1.5 mM for tyrosine and 10 mM for all other compounds). To the right Tm-values (n=3) 
of chTPH2 with the respective compounds are listed in °C ± standard deviation. 
3.4.2 DSF results of rchTPH2 
The transition temperature, Tm, was determined for rchTPH2 in purification buffer; 20 mM HEPES/NH4OH, 
300 mM (NH4)2SO4, pH 7.0. Containing the regulatory domain, rchTPH2, gave rise to inconsistent and 
polyphasic unfolding curves from which no Tm-value could be obtained (Figure 3.3, solid line).  
 
Figure 3.3. Representative examples of raw data from differential scanning fluorimetry of rchTPH2 (enzyme 
concentration of 1 µM) with no ligand (solid line, reference) and with addition of 10 mM L-Trp (dashed line). 
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The ligand screen showed that L-Trp and L-Phe induced a change from continuous unfound to an apparent 
two-state unfolding, as represented in Figure 3.3. None of the other compounds, including D-Phe, were able 
to induce this change in unfolding. The Tm-value of rchTPH2 was increased with increasing concentration of 
L-Phe or L-Trp, Figure 3.4.  
 
Figure 3.4. Representative normalized and baseline corrected DSF curves of rchTPH2. A: DSF curves with 
different L-Trp concentration. B: Tm-values with increasing L-Trp concentration fitted with eq. 2. C: DSF curves 
with different L-Phe concentration. D: Tm-values with increasing L-Phe concentration fitted with eq. 2. 
At 0.1 mM L-Trp, a Tm-value of 46.3 ± 1.4 °C was obtained for rchTPH2. This was increased by 6.1 °C with 
the addition of 10.0 mM L-Trp. A Kd-value of tryptophan binding was estimated by fitting eq. 2 to the data 
presented in Figure 3.4 B. The utilized model (eq. 2) is the most simple for ligand binding and assumes a 1:1 
binding ratio.[122] Furthermore, the model does not account for the change in temperature. A Kd-value of 1.3 
mM, Tm,0-value of 45.7 °C and Tm,max-value of 53.1 °C were determined. 
The transition temperature of rchTPH2 was increased to 51.0 ± 0.9 °C by addition of 10.0 mM L-Phe (Figure 
3.4 D). Insufficient data in the low concentration region was obtained to fit the Tm-values as a function of L-
Phe concentration without constraints. Tm,0 was therefore constrained to the value obtained from the data 
presented in Figure 3.4 B. A Kd-value of 2.3 mM and Tm,max-value of 51.9 °C were determined. 
28 
 
Similar results were obtained for NΔ47-rchTPH2. Continuous unfolding curves were also observed for NΔ47-
rchTPH2 in the absence of a ligand. L-Phe and L-Trp changed the unfolding to apparent two-state, 
comparable to the observations for rchTPH2 (see Appendix E.1). 
As both L-Trp and L-Phe gave rise to increased transition temperatures, a combination of the compounds 
was analyzed. At 10 mM L-Trp, rchTPH2 has a Tm-value of only 0.7 °C from the calculated Tm,max, suggesting 
that saturation is almost attained. However, at 10 mM L-Trp addition of L-Phe seems to increase the Tm-
value in a concentration-dependent manner, Figure 3.5. 
 
Figure 3.5. Tm-values of rchTPH2 with increasing L-Phe concentration at a constant L-Trp concentration of 10 
mM. Data is fitted with eq. 2, Tm at 1 mM L-Phe was omitted from the fit.  
From the data in Figure 3.5, a Tm,max-value of 53.9 °C was determined (1.0 mM L-Phe omitted). The DSF 
data for L-Phe and L-Trp combination was produced on a different day than the data for only L-Trp. The data 
seems to be systematically lower from the day of the combinatorial study of L-Phe and L-Trp (Appendix E.2). 
The Tm,max-value obtained at 10 mM L-Phe in combination with 10 mM L-Trp is therefore lower than expected 
when comparing to the Tm,max-value obtained from addition of only L-Trp. Despite this fact and the large 
standard deviations, Tm seems to increase with increasing concentration of L-Phe at saturated concentration 
of L-Trp. This might suggest an additive effect of the ligand.       
3.4.3 DSF results of chTPH mutant variants 
In chapter 7, mutations in an active site loop is made in both TPH isoforms and analyzed for changes in their 
kinetic parameters. The thermostability of these mutant variants of chTPH1 and chTPH2 was analyzed in 20 
mM TRIS/H2SO4, 100 mM (NH4)2SO4, pH 8.0 and 20 mM HEPES/NH4OH, 100 mM (NH4)2SO4, pH 7.0, 
respectively. Representative examples of the unfolding curves of the TPH variants are presented in Figure 
3.6.  
The transition temperatures obtained for the chTPH variants are summarized in Figure 3.6. The transition 
temperature of chTPH1 is determined to 41.4 ± 0.2 ºC. This value corresponds well with previous 
results.[126] Mutations of Tyr125 to alanine or tryptophan or the three loop-swap mutations only resulted in 
subtle changes in the transition temperature. 
Together with the other chTPH variants the transition temperature of chTPH2 was determined again 
(previous section in this chapter – different buffer solution). The Tm-value was determined to 42.1 ± 0.3 ºC 
which corresponds well with the previous result. As was the case of chTPH1, the substitution of tyrosine to 
alanine or tryptophan in position 171 or the three loop-swap mutations only resulted in small changes in the 
Tm-value. 
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Figure 3.6. Representative normalized and baseline corrected DSF curves of chTPH variants. To the right Tm-
values (n=4-6) of the chTPH variants are listed in °C ± standard deviation. 
3.5 Inactivation results 
3.5.1 Inactivation of hTPH2 variants 
As an alternative to the thermal unfolding measurements, the rates of inactivation at 30 °C was analyzed 
under the same buffer conditions; 20 mM HEPES/NH4OH, 300 mM (NH4)2SO4, pH 7.0. This assay reveals 
whether the unfolding is associated with loss of function and if the dye gives rise to artifacts. The influence of 
L-Phe on the inactivation rates of chTPH2, NΔ47-rchTPH2, and rchTPH2 was analyzed. The results in the 
absence and presence of 3 mM L-Phe are presented in Figure 3.7 A-C.  
From the data in Figure 3.7 A, a half-life at 30 °C (t½) of 203 ± 40 min was determined for chTPH2. With 3 
mM L-Phe, the t½ is 193 ± 29 min. L-Phe does therefore not change the inactivation rate of chTPH2. This 
result is consistent with the result obtained from the DSF experiments.  
The data in Figure 3.7 B and C show that rchTPH2 and NΔ47-rchTPH2 display t½-values of only 15 ± 2 and 
18 ± 3 min, respectively. The presence of the regulatory domain hence results in a >10-fold increase in the 
inactivation rate. The N-terminus, however, do not seem to have an influence on the inactivation rate. 
In contrast to chTPH2, L-Phe has a significant impact on the t½-values of the variants containing the 
regulatory domain. The t½-vaules were increased to 41 ± 3 min for rchTPH2 and 49 ± 5 min for NΔ47-
rchTPH2. Again, these results correlate with the observations from the DSF experiments, where L-Phe 
increased the transition temperature of variants containing the regulatory domain.  
The half-life of full-length hTPH2 was also determined in the presence of L-Phe, Figure 3.7 D. Here a t½-
value of 30.3 ± 3.3 min was obtained, suggesting that tetrameric hTPH2 is slightly less stable under the used 
conditions compared to dimeric rchTPH2 and NΔ47-rchTPH2 (oligomeric states are further discussed in 
chapter 4).     
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Figure 3.7. Heat inactivation of TPH2 variants; A: chTPH2 (n=3), B: NΔ47-rchTPH2 (n=3), C: rchTPH2 (n=3), and 
D: hTPH2 (n=2) with 3 mM L-phe (closed circles) or no ligand (open circles). Enzyme samples (5 µM) were 
incubated at 30 °C, and residual activity in % of initial activity at t0 was assayed in time intervals. 
3.5.2 Inactivation of hTPH1 
The inactivation rate of full-length hTPH1 was analyzed in 20 mM TRIS/H2SO4, 300 mM (NH4)2SO4, pH 8.0. 
The results are presented in Figure 3.8 and show that hTPH1 is not inactivated at 30 °C within two hours.   
 
Figure 3.8. Heat inactivation of hTPH1 (n=3). Enzyme samples (5 µM) were incubated at 30 °C, and residual 
activity in % of initial activity at t0 was assayed in time intervals. 
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3.6 Discussion   
Characterization of the TPH isoforms, especially TPH2, has been limited because of inherent instability and 
tendency to aggregate. Utilizing differential scanning fluorimetry, it was identified that L-Phe and L-Trp 
changed the unfolding behavior of TPH2 variants containing the regulatory domain from continuous and 
polyphasic to apparent two-state. The change in unfolding behavior was accompanied by a significant 
increase in thermal stability which, as described in chapter 2, resulted in a several fold increase in 
purification yields.  
The observed transition temperatures of chTPH1 and chTPH2 were similar and corresponds with values 
previously observed.[126] DSF measurements were conducted for chTPH2 at 100 mM and 300 mM 
(NH4)2SO4 and resulted in the same Tm-value, suggesting that 100 mM is sufficient for chTPH2 stability.  
The transition temperature of chTPH2 did not increase in the presence of ligands. In contrast, L-Phe and L-
Trp increased the Tm-values of rchTPH2 and NΔ47-rchTPH2. This implies that the ligands stabilize through 
binding in the regulatory domain and do not seem to involve the 47 N-terminal residues. In the presence of 
these ligands, the TPH2 variants display Tm-values comparable to the ones observed for hPAH and hTH (in 
the absence of ligands).[115,116,120,121] A greater Tm-value (55.5 °C) has been determined for full-length 
hTPH2, despite similar buffer conditions; 20 mM HEPES, 200 mM NaCl, pH 7.0.[119] The assay, however, 
contained 2.5 % DMSO, and 8-anilino 1-naphthalenesulfonic acid (ANS) was used as the dye.[119] 
Furthermore, the TPH sample was purified according to a purification procedure by McKinney et al.[127], 
where 10 % glycerol (v/v) is included. Glycerol has a known stabilizing effect and tendency to bind the 
catalytic site of TPH.[126]   
In line with the observations in the DSF experiments, only variants containing the regulatory domain 
displayed an increased t½-value at 30 °C in the presence of L-Phe. For rchTPH2 and NΔ47-rchTPH2, t½ was 
increased ~3-fold, whereas chTPH2 was not significantly influenced by L-Phe. The very short half-lives 
determined in this study, are comparable to values previously determined for hTPH2 variants [123,128,129] 
and confirms that TPH2 is instable and hence a challenge to characterize. In contrast, it was demonstrated 
that hTPH1 is very thermostable, as it maintained full activity upon incubation at 30 °C for 2 hours. Longer 
half-lives has also been observed for the more stable hTH, which is therefore more thoroughly 
characterized.[130,131]  
When the DSF results are compared to the inactivation results, it is noticed that in the presence of L-Phe 
chTPH2 has a lower Tm but a higher t½ than e.g. rchTPH2. This might be explained by the presence of dye in 
the DSF measurements which might reduce the apparent stability of isolated catalytic domain. This is, 
however, unlikely, as the raw fluorescence intensity data shows that chTPH2 and rchTPH2 start from the 
same intensity level compared to the baseline. This suggests that the dye does not bind one variant more 
than the other prior to unfolding. Alternatively, chTPH2 retains activity upon the unfolding transition observed 
in the DSF. The activity might then be lost upon aggregation which is achieved at greater temperatures.  
From the DSF experiments Kd-values for L-Trp (1.3 mM) and L-Phe (2.3 mM) were obtained in the milli molar 
range, suggesting very low affinity of these ligands. The substrate dissociation constant in the AAAHs are 
usually in the low micro molar range.[126,132,133] The observed Kd-values are therefore around two orders 
of magnitude larger than expected for substrates binding in the active site. This suggests that the increase in 
Tm occur through binding of L-Trp and L-Phe in a low affinity site. Such an allosteric site has been identified 
in PAH, where Tm similarly has been found to increase with increasing L-Phe concentration.[118,134] In this 
low affinity site of PAH, L-Phe displays a Kd-value of 174 ± 9 µM [134], which similarly is significantly higher 
than values observed for binding in the active site [135]. Binding of L-Phe in the allosteric site of PAH is 
associated with dimerization of the regulatory domains.[118,134] The influence of L-Trp and L-Phe on the 
oligomeric state of TPH2 upon binding in a potential allosteric site will be discussed in chapter 4.  
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3.7 Conclusion 
This chapter describes how differential scanning fluorimetry was utilized to identify tryptophan and 
phenylalanine as thermostabilizing ligands for hTPH2 variants containing the regulatory domain. The results 
show that the regulatory domain is involved in the induced thermostability, as binding of the amino acids only 
has an effect on variants comprising this domain. It was demonstrated that the binding to the hTPH2 variants 
is specific, as only one of the stereoisomers of phenylalanine increased the transition temperature.  
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4 Subunit assembly of TPH variants 
This chapter concerns the quaternary structure of tryptophan hydroxylase and how the domains are involved 
in the inter-subunit assembly. The three domains in the aromatic acid hydroxylases are introduced and their 
roles on the quaternary structure are presented and discussed. As very limited knowledge prevails on 
especially the regulatory domain of the TPH isoforms, the structure and function of the homologues 
regulatory domain in PAH will be presented. 
Analytical gel filtration was utilized to analyze the oligomeric state of three TPH2 variants; chTPH2, rchTPH2, 
and NΔ47-rchTPH2. The experimental procedure to determine the oligomeric state is presented. In chapter 
3, it was described how it was found that ligands increase the thermostability of TPH2 variants containing the 
regulatory domain. In this chapter, the influence of these ligands on the oligomeric state of the TPH2 variants 
are presented and discussed. The majority of the results presented in this chapter have been published in 
FEBS Open Bio (Appendix A.1) 
 
 
 
 
 
4.1 The AAAH domains 
All mammalian aromatic amino acid hydroxylases (AAAHs) consists of three domains; An N-terminal 
regulatory domain, a catalytic domain, and a C-terminal tetrameriztion domain.[136] The AAAHs consist of a 
similar number of amino acid residue in the catalytic and tetramerization domains, whereas the number of 
residues in the regulatory domains vary significantly.[137-139] The number of residues in the domains of the 
AAAHs are presented in Figure 4.1, these number may, however, vary in literature as domain borders are 
not rigid entities.  
 
Figure 4.1. Schematic representation of the amino acid residue distribution of the regulatory domain (blue), 
catalytic domain (green), and tetramerization domain (yellow) of the human aromatic amino acid hydroxylases. 
The numbers indicate the number of amino acid residues in the individual domains. 
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Table 4.1 shows the sequence identities of the three domains in the AAAHs based on the length presented 
in Figure 4.1. The catalytic domains are highly conserved with sequence identities ranging from 60 to 81 %, 
whereas the regulatory and tetramerization domains have significantly lower sequence identities. The TPH 
isoforms are very homologous and both share a higher sequence identity with PAH compared to TH. The 
high sequence identities suggest that the structure and function of the domains in the AAAHs are similar.    
Table 4.1. Sequence identity matrix of the domains in the aromatic amino acid hydroxylases. The values are 
given as % identities in the regulatory / catalytic / tetramerization domains, respectively. Values are obtained 
from Clustal Omega multiple sequence alignments.[140]  
 
TPH1 TPH2 PAH 
TPH2 48 / 81 / 39 
  
PAH 34 / 65 / 12 30 / 66 / 20 
 
TH 21 / 60 / 19 17 / 63 / 15 23 / 64 / 24 
 
4.1.1 Tetramerization domain 
The AAAHs form homotetramers through dimers of dimers.[141] The assembly of subunits into a tetramer is 
accomplished using a common folding motif, in which repeats of hydrophobic residues are positioned in an 
α-helix with a distance of four or three amino acid residues. This 4-3 repeat of hydrophobic residues 
produces a hydrophobic face on the α-helix which can interact with other such helices, forming coiled coils 
through hydrophobic interactions.[142] The 4-3 repeat motif has been identified in the C-terminus of all 
members of the AAAH family.[142,143] 
No full-length crystal structure exists of either of the isoforms of TPH. However, full-length structures rat PAH 
have been published.[144,145] These structures confirm a tetrameric assembly, which is held together by 
coiled coils, Figure 4.2. Crystal structures of the catalytic and tetramerization domains of rat TH [139,146] 
show an identical assembly.  
 
Figure 4.2. Cartoon illustration of the tetrameric structure of full-length rat phenylalanine hydroxylase (PDB 
entry: 5FGJ). Subunits A and B are shown in blue and subunits C and D are shown in green. Iron atoms are 
shown as pink spheres. The zoom-in shows the residues (Leu430, Ile437, Val441, Leu444, and Leu448) of the 4-3 
hydrophobic repeat motif of subunit A. 
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Size exclusion chromatography has shown that both isoforms of TPH elute at volumes corresponding to 
tetramers.[147,148] Because of the high sequence identity of the TPH isoforms with PAH and TH, it is 
expected that they form similar quaternary structures.[149]  
The role of the tetramerization domain has been confirmed by deletion mutant variants of both isoforms. 
Removal of the 4-3 hydrophobic repeat (CΔ17), renders TPH1 incapable of forming tetramers and 
monomers are predominantly found.[147] This is also the case in TPH2, where deletion of 19 residues in the 
C-terminus (CΔ19) results in monomers.[143]  
4.1.2 Regulatory domain 
The N-terminal regulatory domain is the most diverse among the AAAHs. The role of this domain is very 
poorly studied in the case of TPH. However, structural and functional information can be gathered from 
studies of PAH and TH. 
The N-terminal regulatory domains of PAH and TH comprise a characteristic βαββαβ-fold motif, referred to 
as an ACT domain (named after aspartate kinase, chorismate mutase, and TyrA [150]).[151,152] ACT 
domains are present in several proteins and are in many cases involved in regulative mechanisms triggered 
by amino acid binding.[153] Binding of an amino acids to an ACT domain often occurs at domain interfaces 
and results in conformational changes.[154] From sequence analysis, TPH has also been proposed to 
contain an ACT domain. [150,155] 
Compared to the C-terminal domain, the effect of the regulatory domain on the macromolecular assembly is 
less clear. It has been found that the first 41 residues of the N-terminus of TPH1 are necessary for tetramer 
formation, as truncation of these residues (NΔ41) predominantly results in a monomeric form.[156] In 
contrast, it has also been found that the tetrameric assembly was retained upon truncation of the regulatory 
domain of TPH1 (NΔ98).[157] A similar observation has been made for TPH2, where a tetramer is observed 
after truncation of the regulatory domain (NΔ150).[158]  
Isolated regulatory domain of TPH1 (rhTPH1), has been found to forms a stable dimer that does not undergo 
a monomer-dimer equilibrium. Furthermore, it was found that L-phenylalanine had no influence on the 
dimer.[159] Similarly, it has been found that L-tryptophan does not thermally stabilize rhTPH1, suggesting 
that L-tryptophan does not bind the regulatory domain of hTPH1.[138]  
 
Figure 4.3. Crystal structure of human rPAH (PDB entry: 5FII). Cartoon representation of the rhPAH dimeric 
structure, one subunit is colored blue (chain A) and one is colored green (chain C). L-phenylalanine ligands are 
shown in sticks.  
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In PAH, the role of the regulatory domain is more thoroughly studied. Isolated regulatory domain of PAH 
(residue 1 to 117; rPAH) elutes as a dimer from a gel filtration column.[160] This dimer has been crystallized 
with bound L-phenylanine, identifying the binding pocket of L-phenylalanine at the subunit-subunit interface 
of the dimer, Figure 4.3.[138]  
Initial sedimentation velocity experiments of rPAH showed that it undergoes a monomer–dimer equilibrium 
(Keq = 46 ± 35 µM) that is shifted towards dimer in the presence of L-phenylalanine (Kd = 8 µM; obtained 
from global fit with a model including binding of two molecules of L-phenylalanine).[161] NMR experiments 
on isolated regulatory domain of PAH (residue 25 to 117; rPAH) in solution have verified that L-
phenylalanine binds at the interface of the domains.[162] 
4.1.3 Catalytic domain 
The catalytic domain is more thoroughly studied and crystal structures of this domain reside in the protein 
data bank for all the AAAHs (tables with all structures are found in chapter 7). Isolating the catalytic domain 
upon truncation of both the regulatory and tetramerization domains of TPH1 or TPH2 (NΔ101/CΔ28 or 
NΔ150/CΔ24), results in predominately monomer.[158,163] Crystallization of the catalytic domain of TPH1 
has therefore resulted in a monomeric structures.[164,165]  
4.1.4 PAH activation 
In recent years, the purpose of the observed dimerization of the regulatory domains has been unraveled. It is 
well documented that phenylalanine hydroxylase is activated cooperatively by preincubation with L-
phenylalanine.[166] However, different mechanisms have been proposed to explain this cooperative 
activation. It has been proposed that this activation is caused by binding of L-phenylalanine in the active site 
[167,168], an allosteric binding site in the interface of the regulatory and catalytic domains[151,169], or in an 
allosteric site in the interface of two regulatory domains from adjacent subunits in the tetramer. The last 
scenario will be discussed in the following, as recent literature has supported this model.   
As described for isolated regulatory domain, dimerization of regulatory domains is also believed to occur in 
full-length PAH. Two crystal structures of full-length rat PAH were recently published by different 
groups.[145,170] Both structures represent a tetramer which is arranged as a dimer of dimers, placing the 
regulatory domains on each side of the tetrameric assembly, Figure 4.4. Both structures present an auto-
inhibited form in which the N-terminus partially blocks access to the active site, Figure 4.4. Removal of the N-
terminus (NΔ30) in PAH results in increased activity, and preincubation with L-phenylalanine is no longer 
required for activation.[171] These observations confirm the inhibitory role of the N-terminus.  
Jaffe et al.[172], have proposed that PAH exists in equilibrium between a high activity tetramer and a low 
activity tetramer. The interchange between these forms is associated with L-phenylalanine binding in the 
allosteric site in the regulatory domain. It is proposed that L-phenylalanine binding induce a conformational 
change involving a rotation of the regulatory domain with respect to the catalytic domain, allowing two 
regulatory domains to form a dimer. This movement propagate to the N-terminus, which is removed from the 
active site, resulting in increased enzymatic activity, Figure 4.5.[172] This model is supported by a 
hydrogen/deuterium exchange study in which L-phenylalanine was found to alter the interaction between the 
regulatory and catalytic domains.[173] In further support, SEC-SAXS experiments show that L-phenylalanine 
induces rearrangements of the regulatory domains of tetrameric PAH.[145,170] Based on SAXS-curves with 
varied concentration of L-phenylalanine, a binding constant of 174 ± 9 µM was determined [145], in 
agreement with results from a kinetic study of the allosteric activation.[174]   
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Figure 4.4. Cartoon illustration of the tetrameric structure of full-length rat phenylalanine hydroxylase (PDB 
entry: 5FGJ). Regulatory domains are colored blue, catalytic domains are colored green, and tetramerization 
domains are colored yellow. Left: side view of full-length tetramer. Right: One subunit of the tetramer illustrating 
how the N-terminus blocks asses of the active site. BH4 is shown in sticks and is superimposed from the crystal 
structure of the catalytic domain of human PAH (PDB entry: 1J8U).  
 
 
 
 
Figure 4.5. Cartoon illustration of a model structure of tetrameric full-length PAH after binding of L-
phenylalanine in the allosteric site (Theoritical model – supporting information of [172]). Regulatory domains are 
colored blue, catalytic domains are colored green, and tetramerization domains are colored yellow. Left: Side 
view of full-length tetramer model. Right: One subunit of the tetramer model illustrating how the N-terminus is 
removed from the entrance of the active site. 
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In support of an allosteric model, it was been confirmed that activation of rat PAH does not require binding of 
L-phenylalanine in the active site.[145,175] All together, activation of PAH is believed to occur through 
dimerization of the regulatory domains upon binding of L-phenylalanine in the allosteric site, which induces a 
conformational change that displaces the N-terminus from the active site, resulting in increased access of 
the substrate.    
For TPH, it has been found that truncation of the N-terminus of TPH2 (NΔ44-TPH2) resulted in an almost 4-
fold increase in activity compared to full-length TPH2.[143] This suggests an inhibitory function of the N-
terminus similar to the one observed for PAH. As no structural information is available for the regulatory 
domain of the TPH isoforms, it is hard to predict how the N-terminus facilitates this inhibitory function. Based 
on the length of the N-terminal domains of PAH, TPH1, and TPH2 (Figure 4.1), it can be hypothesized that 
the N-terminus of TPH2 might similarly block access to the active site, while the N-terminus of TPH1 is 
unable to, due to insufficient length. This could explain the lower activity of TPH2 compared to TPH1, as the 
46 residue extension of the N-terminus in TPH2 is the main difference between the highly homologous 
enzymes.[176] 
4.2 Experimental procedure - analytical gel filtration 
The oligomeric state of the TPH2 variants was analyzed by performing analytical gel filtration utilizing a 
Superdex 200 10/300 GL column. Before the samples were loaded, the column was equilibrated with two 
column volumes of buffer. For chTPH2, 20 mM HEPES/NH4OH, 100 mM (NH4)2SO4, pH 7.0 was used as the 
buffer solution (referred to as Std buffer) and for rchTPH2 and NΔ47-rchTPH2 20 mM HEPES/NH4OH, 300 
mM (NH4)2SO4, pH 7.0 was used (referred to as Std buffer). When the influence of L-phenylalanine, D-
phenylalanine, or L-tryptophan was investigated, the amino acids were added to the buffer solutions prior to 
column equilibration. When 3 mM L-Phe was added to the buffer solution, it is referred to as Phe buffer. The 
amino acids were similarly added to the TPH samples and allowed to equilibrate for 20 min before loading 
onto the column. Samples were loaded with a 500 µL loop and analyzed at a flow rate of 0.5 mL/min. A 
calibration curve of molecular weight versus elution volume was obtained from GE Healthcare [177].   
The obtained chromatograms were deconvoluted using PeakFit v4.12. The chromatograms were fitted with 
the lowest possible number of peaks, and peaks at elution volumes corresponding to molecular weights 
lower than monomer were not introduces. The peaks were fitted using chromatography and Eval4 Area 
Tailed peak type. Tailed was chosen as even mono-disperse solutions deviate from a perfect Gaussian 
shape. From the areas under the curves of the deconvoluted peaks, the equilibrium dissociation constant, 
Keq, was determined using eq. 1. For derivation of eq.1 see Appendix A.1. 
 
    
      
         
  
                
 (eq. 1) 
In eq. 1 AUCM and AUCD are the areas under the curve of the peaks representing the monomer and dimer, 
respectively. [M]total is the concentration of the loaded sample and DF is the dilution factor. The dilution factor 
during elution was measured by the width at half-height of the peak divided by the sample load volume [178]. 
This was performed only on mono-disperse solutions. The mole fraction of dimer, fD, at a specific 
concentration of TPH, was determined from eq. 2. For derivation of eq. 2 see Appendix A.1. 
 
   
 
 
   
        
         
    
        
        
  
  
        
  
 (eq. 2) 
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4.3 Results – oligomeric state of hTPH2 variants 
In chapter 2, hTPH2 was found to elute as a tetramer, with no evidence of dimer or monomer. In this section, 
analytical gel filtration results of variants with deletion of the tetramerization domain (CΔ31), rchTPH2, NΔ47-
rchTPH2, and chTPH2, are presented and discussed. In chapter 3, it was discussed how L-phenylalanine 
and L-tryptophan increased the thermostability of rchTPH2 and NΔ47-rchTPH2 and resulted in a two-state 
unfolding behaviors typically observed for mono-disperse samples. In the following, the influence of the 
thermostabilizing ligands on the oligomeric states of the TPH variants lacking the tetramerization domain are 
investigated.  
4.3.1 Analytical gel filtration – chTPH2  
The results of analytical gel filtration of chTPH2 in either Std buffer or Phe buffer are presented in Figure 4.6 
as black or orange peaks, respectively.  
 
Figure 4.6. Size exclusion chromatography of chTPH2, with no ligand (black) and with the addition of 3 mM L-
phenylalanine (orange). The markers (▲) indicate the expected elution volumes of a dimer and a monomer, 
respectively.[177] Protein loading concentrations are indicated in the chromatograms. A: High loading 
concentration range. B: Low loading concentration range. 
The chromatogram in Figure 4.6 shows that chTPH2 elutes at a volume of ~16 mL corresponding to the 
molecular weight of a monomer (36.2 kDa). chTPH2 was found to elute as a monomer independent of 
loading concentration ranging of 2 to 60 µM. Furthermore, 3 mM L-phenylalanine did not induce any change 
in the elution pattern of the mono-disperse solution.   
To test if there was a saturation of the UV-detector, the maximum UV absorbance as a function of loading 
concentration was analyzed. In Figure 4.7 the correlation between loading concentrations of chTPH2 in Phe 
buffer and peak heights (maximum absorption) is shown. The peak heights were found to be related directly 
to the loading concentration, which means that saturation of the detector does not occur. This was also the 
case for chTPH2 in Std buffer and NΔ47-rchTPH2 in Phe buffer (Appendix F.1 and F.2).  
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Figure 4.7. Max height of elution peak (max UV280nm response) as a function of chTPH2 loading concentration.  
During loading, separation, and elution the concentration of protein will be lowered by a dilution factor 
compared to the loading concentration. To know the actual concentration of TPH on the column the dilution 
factor was calculated as width at half-height of the peak divided by the sample load volume.[178] The dilution 
factors calculated from analytical gel filtrations of chTPH2 in Std or Phe buffer and NΔ47-rchTPH2 in Phe 
buffer are presented in Table 4.2.The dilution factor was calculated based on those chromatograms, as they 
resulted in mono-disperse samples (only one peak, Figure 4.6 and Figure 4.8). The dilution factor is on 
average 1.9 ± 0.1 and is not dependent on the loading concentration. 
Table 4.2. Dilution factor of samples loaded on a Superder200 10/300 GL column. Dilution factors calculated 
from width at half-height (mL) divided by loading volume (mL). Std and Phe for chTPH2 refers to 20 mM 
HEPES/NH4OH, 100 mM (NH4)2SO4, pH 7.0 or 20 mM HEPES/NH4OH, 100 mM (NH4)2SO4, 3 mM L-phenylalanine, 
pH 7.0, respectively. Phe for NΔ47-rchTPH2 refers to 20 mM HEPES/NH4OH, 300 mM (NH4)2SO4, 3 mM L-
phenylalanine, pH 7.0 
Loading conc. chTPH2 (Std) chTPH2 (Phe) NΔ47-rchTPH2 (Phe) 
(µM) Dilution factor 
60.0 2.0 1.9 1.9 
20.0 1.9 1.9 1.8 
10.0 1.8 1.9 1.8 
5.0 1.8 1.8 2.0 
3.5 1.7 1.7 2.0 
2.0 1.8 1.8 2.1 
4.3.2 Analytical gel filtration – NΔ47-rchTPH2  
The results of analytical gel filtration of NΔ47-rchTPH2 in either Std buffer or Phe buffer are presented in 
Figure 4.8 as black or orange peaks, respectively. In the absence of L-phenylalanine the chromatogram of 
NΔ47-rchTPH2 results in two overlapping peaks with elution volumes of ~13 and ~15 mL corresponding to 
molecular weights of a dimer (94.9 kDa) and monomer (47.4 kDa), respectively. The elution peaks are 
gradually shifted from predominantly dimer to a mixture of monomer and dimer with decreasing loading 
y = 1.00x + 0.59 
R² = 1.00 
0.5 
1.0 
1.5 
2.0 
2.5 
0.0 0.5 1.0 1.5 2.0 
L
o
g
(m
a
x
 U
V
 a
b
o
rb
a
n
c
e
 a
t 
2
8
0
 n
m
) 
m
A
U
 
Log(loading concentration) µM 
43 
 
concentration. This illustrates that NΔ47-rchTPH2 is in a concentration-dependent monomer-dimer 
equilibrium.  
 
Figure 4.8. Size exclusion chromatography of NΔ47-rchTPH2 without added L-Phe (black lines) and with added 
L-Phe (orange lines). The markers (▲) indicate the expected elution volume of (from left to right) a tetramer, a 
dimer, and a monomer, respectively.[177] Protein loading concentrations are indicated in the chromatograms. A: 
High loading concentration range. B: Low loading concentration range. 
As the peaks in Figure 4.8 are not baseline separated, the chromatograms were deconvoluted. To assess 
the relative amounts of monomer and dimer the AUCs of the peaks were calculated based on the 
deconvoluted chromatograms. Figure 4.9 shows an example of a deconvoluted chromatogram of NΔ47-
rchTPH2 with a loading concentration of 2 µM. 
 
Figure 4.9. PeakFit deconvolution of the chromatogram of NΔ47-rchTPH2 (2 µM) in 20 mM HEPES/NH4OH, 300 
mM (NH4)2SO4, pH 7.0. The solid line represents data and dashed lines represent deconvoluted peaks.  
From the extracted AUCs, while taking the determined dilution factor into account, the monomer-dimer 
equilibrium dissociation constant, Keq, can be determined using eq. 1. The equilibrium dissociation constants 
calculated from the six loading concentrations of NΔ47-rchTPH2 are presented in Table 4.3. 
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Table 4.3. Equilibrium dissociation constant, Keq, of the dimerization of NΔ47-rchTPH2 in 20 mM HEPES/NH4OH, 
300 mM (NH4)2SO4, pH 7.0 determined at different loading concentrations. 
Loading conc. (µM) Kd (µM) 
60.0 1.28 
20.0 1.15 
10.0 1.36 
5.0 1.26 
3.5 1.27 
2.0 1.30 
From Table 4.3, an average Keq-value of 1.3 ± 0.1 µM can be calculated for the dimerization of NΔ47-
rchTPH2 in absence of L-phenylalanine. The mole fraction of dimer, fD, at a specific NΔ47-rchTPH2 
concentration can be calculated from the determined concentration of monomer and dimer. fD as a function 
of NΔ47-rchTPH2 concentration is presented in Figure 4.10. The same dissociation constant of 1.3 µM can 
be obtained from a nonlinear regression of the data in Figure 4.10 with eq. 2. 
 
Figure 4.10. Fraction of dimer as a function of NΔ47-rchTPH2 concentration (loading concentration divided by 
dilution factor). The solid line represents the nonlinear regression with equation 2. 
The effect of L-phenylalanine on the monomer-dimer equilibrium was analyzed by performing analytical gel 
filtration on NΔ47-rchTPH2 samples with addition of 3 mM L-phenylalanine. The results are presented in the 
chromatogram in Figure 4.8 (orange peaks). It is evident that the presence of 3 mM L-phenylalanine shifts 
the monomer-dimer equilibrium towards dimer. The dimerizing effect of L-phenylalanine is obvious at a 
loading concentration of 2 µM NΔ47-rchTPH2. Here the equilibrium is shifted from predominately monomer 
to almost exclusively dimer. A Keq-value of 0.2 ± 0.1 µM was obtained for the dimerization of NΔ47-rchTPH2 
in the presence of 3 mM L-phenylalanine. Only loading concentrations of 2, 3.5, 5, and 10 µM were used to 
calculate this value, as no monomer was observed upon deconvolution of the chromatograms of loading 
concentrations 20 and 60 µM.  
The concentration dependency of L-phenylalanine was analyzed by performing analytical gel filtration on 
NΔ47-rchTPH2 with a loading concentration of 2 µM at varied concentrations of L-phenylalanine. Results 
with 1, 2, and 3 mM L-phenylalanine are presented in Figure 4.11. The dimerizing effect of L-phenylalanine 
is obvious as the equilibrium is shifted towards dimer with increase concentration. Keq-values of 1.2, 0.7 and 
0.2 µM were obtained for 1, 2, and 3 mM L-phenylalanine, respectively.  
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Figure 4.11. Size exclusion chromatography results of NΔ47-rchTPH2 with 1 mM L-phe (dashed line), 2 mM L-
phe (solid line), or 3 mM L-phe (dotted line). 
In chapter 3, L-tryptophan was found to increase the thermostability of NΔ47-rchTPH2, while D-
phenylalanine had no influence on the stability. To see if this correlates with a dimerizing effect, analytical gel 
filtrations of NΔ47-rchTPH2 were conducted in the presence of 0.5 and 1.0 mM L-tryptophan and 3 mM D-
phenylalanine. The results are presented in Figure 4.12.    
The influence of L-tryptophan at 3 mM could not be studied by analytical gel filtration with a UV-Vis detector 
because the absorption by L-tryptophan overlaps with that of the protein (primarily tryptophan). This results 
in high background noise, which limits the measurements to either high protein concentrations or low L-
tryptophan concentrations. As a consequence, the influence of L-tryptophan was investigated at 0.5 and 1 
mM. Even at these concentrations a lot of noise is observed in the chromatograms, Figure 4.12 B and C. 
Due to noise limitations, measurements at 1 mM L-tryptophan with NΔ47-rchTPH2 concentrations lower than 
5 µM could not be conducted.  
 
Figure 4.12. Size exclusion chromatography results of NΔ47-rchTPH2 with L-tryptophan or D-phenylalanine. 
Protein loading concentrations are indicated in the chromatograms. The markers (▲) indicate the expected 
elution volumes of a tetramer, a dimer, and a monomer, respectively. A: High loading concentration range with 
addition of 0.5 mM L-tryptophan (blue) or 3 mM D-phenylalanine (red). B: Low loading concentration range with 
addition of 0.5 mM L-tryptophan (blue) or 3 mM D-phenylalanine (red).  C: Addition of 1 mM L-tryptophan.  
From Figure 4.12 A and B it is evident that 0.5 mM L-tryptophan or 3 mM D-phenylalanine do not shift the 
equilibrium to predominantly dimer as observed for 3 mM L-phenylalanine. From the monomer-dimer 
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distribution obtained at the six concentrations of NΔ47-rchTPH2, dimerization Keq-values of 1.6 ± 0.7 µM and 
1.8 ± 0.9 µM were determined for L-tryptophan and L-phenylalanine addition, respectively. Hence, neither 3 
mM D-phenylalanine nor 0.5 mM L-tryptophan have a significant impact on the monomer-dimer equilibrium.  
In the chromatograms of NΔ47-rchTPH2 in the presence of 1 mM L-tryptophan (Figure 4.12 C) significant 
levels of noise are present. However, based on the elution volumes it seems that the majority of the protein 
is present as monomer at loading concentrations of 5 and 10 µM.   
4.3.3 Analytical gel filtration – rchTPH2  
The results of analytical gel filtration of rchTPH2 in either Std buffer or Phe buffer are presented in Figure 
4.13 as black or orange peaks, respectively. As for NΔ47-rchTPH2, the monomer-dimer equilibrium of 
rchTPH2 is found to shift significantly towards dimer in the presence of 3 mM L-phenylalanine. This result 
demonstrates that the effect of L-phenylalanine does not involve the N-terminus.    
 
Figure 4.13. Size exclusion chromatography of rchTPH2 (loading concentration of 2 µM), with no ligand (black 
line) and with the addition of 3 mM L-Phe (orange line). The markers (▲) indicate the expected elution volumes 
of a tetramer, a dimer, and a monomer, respectively. 
4.3.4 Analytical gel filtration – chTPH mutant variants  
In chapter 7, a mutational study is conducted on an active site loop of both TPH isoforms. Here, point 
mutations of residue 125 in chTPH1 and 171 in chTPH2 were conducted. To assure that the mutations did 
not result in changes in the oligomeric state of the catalytic domain of the TPH isoforms analytical gel 
filtration was performed.  
The chromatograms display that all TPH variants of the two isoforms are monodisperse, Figure 4.14. The 
chTPH1 variants elute at volumes from 15.5 to 15.6 mL (n=3) while the chTPH2 variants from 15.7 to 15.8 
mL (n=3) (data found in Appendix F.3). These results show that all the TPH variants reside as monomers 
and that no significant changes within each variant occur as a consequence of mutation. Despite the slightly 
higher molecular weights of the chTPH2 variants (36274 to 36362 Da) compared to chTPH1 counterparts 
(36128 to 36250 Da), they elute at a slightly greater elution volume, which indicate that the chTPH2 variants 
are more compact.  
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Figure 4.14. Normalized size exclusion chromatography results of the chTPH variants. 
4.4 Discussion 
Full-length TPH2 exists as tetramers with no sign of dimer or monomer. In this study, deletion of the 
regulatory and tetramerization domains resulted in a mono-disperse solution with retention volume 
corresponding to the molecular weight of a monomer. This finding is in consensus with previous studies on 
the catalytic domain of TPH.[157,158,179] When only the tetramerization domain is deleted, a concentration-
dependent monomer-dimer equilibrium is established. This result demonstrates that the dimerization is 
caused by the regulatory domain as chTPH2 was found only as a monomer.  
The equilibrium dissociation constant of the dimerization of NΔ47-rchTPH2 was determined to 1.3 ± 0.1 µM. 
This value is lower than 46 ± 35 µM determined for the dimerization of the regulatory domain of PAH.[161] 
The lower value might be explained by the presence of the catalytic domain. Two C-terminal β-strands in the 
catalytic domain of PAH have been found to be important for dimer formation.[180] These β-strands are also 
present in the C-terminal of the cataltyic domain of TPH2. The strands are found buried at the interface 
between two catalytic domains in the crystal structyre of cthTPH2 (PDB entry: 4V06). 
The ability of the regulatory domain to facilitate dimerization in a TPH variant containing the catalytic domain 
has not previously been studied. Very little is known in regards to the regulatory domain and there is no data 
available in the literature on dimerization of isolated regulatory domain of TPH2. However, isolated 
regulatory domain of TPH1 forms a stable dimer.[138,159] This observation together with the results 
obtained for NΔ47-rchTPH2 indicate that the regulatory domain of TPH might be involved in a dimerization 
mechanism similar to the one observed for PAH. The result of dimerization in PAH has been hypothesized to 
be the origin of the cooperative L-phenylalanine activation mechanism.[172] No evidence has been 
presented for a similar cooperative activation of TPH. This leaves the question of whether the observed 
dimerization in TPH2 is in vivo relevant or just an inherited trade which can only be detected in vitro. 
In chapter 3, it was demonstrated that NΔ47-rchTPH2 was thermostabilized by L-phenylalanine but not by D-
phenylalanine. In agreement with these observations, this chapter demonstrates that of the two 
stereoisomers of phenylalanine only L-phenylalanine caused a shift in the monomer-dimer equilibrium. The 
DSF results with L-phenylalanine showed that the unfolding of NΔ47-rchTPH2 was changed from polyphasic 
to two-state. Such a change has previously been shown in a DSF study to indicate increased mono-
dispersity and stability.[181] This correlates well with a change from a mixture of monomer and dimer to 
exclusively dimer.  
The fact that only one stereoisomer of phenylalanine induces dimerization and thermostabilization suggests 
that it is caused by specific binding of phenylalanine rather than its amphiphilic nature. The binding affinity of 
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this specific binding must, however, be very low as 3 mM is required to obtain complete dimerization. Low 
affinity is also observed in full-length PAH as a Kd-value for L-phenylalanine binding in the allosteric site is 
174 ± 9 µM and 1 mM is required for full effect.[145] One could speculate that L-phenylalanine is not the 
most potent ligand for allosteric binding in TPH. The more obvious ligand would be L-tryptophan which was 
also found to thermostabilize NΔ47-rchTPH2 and induce two-state unfolding at concentration <1 mM. 
However, tryptophan did not induce a change in the monomer-dimer equilibrium at concentration of 1 mM. 
This suggests that stabilization occurs through a different mechanism.  
In a study by Patel et al., it was demonstrated that, among the regulatory domains of TH, PAH, and TPH1, 
only PAH is thermostabilized by its natural substrate.[138] This suggests that only the regulatory domain of 
PAH binds substrate. Furthermore, the oligomeric state of rhTPH1 was not influenced by L-Phe (1 mM).[159] 
In line with these results, analytical gel filtration on NΔ47-rchTPH2 shows that L-tryptophan most likely does 
not bind in the regulatory domain of TPH2, whereas L-phenylalanine does. This indicates that TPH2 might 
have an allosteric site in the regulatory domain that TPH1 does not have. This hypothesis is supported by 
observations from TPH purifications (chapter 2), where it was found that purification yields were significantly 
increased for TPH2 variants containing the regulatory domain, whereas the yield of the TPH1 variants were 
not influenced. However, it might also be the case that only TPH2 is able to bind phenylalanine in the 
regulatory domain, but both isoforms are able to bind a so far unknown ligand.  
Phylogenetically PAH and TPH2 are related [182] which might mean that TPH2 has just retained the ability 
to bind L-phenylalanine in the regulatory domain. This cannot be ruled out, however, the affinities of PAH 
and TPH2 for L-phenylalanine are presumably not very different which implies an importance of the 
conserved site. 
TPH is able to catalyze hydroxylation of L-phenylalanine [163], which means that it binds in the catalytic site. 
L-phenylalanine did not cause dimerization of the catalytic domain; however, it opens up the possibility that 
active site binding somehow affects the regulatory domain. To confirm that dimerization is not induced by 
active site binding more experiments have to be conducted. Studies should be conducted on isolated 
regulatory domain of TPH2. If L-phenylalanine induces dimerization or increase Tm for this variant, the 
allosteric binding site hypothesis would be strengthened. Alternatively, mutations of substrate binding 
residues would diminish active site binding, and dimerization experiments on this mutant variant could reveal 
whether active site binding was involved.   
4.5 Conclusion 
In this chapter, it is demonstrated that isolated catalytic domain of hTPH2 exists as a monomer while the 
presence of the regulatory domain induces a monomer-dimer equilibrium with a Keq-value of 1.3 µM. This 
equilibrium is shifted significantly towards dimer in the presence of 3 mM L-phenylalanine resulting in a 
mono-disperse solution. Of the two stereoisomers of phenylalanine, only L-phenylalanine induces 
dimerization which demonstrates that the change in equilibrium is caused by specific binding.   
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5 Reaction mechanism of TPH 
This chapter concerns the reaction mechanism of the TPH isoforms. In chapter 1, it was introduced how TPH 
catalyzes the reaction of tryptophan to 5-hydroxytryptophan utilizing 6R-L-erythro-5,6,7,8-tetrahydrobiopterin 
(BH4) and O2. In the following, a more detailed reaction mechanism including the role of BH4 and iron will be 
presented. 
During conversion from a substrate to a product, one or more reaction intermediates are formed transiently. 
During a 3 month research stay in Prof. Edward I. Solomon’s group at Stanford University, stopped-flow 
kinetic experiments were conducted on chTPH2 in pursuit of such reaction intermediates. Stopped-flow 
absorbance spectroscopy will be introduced, and results obtained utilizing this method will be presented and 
discussed. 
 
 
 
 
 
 
 
5.1 The reaction mechanism of TPH 
The TPH isoforms are nonheme iron-dependent monooxygenases which catalyze the insertion of one 
oxygen atom from O2 into the aromatic ring of tryptophan. In this process, BH4 accepts the second oxygen 
atom from O2, forming 4a-hydroxy-BH4, Figure 5.1.[183] 4a-hydroxy-BH4 has been observed in the reaction 
of all the AAAHs [184-186], and it is believed that the enzymes share a common catalytic mechanism of 
hydroxylation.[187] 4a-hydroxy-BH4 is converted to qBH2 which in turn is reduced back to BH4, as described 
in chapter 1. 
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Figure 5.1. Schematic illustration of the TPH catalyzed reaction.  
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The reaction in Figure 5.1 is believed to occur through two consecutive steps; reaction between the active 
site Fe
II
, O2, and BH4 to form a reactive hydroxylating intermediate, followed by hydroxylation of tryptophan. 
The hydroxylating intermediate in the first part of the reaction is believed to be a ferryl oxo species (Fe
IV
O), 
as Fe
IV
 has been observed experimentally in the reactions of TH and PAH.[188,189]  
Preceding the formation of Fe
IV
O, the reaction is believed to occur through a Fe
II
-peroxypterin intermediate, 
Figure 5.2.[190] Such an intermediate is attractive because heterolytic cleavage of the oxygen-oxygen bond 
would result in 4a-hydroxy-BH4 and Fe
IV
O directly. The presence of such an intermediate is supported by a 
study of PAH with tyrosine as substrate. Here, unproductive consumption of BH4 and O2 results in H2O2 
which is consistent with the breakdown of a peroxypterin intermediate.[191,192] This intermediate has never 
been isolated experimentally, however, evidence of an intermediate species preceding the formation of 
Fe
IV
O has been detected for the TPH1 catalyzed reaction.[193]  
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Figure 5.2. Scheme illustrating the reaction of Fe
II
, O2, and BH4 to yield Fe
IV
O and 4a-hydroxy-BH4 through a Fe
II
-
peroxypterin intermediate.  
In the second half of the reaction, the electrophilic Fe
IV
O intermediate undergoes a nucleophilic attack from 
the aromatic ring of tryptophan which results in formation of a C-O bond, Figure 5.3.[188] The aromaticity of 
the ring is restored by a 1,2-hydride shift followed by a loss of a hydrogen to yield 5-HTP.[186]  
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Figure 5.3. Scheme illustrating the mechanism by which tryptophan is hydroxylated by the Fe
IV
O intermediate. 
5.2 Stopped-flow absorbance spectroscopy 
Stopped-flow absorbance spectroscopy is a useful method to investigate the kinetics of a reaction in a 
timescale of milliseconds to seconds.[194] In this time range, detailed information of a reaction pathway can 
be obtained. If e.g. a reaction intermediate has unique spectral properties, its formation and decay can be 
monitored providing time-resolved information on the reaction.  
In stopped-flow absorbance spectroscopy, two reactants are expelled from a set of syringes into a mixer 
where the reaction is initiated. This reaction mixture is rapidly transferred into an observation cell which is 
irradiated with a light source. The absorption of the mixture in the observation cell is measured as a function 
of time by an absorbance detector, e.g. photodiode array detector, Figure 5.4.[195] 
The data produced in a stopped-flow experiment comprise progress curves of the monitored molecular 
processes. The analysis of such progress curves for a reaction can yield rate constants of the molecular 
processes. Under pseudo-first-order conditions (the monitored reactant is in great excess over the other 
reactant) the kinetic traces can be fitted to an exponential function or a sum of exponential functions, and the 
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observed rate constant(s), kobs, can be determined. The rate constant can then be obtained from the slope of 
the linear plot of kobs versus ligand concentration.[195]    
 
Figure 5.4. Schematic diagram of a stopped-flow absorbance spectroscopy setup. 
5.3 Stopped-flow kinetics of the AAAHs 
The reaction mechanisms of TH, PAH, and TPH1 have been investigated utilizing stopped-flow absorbance 
spectroscopy. In most studies, the ternary complex, E•Fe
II
•pterin•substrate, is mixed under single-turnover 
conditions with an O2 solution to initiate the reaction. The reaction is then followed by continuously 
measuring the absorbance at various wavelengths as the reactants and intermediates have distinctive 
absorbance spectra. 
Utilizing stopped-flow kinetic experiments, the reaction of rat TH was fit to a model comprising the 
consecutive steps; reversible binding of O2, formation of 4a-hydroxy-6MePH3 (6MePH4 is a BH4 analogue), 
formation of DOPA from tyrosine, and dehydration of 4a-hydroxy-6MePH3 to q-6MePH2.[196] Another study 
on rat TH supported this model and furthermore found that kcat depends on the viscosity of the medium, 
suggesting that product release is the rate-limiting step in the reaction.[197] 
In a stopped-flow kinetic study of rabbit cTPH1, it was found that the first events in the reaction upon mixing 
TPH•Fe
II
•6-MePH4•tryptophan with oxygen were reversible O2 binding, followed by the formation of a 
transient intermediate with maximal absorbance at 420 nm.[193] Furthermore, the rate of decay of the 
intermediate matched the rate of formation of 4a-hydroxy-6-MePH4, suggesting that the intermediate 
precedes formation of Fe
IV
O. A rapid-quench technique was used to determine the rate of 5-
hydroxytryptophan (5-HTP) formation. Formation of 5-HTP comprised a burst-phase followed by slow 
steady-state phase which is presumably limited by the rate of product release.  
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Evidence of such an intermediate is supported by a study of rat PAH.[198] Here, stopped-flow kinetics was 
used to monitor binding events prior to formation of the ternary complex. This was achieved by monitoring 
absorption changes at different combinations of PAH, BH4, and phenylalanine in the absence of O2. It was 
found that the first steps in the reaction are binding of BH4, followed by phenylalanine and then reversible 
binding of O2. In a similar study of bacterial PAH, the reaction mechanism was found to be initiated by 
random binding order of pterin and phenylalanine, favored by pterin binding first, followed by binding of 
O2.[199] 
5.4 Experimental procedure 
The TPH samples for the stopped-flow experiments were prepared anaerobic in a glovebox. The 
concentration of the TPH sample was determined by UV-vis absorption with ε280 = 39310 M
-1
 cm
-1
. The 
sample was added two equivalents of freshly prepared sodium dithionite to reduce the active site iron. The 
dithionite was removed by buffer exchange using centrifugation with 10 kDa filters. After buffer exchange, 
the protein concentration was determined and diluted to the desired concentration with a buffer solution 
comprising 150 mM HEPES/NaOH, 100 mM (NH4)2SO4, 20 w/v% sucrose, pH 7.0. 
Stopped-flow experiments were conducted using an Applied Photophysics SX20 stopped-flow absorption 
spectrophotometer (~2 ms dead time and cell path length of 1 cm) equipped with a Hg/Xe Arc lamp and 
outfitted with PEEK tubing. The temperature was maintained at 4 °C using a water temperature bath (Fisher 
Scientific Isotemp 3016). The experiments were performed in an anaerobic glovebox. Both drive syringes of 
the stopped-flow instrument were degassed with 50 mM sodium dithionite for ~2 h and washed with 
anaerobic water and buffer solution.  
To the anaerobic protein samples, tryptophan and BH4 were added in concentrations corresponding to 0.95 
mole equivalents. The O2-solutions were prepared by mixing an O2-saturated buffer solution with an 
anaerobic buffer solution. The O2 saturated solution (~2 mM) was prepared by sparging a buffer solution with 
O2 in an ice bath for >30 min. The ternary complex (125 µM) was loaded into one drive syringe and a buffer 
solution with a desired O2 concentration was loaded into the other. The absorption was monitored with a 
photodiode array detector. 
5.5 Stopped-flow kinetic results – chTPH2 
Stopped-flow kinetic experiments were conducted on chTPH2 in pursuit of a reaction intermediate preceding 
formation of 4a-hydroxy-BH4. The initial results from this experiment revealed that a transient species with a 
strong absorption peak with maximum at 442 nm was formed, Figure 5.5 A and B. BH4 and 4a-hydroxy-BH4 
do not have any absorbance peaks in the range of > 440 nm.[200] Hence, at wavelengths greater than 440 
nm the spectral changes of these species do not interfere with the spectrum of the intermediate. The time-
resolved spectrum in Figure 5.5 C provides a clear evidence for the formation and decay of an intermediate.   
To investigate the O2-dependence of the rates of formation and decay of the intermediate, the stopped-flow 
experiment was repeated with different concentrations of oxygen, Figure 5.6 A. The O2 concentration was 
varied from 16 to 500 µM (0.25 to 8 mole equivalents). At all O2 concentrations, the change in absorbance at 
442 nm as a function of time is biexponential. The time traces in Figure 5.6 A were therefore fitted with eq. 1;  
       
           
        (eq. 1) 
where At is absorbance at a given time, Ai (i=1,2) is the amplitude of the phase, and ki,obs (i=1,2) is the 
observed rate constant of the phase at a given O2 concentration. Figure 5.6 A shows that eq. 1 fits very well 
to the kinetic data, except for the absorbance trace at 500 µM O2 which deviates at around 1 sec. From the 
fits, k1,obs and k2,obs values were extracted at the various O2 concentrations and plotted in Figure 5.6 B.  
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Figure 5.5. Stopped-flow kinetic results of 125 µM chTPH2 in 150 mM HEPES/NaOH, 100 mM (NH4)2SO4, 20 w/v%, 
pH 7.0. In the assay the concentrations of Trp, BH4, and O2 were 120, 120, and 250 µM, respectively. A: 3D plot of 
raw data acquired from a single experiment. B: Replot of data in A at only three time values. Dashed lines 
represent chosen wavelengths where significant changes in the spectra were observed. C: Time traces of the 
selected wavelengths in B. 
To obtain the actual rate constants, the data in Figure 5.6 B was fitted with eq. 2 and eq. 3.[198,201,202] Eq. 
2 describes a direct correlation between the observed rate constants and the concentration of O2, which 
corresponds to a simple second-order reaction where k1 and k-1 are rate constants of the forward and 
reverse reactions, respectively. Eq. 3 describes a rapid initial binding event, which does not induce a change 
in absorption, followed by a reaction, where k1, k-1, and Kd are the rate constants of the forward and reverse 
reactions and the dissociation constant, respectively. 
                 (eq. 2) 
 
         
      
       
 (eq. 3) 
Fitting the k1,obs–values (closed circles) of intermediate formation with eq. 3 resulted in a significantly better fit 
compared to eq. 2 (p < 0.05, F-test). The fit resulted in k1 and k-1 values of 17.1 M
-1
s
-1
 and 7.5 s
-1
, 
respectively, and a Kd-value of 0.4 mM. This implies that the steps in the formation of the intermediate are 
reversible O2 binding followed by a reaction between O2 and presumably BH4 and Fe
II
.  
The observed rate constants of the decay of the intermediate, k2obs, showed a linear dependence on the O2 
concentration, Figure 5.6 B (open circles). The linear relation suggests that the decay of the intermediate 
occur via a simple second-order reaction. By fitting with eq. 2, k2 and k-2-values of 4.0 M
-1
s
-1
 and 0.65 s
-1
 
were obtained, respectively. 
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Figure 5.6. Stopped-flow traces showing the formation of an intermediate in the reaction of chTPH2. A: Baseline 
subtracted kinetic traces measured at 442 nm at different O2 concentrations. B: Rate constants derived with eq. 
1, for the two phases at the various O2 concentrations. The measurements were conducted at 62.5 µM chTPH2, 
60 µM tryptophan, and 60 µM BH4 in 150 mM HEPES/NaOH, 100 mM (NH4)2SO4, 20 w/v%, pH 7.0. 
5.6 Discussion 
The reaction mechanisms of the AAAHs have been studied extensively. Despite great efforts, the first half of 
the reaction mechanism involving formation of Fe
IV
O remains elusive. A reaction intermediate which 
precedes the formation of the observable 4a-hydroxy-BH4 has been proposed in several studies.[183,187] 
The first evidence of such an intermediate was presented by Pavon et al.[193] This species displayed a 
maximum absorbance at 420 nm and an extinction coefficient of only 220 M
-1
 cm
-1
 at this wavelength. The 
identity of this species is undetermined but Fe-peroxy-6-MePH4 is a plausible candidate.  
In the present study, the presence of a transient species with a strong absorption feature at ~440 nm was 
identified. BH4, 4a-hydroxy-BH4, and q-BH2 do not have any absorption features above ~400 nm.[200,203] 
This strongly suggests that the observed transient species is a reaction intermediate preceding the formation 
of 4a-hydroxy-BH4 and hence also Fe
IV
O.  
The fit of the hyperbolic saturation curve observed for the rate constants of formation suggests that the 
reaction of the intermediate consists of an O2 binding step followed by reaction of O2 with presumably Fe
II
 
and BH4. This observation is in agreement with the proposed reaction mechanism of rabbit TPH1, rat TH, 
and PAH from rat and chromobacterium violaceum.[183,193,197,199] 
In the current study, very high yield of the intermediate was obtained. A change in absorption monitored at 
442 nm was measured to as much as ~0.4 absorption units during the reaction. This is ~40-fold greater than 
the change in absorbance observed in the study by Pavon et al [193], which suggests that significantly 
higher yield was obtained under the conditions chosen in this current study. The difference in absorption and 
probably yield might be explained by choice of e.g. TPH variant and co-substrate. In the current study, 
chTPH2 was investigated together with the natural co-substrate BH4. In the study by Pavon et al. [193], 
rabbit cTPH1 was used together with the co-substrate analogue 6-MePH4.      
The identity of the intermediate is still undetermined but Fe
II
-peroxy-BH4 is a likely candidate. The high yield 
obtained in this study enables isolation of the intermediate by rapid freeze-quench techniques. By isolating 
the intermediate, its identity can conclusively be determined by e.g. raman spectroscopy.  
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5.7 Conclusion 
The reaction mechanisms of especially PAH and TH have been studied extensively, and consensus it that a 
transient species if formed prior to formation of 4a-hydroxy-BH4. This transient species is hypothesized to be 
Fe
II
-peroxy-BH4, however, this has never been verified experimentally. In this chapter, it was demonstrated 
that under the chosen conditions for chTPH2, the transient intermediate is formed in quantities sufficient for 
characterization by e.g. raman spectroscopy. The identity of the intermediate is still undetermined. However, 
the presented results promote future identification of the intermediate. 
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6 Steady-state kinetic mechanism 
Enzyme kinetics is a fundamental part of enzymology and deals with the rates of enzyme catalyzed 
reactions. In enzyme kinetics, it is possible to deduce a kinetic mechanism of the reaction by measuring the 
initial reaction velocities at variable substrate and product concentrations. The kinetic mechanism is the 
order of which substrates bind the enzyme and products leave the enzyme. Knowing the mechanism of an 
enzyme gives great insight into how it works and helps to predict how the enzyme behaves and is controlled 
in living organisms.  
In this chapter, general enzyme kinetics is discussed and more advanced kinetic mechanisms and velocity 
equations are presented. The activity assay for determining initial rates of TPH is introduced and the 
experimental procedure is presented. Steady-state kinetic data for chTPH1 is presented and kinetic models 
are fitted to the observed data and discussed in detail. Some of the results presented in this chapter have 
been included in a submitted manuscript. (Appendix A.2)   
 
 
 
 
 
6.1 Kinetic analysis 
The simplest kinetic model of an enzyme catalyzed reaction involving a single substrate may be represented 
by the mechanism:  
 
This model can be analyzed with the Michaelis-Menten equation (eq. 1) which is applicable under steady-
state conditions.[204] Here, v0 is initial velocity, [S] is the initial substrate concentration, Vmax is velocity at 
saturated [S], Km is a constant that describe the substrate concentration as which the reaction rate is half of 
Vmax. 
 
   
       
       
 (eq. 1) 
Chapter 6 
Outline 
6.1    Kinetic analysis………………….…………………………….……………………..………………………. 
6.2    Steady-state kinetics of chTPH1………………………………………………..................................... 
6.3    Discussion of kinetic results…………………………………………………………...……………………. 
6.4    Conclusion………………………………………………………………………………...………………….. 
6.5    References…………………………………………………………………………………..………….……. 
59 
65 
75 
77 
77 
 
 
60 
 
 
   
       
       
    
  
 
 
(eq. 2) 
Steady-state is reached when the ES complex is formed and decomposed at the same rate and occurs 
shortly after mixing enzyme and substrate, and constitutes the time interval when the rate of reaction is 
constant with time. If the concentration of S is much greater than E, the concentration of free S will be 
approximately equal to the total substrate added. Hence during the time period of the measurement, the 
concentration of the ES complex is approximately constant. As the initial rate is measured, the reverse 
reaction of product formation can be ignored.[205] At a fixed low concentration of enzyme, a series of 
experiments in which only [S] is varied can be conducted. Under these conditions, the initial reaction velocity 
will increase until it reaches a substrate independent velocity. From this type of data, Vmax and Km can be 
determined by fitting eq. 1 to the rate as a function of [S]. In cases where S binds an unproductive form of 
the enzyme, substrate inhibition will be apparent. If substrate inhibition occurs at elevated concentration of S, 
eq. 2 can be utilized, where Ki is the substrate inhibition constant.[206] The values of Vmax, Km, and Ki will be 
apparent values in the case of multi-substrate enzymes. 
6.1.1 Multi-substrate reactions 
In multi-substrate enzymes, Vmax and Km can only be determined if saturation is reached for all substrates. 
This is often not possible and apparent values are determined instead. These values will depend on the 
concentration of the fixed substrates. When multiple substrates are involved in a reaction, more complicated 
mechanisms will apply. In cases where binding and dissociation of the substrates occur very rapidly 
compared to the catalytic step, the reaction is said to follow a rapid equilibrium mechanism.[207] Here, 
dissociation constants can be obtained. If the catalytic step is not rate limiting, a steady-state reaction, where 
all enzyme species reach a steady-state concentrations, is observed. Here Michaelis constants are obtained 
rather than dissociation constants. A steady-state reaction can either follow a sequential or a Ping Pong 
mechanism. In a sequential mechanism, all substrates must bind to the enzyme before any product is 
released. In a sequential mechanism substrates can either bind in an ordered or random fashion. If a product 
is released between the additions of two substrates, the mechanism is defined as a Ping Pong 
mechanism.[208]  
TPH catalyses a ter bi reaction as it uses three substrates, BH4, O2, and Trp, to produce two products, 4a-
hydroxy-BH4, and HO-Trp. Discrimination between enzymatic mechanisms with three substrates can occur 
through graphical methods. In the method described by Viola and Cleland [209], one substrate is held at 
saturation (>100Km) while the other substrates are varied. Alternatively, each substrate can be varied 
separately at fixed concentrations of the other two substrates maintained at a constant concentration 
ratio.[210] The obtained data can govern mechanistic information based on graphical appearance. However, 
kinetic parameters should be determined with great caution from these double reciprocal plots (Lineweaver-
Burk plots) because the data points will be weighted differently.[211] The parameters are more accurately 
determined by fitting an appropriate velocity equation to the measured initial velocities using non-linear 
regression.   
In this study, the concentration of O2 was not varied, and the reaction catalyzed by TPH is therefore treated 
as a bi bi reaction. In the following, some common bi bi reactions will be described and illustrated using 
Cleland nomenclature [212], where A and B represent substrates, P and Q represent products, kx are rate 
constants, KA and KB are dissociation constants for A and B, and Km,A and Km,B represent Michaelis 
constants for A and B. As TPH1 exhibits substrate tryptophan inhibition, substrate inhibition in the following 
mechanisms will also be considered.   
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6.1.2 Kinetic mechanisms 
6.1.2.1 Sequential mechanisms 
If A and B bind in an obligatory order before products P and Q are formed, the reaction follows an ordered bi 
bi mechanism, illustrated in Scheme 1. In the absence of products, the velocity equation is given as eq. 
3.[208] KA is the dissociation constant of A to free enzyme (k-1/k1). 
 
Scheme 1 
If KA is not much smaller that Km,A the slopes of the double reciprocal plots of v versus the concentration of 
varied substrate will increase linearly with decreasing concentration of the fixed substrate. In cases where KA 
<< Km,A, the slopes of the plots will appear parallel. 
 
  
          
                          
 (eq. 3) 
Two different competitive substrate inhibition mechanisms can occur in ordered bi bi mechanisms; formation 
of a dead-end EB complex or a dead-end EA2 complex (dotted arrows in Scheme 1). In the former, B bind 
free enzyme to form a dead-end complex, while in the latter two molecules of A bind the enzyme to form a 
dead-end complex. In the presence of a dead-end inhibitor, the velocity equation is modified by multiplying 
the factor (1+[I]/Ki) with the terms in the denominator representing the enzyme form which combines with the 
inhibitor.[208] In the presence of substrate inhibition, the velocity equations will take the form of eq. 4 and eq. 
5 for EB and EA2, respectively.[208]  
 
  
          
        
   
  
           
   
  
               
 
(eq. 4) 
 
  
          
                      
   
  
        
 
(eq. 5) 
In the case of EB dead-end formation, the double reciprocal v versus [A] plots will be linear at all 
concentrations of B. The slopes will be affected by the concentration of B; with increasing concentration the 
slope will decrease, pass through a minimum, and then start to increase as substrate inhibition becomes 
more pronounced (Figure 6.1 a). The slope of the plots is described by eq. 6.[208]  
 
           
   
      
    
     
    
      
   
    
   
     
     
  (eq. 6) 
The inhibition by B is obvious from the 1/v versus 1/[B] plot, which will pass through a minimum and then 
curve up as they approach the 1/v-axis (Figure 6.1 b). At low concentrations of A, these plots will appear 
linear only at high values of 1/[B]. With saturating concentrations of A, the inhibition is overcome and the 
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plots are linear. The slopes of these plots will decrease with increasing [A]. Similar plots will occur in the case 
of EA2 complex formation. 
 
Figure 6.1. Theoretical plots illustrating substrate inhibition by B in an ordered sequential bi bi mechanism (Vmax 
= 200, Km,A = 20, Km,B = 50, Ki = 20, KA = 50). (a) Double reciprocal plot of v versus [A] at different concentrations 
of B. (b) Double reciprocal plot of v versus [B] at different concentrations of A. 
6.1.2.2 Ping Pong mechanism  
If a product is released between binding of A and B, the mechanism is called Ping Pong. The Ping Pong 
mechanism is illustrated in Scheme 2, where F is modified enzyme (i.e. covalently modified by accepting a 
molecule from substrate A). This type of mechanism is common in group transfer reactions, where the 
enzyme is covalently modified. In the absence of products, the velocity equation is given as eq. 7.[208]  
 
Scheme 2 
If the enzyme follows a Ping Pong mechanism, the double reciprocal plots of v versus [A] or [B] will be linear, 
and with increasing concentration of the fixed substrate the plots will be parallel shifted to lower 1/v intercept 
until 1/Vmax is reached. The properties that account for the parallel plots are, however, not always the 
formation of a covalent enzyme intermediate, but might be the occurrence of a kinetically irreversible step 
between binding of the substrates.[213] 
 
  
          
                    
 (eq. 7) 
 
  
          
         
   
  
               
 
(eq. 8) 
Competitive substrate inhibition can occur in a Ping Pong mechanism if B can bind F as well as E, see 
dotted arrow in Scheme 2. This will result in the modified velocity eq. 8.[208] At low concentrations of B, the 
1/v versus 1/[A] plots will appear parallel as usual. As the fixed concentrations of B increases, the slope of 
the plots will increase linearly and the 1/v-axis intercept will decrease to the limit of 1/Vmax, Figure 6.2 a. 
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Opposed to a sequential mechanism, the secondary plot of slope1/A versus 1/[B] will be linear. The 1/v versus 
1/[B] plots will appear parallel at high 1/[B] values but pass through a minimum and increase as they 
approach the 1/v-axis.  
 
Figure 6.2. Theoretical plots illustrating substrate inhibition by B in a Ping Pong bi bi mechanism (Vmax = 200, 
Km,A = 20, Km,B = 50, Ki = 20). (a) Double reciprocal plot of v versus [A] at different concentrations of B. (b) Double 
reciprocal plot of v versus [B] at different concentrations of A. 
6.1.2.3 Rapid equilibrium random mechanism 
If A and B bind in random order and the catalytic step is rate limiting, the system can be described as a rapid 
equilibrium random bireactant system, as illustrated in Scheme 3. 
 
Scheme 3 
The velocity equation, derived under rapid equilibrium assumptions, is given as eq. 9.[214] KiA and KA are the 
dissociation constant of A to free enzyme and EB complex, respectively. The slopes of the double reciprocal 
plots of v versus the concentration of varied substrate will increase linearly with decreasing concentration of 
the fixed substrate. 
 
  
          
                        
 (eq. 9) 
 
   
          
        
   
  
          
   
   
              
 
(eq. 10) 
If one substrate has affinity for the binding site of the other substrate, dead-end BE or BEB complexes can 
form. In this case, the velocity equation will take the form of eq. 10, where α is a factor describing the change 
in dissociation constant for binding of the second B, and Ki is the inhibition constant of B binding in A’s site. 
In the case of inhibition, the slopes in a 1/v versus 1/[A] plot will decrease with increasing concentrations of 
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[B] but eventually start to increase, and the 1/v versus 1/[B] will pass through a minimum and then curve up 
as it approaches the 1/v-axis, similarly to an ordered sequential mechanism in Figure 6.1. 
6.1.2.4 Hybrid Ping Pong-ordered mechanism 
In special cases, hybrids of a Ping Pong bi bi mechanism and an ordered or sequential mechanism can 
occur. Steady-state kinetic data obtained for chTPH1 suggest such a case, and a hybrid Ping Pong-ordered 
mechanism is therefore presented. In such a mechanism, A can bind in an ordered fashion and participate in 
a Ping Pong mechanism by donating a group to E. Alternatively, B can bind EA and the reaction will occur 
through a sequential mechanism, see Scheme 4. In the sequential mechanism the group can be passed 
from A to B directly or it can be passed from A to E and then from E to B.[208] 
 
Scheme 4 
A reaction mechanism similar to the one in Scheme 4, has been proposed by Mannervik [215,216]. Here the 
velocity eq. 11 was proposed, where V1, V2, and K3 and K4 are constants. In the total sequence, A adds once 
while B adds twice and the velocity equation thus contains the [B]
2
 terms. When the concentration of B is 
low, the [B]
2
 terms can be neglected and the equation will degenerate to the velocity equation of a Ping Pong 
mechanism (eq. 7).  
 
  
                 
 
                          
          
 
 (eq. 11) 
When competitive substrate inhibition, by binding of a second molecule of A (dead-end EA2 complex), is 
observed the velocity equation is modified to eq. 12.[217] 
 
  
                 
 
                
   
  
              
          
 
 (eq. 12) 
Alternatively, competitive substrate inhibition can occur through formation of a dead-end EB complex. The 
velocity equation for such a model is obtained by multiplying the terms in the denominator representing free 
enzyme with (1+[B]/Ki).[218] By this operation eq. 11 is modified to eq. 13. 
 
  
                 
 
         
   
  
                     
          
 
 (eq. 13) 
In these hybrid mechanisms with substrate inhibition, the 1/v versus 1/[A] plots will appear parallel at high 
1/[A] values but pass through a minimum and increase as they approach the 1/v-axis, Figure 6.3 b. Similar to 
a regular Ping Pong mechanism, the 1/v versus 1/[B] plots will appear parallel at low concentrations of A, but 
as the fixed concentrations of A increase the slope of the plots will increase and the 1/v-axis intercept will 
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decrease to the limit of 1/Vmax (Figure 6.3 a). However, the difference is that at low values of 1/[B] the curves 
will deviate from linearity. This effect is more pronounced at low concentrations of A, Figure 6.3 a. 
 
Figure 6.3. Theoretical plots illustrating substrate inhibition by A in a hybrid Ping Pong-ordered bi bi mechanism 
(Vmax = 200, Km,A = 20, Km,B = 50, Ki = 50, K3 = 0.05, K4 = 0.001). (a) Double reciprocal plot of v versus [B] at 
different concentrations of A. (b) Double reciprocal plot of v versus [A] at different concentrations of B. 
6.1.3 Statistical model comparison 
To compare the fits of the kinetic models, an F-test was used.[219] This test accounts for the fact that it is 
easier to fit a complicated model with more parameters compared to a simple model. To determine if a more 
complicated model, despite the greater number of parameters, is statistically superior, the F-ratio is used. 
The F-ratio is defined as follows, 
  
            
     
            
     
  
where SSnull and SSalt are the sum of squares of deviation of the data points from the null hypothesis model 
and alternative model, respectively. DFnull and DFalt are the degrees of freedom of the null hypothesis model 
and alternative model, respectively.The DF-values equal the number of data points minus the number of 
fitted parameters. From the F-ratio a p-value can be calculated.[219] 
6.2 Steady-state kinetics of chTPH1 
In this following, the kinetic mechanism of chTPH1 is investigated. The assay for determining TPH activity 
and the experimental procedure is presented. The present knowledge about the kinetic mechanism of the 
aromatic amino acid hydroxylases is outlined. The mechanistic insight is mainly based on studies on PAH 
and TH because a very limited amount of data has been published on TPH. Steady-state kinetic results of 
chTPH1 will be presented, analyzed graphically and by non-linear regression, and discussed.   
6.2.1 TPH assay 
The activity of TPH was assayed by continuously monitoring the fluorescence of 5-hydroxytryptophan formed 
in the presence of substrates, as described by Moran and Fitzpatrick [220]. This assay is based on the 
different spectral characteristics of tryptophan and 5-hydroxytryptophan. The hydroxylation of tryptophan 
results in shift of the UV-absorbance transitions to longer wavelengths, Figure 6.4. At 300 nm the 
absorbance is almost exclusive for 5-hydroxytryptophan which makes excitation at this wavelength suitable 
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for monitoring product formation. The emission was monitored at 330 nm, as the emission maximum of 5-
hydroxytryptophan is at 330 nm when excited at 300 nm.[220] 
 
Figure 6.4. Absorbance spectra of tryptophan and 5-hydroxytryptophan measured in 10 mM HCl. 
To stabilize TPH and to ensure continuous product formation, several components are added to the assay.  
TPH is only active when iron is in its ferrous form, and (NH4)2Fe(II)(SO4)2
.
6H2O is therefore added in excess 
to insure that all TPH is loaded with Fe
2+
. (NH4)2SO4 has been found to stabilize TPH [221], hence additional 
(NH4)2SO4 is added. Catalase is added to consume the H2O2 which is formed upon autooxidation of BH4 to 
qBH2. BH4 has a high absorption at 300 nm and the fluorescence signal from 5-hydroxytryptophan is 
reduced by BH4 attenuating the incoming light. A constant amount of BH4 is therefore desirable, and the 
reducing agent dithiothreitol (DTT) is added to ensure a constant concentration of BH4 throughout the assay. 
Furthermore, DTT maintains iron in its reduced form. Because of the concentration dependent reduction of 
the 5-hydroxytryptophan fluorescence signal caused by BH4, standard curves of 5-hydroxytryptophan 
fluorescence at all BH4 concentrations were produced (see Appendix G.1).  
6.2.2 Experimental procedure 
Activity measurements were conducted on a Varian Cary Eclipse fluorescence spectrophotometer. The 
excitation and emission wavelengths were 300 and 330 nm, respectively and slit widths of 5 nm were used. 
The photomultiplier tube voltage was set to 650 V. The measurements were done in a 10.00 x 10.00 mm QS 
quartz cuvette (2500 µL total). The spectrophotometer is equipped with a temperature controlled cuvette 
holder with magnetic stirring. The concentration of O2 in the assay was determined using a MI-730 Oxygen 
electrode and an OM-4 Oxygen Meter from Microelectrodes, Inc., Londonderry, NH, USA. The O2 
concentration was controlled as described by Nielsen et al.[222] The electrode was calibrated in a cuvette 
containing 50 mM HEPES/NH4OH, 200 mM (NH4)2SO4, pH 7.0 at 15 °C. In the calibration, the zero set point 
was obtained by sparging with N2 until saturation and the 100 % O2 point was obtained by sparging with O2 
until saturation. At 15 °C and 101.325 kPa, the solubility of O2 at (100 %) was assumed to be equal to1528 
µM.[223] The desired O2 concentration was obtained by sparging with a mixture of N2 and O2. Mixing of the 
gases was performed with Mass Flow controllers model 5850 TR from Brooks Instruments B. V. Veenendaal, 
Holland. The gas flow controllers were operated using a monitor model 0152 from Brooks Instruments. In 
addition to the cuvette containing the reaction mixture, a reference cuvette was used to monitor the O2 
concentration. When the reaction cuvette was added enzyme and BH4, the reference cuvette was added 
equivalent volumes of water. 
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All measurement were performed under the following conditions; 50 mM HEPES/NH4OH, 200 mM 
(NH4)2SO4, pH 7.0, 0.025 g/L (8823 U/mg) catalase, 25 μM (NH4)2Fe(II)(SO4)2•6H2O, and 7 mM DTT. The 
concentration of tryptophan and BH4 varied. (6R)-5,6,7,8-tetrahydro-L-biopterin dihydrochloride (BH4) was 
bought from Schircks Laboratories, Jona, Switzerland. All other chemicals used were analytical grade 
obtained from Sigma-Aldrich and all solutions were prepared using 18.2 MΩ•cm water from a Milli-Q 
synthesis A10 Q-Gard system (Millipore). 
Protein solutions, stored at -80 °C, were thawed and diluted to 5 µM in the buffer in which they were purified. 
Stock solutions of catalase, Trp, and BH4 were thawed from -20 °C and used together with freshly prepared 
DTT and (NH4)2Fe(II)(SO4)2•6H2O solutions. The concentrations of the tryptophan and BH4 stocks were 
determined by UV-Vis using ε(278) = 5500 M
-1
cm
-1
 and ε(266) = 18000 M
-1
cm
-1 
(2 M HCl), respectively.[220] 
Buffer, water, (NH4)2Fe(II)(SO4)2•6H2O, DTT, and tryptophan were added to the reaction cuvette and the 
equivalent volume of buffer and water was added to the reference cuvette.  
Both cuvettes were sealed with lids using parafilm, and gas tubes were inserted through holes in the lids into 
the solutions. The reference cuvette was added an O2 electrode and both cuvettes were stirred at 15 °C until 
the desired concentration of O2 was reached. Then the tubes were pulled up over the surface of the solution, 
purging the head space to maintain the O2 concentration. Catalase and TPH were added to the reaction 
cuvette, while water was added to the reference cuvette. After addition, the solutions were stirred for another 
2 min before the reaction was initiated by the addition of BH4. The initial rate slope (intensity/min) of the 
monitored fluorescence signal was quantified using Varian spectrophotometer software. Quantification 
occurred through linear regression on a manually placed interval of minimum 0.04 min of the initial curve. 
The initial rates were converted to µM 5-hydroxytryptopan per minute by dividing with the slopes of the 
standard curve at the given BH4 concentration. 
Standard curves were produced by measuring the fluorescence of 5-hydroxytryptophan (0.5 - 20 µM) in 50 
mM HEPES/NH4OH, 200 mM (NH4)2SO4, pH 7.0 at various BH4 concentration (10 – 750 µM). The 
concentration of 5-hydroxytryptophan was determined in 10 mM HCl using ε(278) = 5500 M
-1
cm
-1
.[220] The 
standard curves can be found in Appendix G.1. 
6.2.3 AAAH – Kinetic mechanism 
The fundamental mechanisms of aromatic amino acid hydroxylation by the AAAH members have been under 
investigation for decades. Despite great efforts to dissect the mechanism, ambiguities still exist. Of the 
AAAHs, PAH and TH have been more thoroughly studied by steady-state kinetic assays and spectroscopy.   
6.2.3.1 Evidence for Ping Pong mechanism 
Based on steady-state kinetic measurements, Ikeda et al.[224] have found that bovine TH follows a Ping 
Pong mechanism in which the substrates bind in a ordered fashion where pterin (6,7-Dimethyl-5,6,7,8-
tetrahydropterine, DMPH4) binds before Tyr. Here it was found that the first step of the reaction occurs 
between TH and pterin and the second step is aerobic oxidation of Tyr. 
From bovine TH, parallel lines in a double reciprocal Lineweaver-Burk plot of velocity against BH4 
concentration at varied Tyr concentrations were obtained by Oka et al., similarly suggesting a Ping Pong 
mechanism.[225] Substrate inhibition by Tyr was observed and it was found that Tyr inhibition was 
decreased by increased concentrations of BH4. At concentrations of BH4 up to a limit of 220 uM, Tyr at 50 
µM was inhibitory. At higher BH4 concentrations, Tyr at this concentration was not inhibitory. This resulted in 
biphasic curves in the Lineweaver-Burk plots with BH4. For this reason, two different Km values of the 
substrates were obtained depending on whether the concentration of BH4 was lower or higher than the 
threshold of 220 µM. The biphasic behavior was explained by the potential presence of two enzyme forms or 
two different conformations.  
In support of a Ping Pong mechanism is the observation that in rat TH, oxidation of BH4 can occur in the 
absence of substrate Tyr at pH of 8.2 with rates only two fold lower than in the presence of Tyr.[226] The 
oxidation occurs at slower rates at pH 7.2 and not at all at pH 6.5.[226,227] The reaction between TH, pterin, 
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and O2, in the absence of Tyr is supported by the gradually lower hydroxylation yield of substrate Tyr 
observed when Tyr is added as the last substrate in the reaction.[226] This suggests the breakdown of a 
reactive intermediate formed by TH, pterin, and O2.  
6.2.3.2 Evidence for sequential mechanism 
The mechanism of rat TH has also been studied by Fitzpatrick [227], where 6-MePH4, O2, and Tyr were 
varied pairwise with the third substrate at non-saturating concentrations. This study finds the order of binding 
being 6-MePH4, O2, and Tyr and that Tyr forms a dead-end complex with TH at high concentrations. The 
reaction mechanism is, however, contradicting the observations from bovine TH, as intersecting lines are 
found in the double reciprocal plots. This suggests an ordered sequential mechanism involving a quaternary 
complex with all three substrates bound.  
The mechanism has also been probed by stopped-flow absorbance spectroscopy. Single turn-over kinetic 
analysis was performed on PAH from Chromabacterium violaceum by Subedi et al.[228] Here absorbance 
traces upon pterin binding under anaerobic conditions and formation of reaction intermediates were used in 
combination with rapid mixing chemical quenching for detection of Tyr, to decipher the mechanism. The 
obtained data was fitted with a mechanistic model in which pterin and Phe bind in a random order, favored 
by pterin binding first, followed by reversible O2 binding. No evidence of Phe substrate inhibition is 
presented.  In contrast, a steady-state kinetic analysis of PAH from Chromabacterium violaceum showed that 
the enzyme follows a sequential mechanism in which DMPH4 binds first followed by Phe and then O2. Here 
substrate inhibition by Phe was observed but only at concentrations greater than 1 mM.[229] 
A similar single-turnover study using stopped-flow absorbance spectroscopy was made by Roberts et al. for 
a truncated rat PAH variant lacking the N-terminal regulatory domain.[230] Here, it is found that a productive 
ternary complex is formed in an ordered sequential fashion where BH4 binds before Phe. O2 binds the 
ternary complex and initiates the reaction. Here it is proposed that both BH4 and Phe (Kd value = 1.3 mM) 
can form an inhibitory binary complex upon binding to free PAH.  
The same sequential mechanism, in which O2 binds after formation of a ternary complex, has been proposed 
in a study by Chow et al., where X-ray absorbance spectroscopy and magnetic circular dichorism were 
utilized to find that Fe(II) in rat TH undergoes a six-coordinate (6C) to five-coordinate (5C) conversion only 
when both Tyr and 6-MePH4 is bound.[231] The 5C geometry is assumed to be the active state of the active 
site which is able to bind O2 and initiate reaction. This type of O2-activation has been observed in other O2-
activating nonheme iron enzymes.[232]  
Single turn-over kinetics has also been carried out for the catalytic domain of rabbit TPH1.[233] In this study, 
a model in which a ternary complex, TPH•6-MePH4•Trp, is formed followed by equilibrium binding of O2, fits 
the data. No evidence of Trp substrate inhibition is presented.  
 
Binding of BH4 as the first substrate is consistent with finding in TPH1 where inhibitors display uncompetitive 
inhibition towards 6-MePH4, which indicates that the pterin binds first.[234] Additionally, the crystal structure 
of chicken TPH (PDB entry: 3E2T) shows that binding of L-tryptophan results in a closed conformation, 
which indicates the formation of a dead-end complex.[235] 
 
Collectively, the kinetic mechanism of the AAAH’s has been studied with a number of methods with 
contradictory conclusions. In general, it seems that the most recent beliefs are in favor of an ordered 
sequential mechanism where the order of binding is pterin, amino acid substrate, and O2. Several of these 
studies are, however, conducted with very high substrate concentrations (typically 0.5 mM+ range) 
[228,230,231,233] and with 6-MePH4 instead of BH4. 
6.2.4 Steady-state kinetic results of chTPH1 
Kinetic parameters for chTPH1 were determined according to the method of Viola et al.[209], in which the 
concentration of BH4 and Trp are varied while the concentration of O2 is held at constant. Ideally, in this 
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method O2 concentration would be at saturation level (>100Km). However, this is not possible because of the 
solubility of O2. The kinetics experiments in this section are performed with an O2 concentration of 500 µM to 
enable comparison with data produced previously in the Metalloprotein Chemistry and Engineering Group at 
DTU.[222,236] The derived kinetic parameters are therefore apparent values throughout this section. The 
apparent Km,O2 for chTPH1, at 70 µM tryptophan and 300 µM BH4, is 109 ± 7 µM [236], which means that the 
O2 concentration in this study is ~5-fold Km,O2.  
To explore the kinetic mechanism of TPH1, the initial velocity of chTPH1 were determined at various 
tryptophan and BH4 concentrations. The concentrations of the substrates were varied in a concentration 
matrix of fourteen tryptophan concentrations and six BH4 concentrations. This data is presented in Figure 
6.5. 
 
Figure 6.5. Initial velocity of chTPH1 against tryptophan concentration at fixed concentrations of BH4. The 
oxygen concentration was 500 µM in all measurements. The plots are fitted with eq. 2. 
Figure 6.5 A shows that the data deviates from the classical hyperbolic curve and can be fitted very well with 
eq. 2 which describes linear substrate inhibition resulting from dead-end complex formation between 
substrate and a nonproductive enzyme form.[218] Similarly, Figure 6.5 B does not represent a family of 
straight lines, rather the double reciprocal plots are only linear at high values of 1/[Trp]. As the plots 
approach the 1/v0-axis they pass through a minimum and bend upward which is expected when substrate 
inhibition is occurring. The linear parts (high 1/[Trp]) of the 1/v0 versus 1/[Trp] plots seem parallel. Parallel 
lines in this plot only occur in mechanisms that follow a Ping Pong system (section 6.1.2.2, Figure 6.2 b). 
However, in sequential mechanisms where KA<<Km,A the KA term in eq. 7 will be insignificant and the plots 
will appear parallel. Because of the non-linear nature of the double reciprocal plots, slopes (Km/Vmax) and 
intercepts (1/Vmax) are hard to determine graphically. Apparent Vmax, Km,Trp, and Ki values were, therefore, 
determined by fitting velocity equation 2 to the data. The obtained values were used to produce the 
secondary plots in Figure 6.6.  
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Figure 6.6. Secondary plots of Vmax and Ki-values obtained from fitting the plots in Figure 6.5 with eq. 2. 
The secondary plots show that chTPH1 displays BH4 concentration-dependent substrate inhibition. At low 
fixed concentrations of BH4 (20 µM), chTPH1 has an apparent Ki of 24 µM, while at high concentration (400 
µM) the apparent Ki is increased to 206 µM. The apparent Vmax also increase with increasing concentration 
of BH4. Here a value for Vmax can be determined to 149 µM/min from the interception with the 1/Vmax-axis. 
Km,Trp also seems to be BH4 concentration-dependent (Table 6.1).  
Table 6.1. Apparent kinetic parameters for chTPH1 determined from fitting the kinetic data in Figure 6.5 with eq. 
2. 
  BH4 (µM) 
 
20 50 100 200 300 400 
Vmax (µM/min) 36 61 96 110 126 135 
Km,Trp (µM) 4.9 8.7 12.2 14.1 12.7 12.5 
Ki (µM) 24 36 54 102 158 206 
 
When the data in Figure 6.5 is replotted as v0 versus [BH4], the plots in Figure 6.7 are obtained. The plots 
have the classic hyperbolic shape and eq. 1 fits well. From visual inspection, it is clearly seen that both Vmax 
and Km,BH4 are increased with increasing concentration of tryptophan and that there are no sign of substrate 
inhibition. The values of Vmax and Km,BH4 were determined using eq. 1, and are summarized in Table 6.2. 
Table 6.2. Apparent kinetic parameters for chTPH1 determined from fitting the kinetic data in Figure 6.7 with eq. 
1. 
  Trp (µM) 
  1.5 2.5 5 10 15 20 30 40 50 70 100 150 200 300 
Vmax (µM/min) 14 22 37 59 81 102 117 145 146 159 207 215 268 1071 
Km,BH4 (µM) 22 28 36 49 79 114 152 237 252 344 571 791 1227 6989 
The concentration of tryptophan clearly has an influence on the value of Km,BH4. At low concentration of 
tryptophan (1.5 µM) Km,BH4 is 22 µM while at 70 µM tryptophan, which is considered standard in TPH assays, 
Km,BH4 is 344 µM. The kinetic parameters determined at higher concentrations of tryptophan are unreliable 
because only v0-values at BH4 concentrations well below Km,BH4 are determined. Hence, only Km,BH4/Vmax 
values are reliable. 
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Figure 6.7. Initial velocity of chTPH1 against BH4 concentration at fixed concentrations of tryptophan. The 
oxygen concentration was 500 µM in all measurements. The plots are fitted to eq. 1. 
The data from Figure 6.7 is replotted as 1/v0 versus 1/[BH4] in Figure 6.8 A. For clarity, only the two highest 
and lowest tryptophan concentrations are included in the plot. Plots of all the concentrations can be found in 
Appendix G.2. The values of Km,BH4/Vmax (slope1/BH4) were calculated from values in Table 6.2, and are 
presented in Figure 6.8 B as a function of [Trp].  
 
Figure 6.8. (a) Double reciprocal v0 versus [BH4] plots of the two highest and lowest concentrations of 
tryptophan from Figure 6.7. Data is fitted with eq. 1. (b) Slopes (Km/Vmax) obtained from fits with eq. 1 of data 
from Figure 6.7, and are fitted with eq. 6.  
Figure 6.8 B shows that the slopes of the plots in Figure 6.8 A are not linearly correlated with the 
concentration of Trp, as is expected in the case of a Ping Pong mechanism. A slope1/[B] versus [A] plot that 
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passes through a minimum and bends up is indicative of a sequential mechanism, Figure 6.1 a. The 
deviation from linearity of the slope1/BH4-plot occurs at very low tryptophan concentrations, which is indicative 
of a very small value of KA. 
Noteworthy is, that at low tryptophan concentration in Figure 6.8 A (1.5 and 2.5 µM Trp), the data deviates 
from linearity. This phenomenon is expected from a hybrid Ping Pong-ordered mechanism, see Figure 6.3 
(section 6.1.2.4). The dataset was therefore split into two datasets to test if the data represent two distinct 
mechanisms, which is the case in a hybrid Ping Pong-ordered system. One dataset contained initial 
velocities from combinations of all tryptophan concentrations with the BH4 concentrations 20, 50, and 100 µM 
and the second dataset with 200, 300, and 400 µM BH4. Both datasets were fitted with eq. 1 for every 
tryptophan concentration, and the slopes (Km/Vmax) were calculated, Figure 6.9. The obtained kinetic 
parameters can be found in Appendix G.3. 
 
Figure 6.9. Slopes (Km/Vmax) obtained from fits with eq. 1 of data from Figure 6.7 split into two datasets. White 
circles represent slopes obtained from the dataset containing [BH4] = 20, 50, and 100 µM (fitted with eq. 6) and 
gray circles represent slopes obtained from the dataset containing [BH4] = 200, 300, and 400 µM (fitted with 
linear regression).  
Figure 6.9 shows that the two parts of the dataset result in different fits. Using the dataset with low 
concentrations of BH4 (white circles), results in slope1/BH4-values which are linearly increasing with tryptophan 
concentration. This trend is expected for a Ping Pong mechanism. With the dataset containing high 
concentrations of BH4 (gray circles), the slope1/BH4-values are clearly not linear. Here, the slope1/BH4-values 
decrease, pass through a minimum, and increase linearly with increasing [Trp]. This trend is expected for a 
sequential mechanism. 
6.2.4.1 Data analysis by global fitting on split dataset  
Based on the graphical interpretation and fitting with eq. 1 and 2, the mechanism cannot conclusively be 
decided. From analyzing the entire dataset a sequential mechanism with a small KA compared to Km,A seems 
favorable. However, when the dataset is split into high and low concentrations of BH4, a mechanism that 
branches into a Ping Pong and a sequential pathway seems attractive.  
To evaluate which mechanism the kinetic data represents, global fitting with the two-substrate equations was 
conducted for the two datasets. The datasets were fitted to the velocity equations describing i) dead-end EB 
complex formation in a Ping Pong mechanism, ii) dead-end EB complex formation in a sequential 
mechanism, and iii) dead-end EA2 complex formation in a sequential mechanism. The resulting parameters 
of the fits are summarized in Table 6.3. 
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Table 6.3. Kinetic parameters derived from fitting the data with a Ping Pong mechanism (eq. 7), a sequential 
mechanism with a dead-end EB complex (Seq. EB - eq. 4), and a sequential mechanism with a dead-end EA2 
complex (Seq. EA2 - eq. 5). Parameters have been derived for two datasets; one containing initial velocities at 
BH4 concentrations of 20, 50 and 100 µM and one containing initial velocities at BH4 concentrations of 100, 200, 
and 300 µM. The model error is given by the sum of squared residuals. *: F-test, p<0.01. 
 
Mechanism 
Vmax 
(µM/min) 
Km,Trp 
(µM) 
Km,BH4 
(µM) 
Ki       
(µM) 
KA 
(µM) 
Error 
Low [BH4] 
range 
Ping Pong EB 314 42 208 32 - 59.4 
Seq. EB 314 42 208 32 0 59.4 
Seq. EA2 314 42 208 32 0 59.4 
High [BH4] 
range 
Ping Pong EB 299 31 426 92 - 245.7 
Seq. EB 236 17 235 64 124 207.3* 
Seq. EA2 236 17 268 73 8.0 207.3* 
 
From Table 6.3, it can be seen that at low concentrations of BH4 all the mechanism have the same 
parameters and the same model errors. When fitting the data to the sequential mechanisms, the parameter 
KA is reduced to zero, which results in a collapse of eq. 4 and 5 into eq. 7, describing a Ping Pong 
mechanism. At high BH4 concentrations, fits to the sequential mechanisms result in better models compared 
to the Ping Pong mechanism, as the error is 16 % lower (F = 14.6, p<0.01). The sequential mechanisms 
result in identical model errors and both give reasonable kinetic parameters (µM range). One sequential 
mechanism can therefore not be chosen over the other based on these fits.  
6.2.4.2 Data analysis by global fitting on entire dataset  
Global fits to the entire dataset were conducted to test if the data represents one of the branching 
mechanisms presented in Figure 6.10 and Figure 6.11. In Figure 6.10, the reaction can either occur through 
a Ping Pong or a sequential mechanism depending on the concentration of tryptophan, and substrate 
inhibition is caused by formation of a dead-end EB (TPH•Trp) complex formed if tryptophan binds before BH4 
(hybrid EB mechanism). 
 
Figure 6.10. Basic scheme for a branching mechanism of chTPH1. The scheme corresponds to a hybrid Ping 
Pong-ordered mechanism with a dead-end TPH•Trp complex (EB). TPH* indicates a TPH that has undergone an 
irreversible change (e.g. formation of Fe
IV
O). Upper path represents a Ping Pong mechanism and the lower path 
represents a sequential mechanism. 
Figure 6.11 present a reaction in which the concentration of BH4 determines the reaction mechanism, and 
substrate inhibition occurs through binding of a second tryptophan forming a dead-end TPH*•Trp2 complex 
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(hybrid E*A2 mechanism). In this mechanism, the upper path is not a conventional Ping Pong mechanism 
where a product is released before the next substrate binds. Rather it represents a mechanism in which an 
irreversible change occurs in TPH after binding of tryptophan. Such an irreversible change can account for 
data which appear to represent a Ping Pong mechanism.[213]   
 
Figure 6.11. Basic scheme for a branching mechanism of chTPH1. The scheme corresponds to a hybrid Ping 
Pong-ordered mechanism with a dead-end TPH*•Trp2 complex (E*A2). TPH* indicates a TPH that has undergone 
an irreversible change (e.g. loop closure). Upper path represents a Ping Pong mechanism and the lower path 
represents a sequential mechanism.  
For comparison, the full dataset was fitted with the six different mechanisms including the branched 
mechanisms. In Figure 6.12 fits are shown for a Ping Pong mechanism (solid line), the hybrid E*A2 
mechanism (dashed lines), and the hybrid EB mechanism (dotted lines). The sequential mechanisms 
resulted in identical fits, as KA was reduced to zero resulting in a reduction of the equations to that of a Ping 
Pong mechanism. Similarly, the equation of a rapid equilibrium random mechanism is collapsed into the 
equation of a Ping Pong mechanism by reducing KA to zero and α to one. For this reason, identical kinetic 
parameters were obtained for the four mechanisms (Table 6.4). Based on this analysis of the conventional 
non-branched mechanisms, a Ping Pong mechanism fits the total dataset best.  
  
Figure 6.12. Global fits to initial velocity measurements for chTPH1. The oxygen concentration was 500 µM in all 
measurements. Left: initial velocities versus tryptophan concentration at fixed concentration of BH4. Right: 
double reciprocal plots of v0 versus [BH4]. The plots are fitted with eq. 7 (Ping Pong mechanism - solid lines), eq. 
12 (Hybrid Ping Pong-ordered E*A2 mechanism - dashed lines), or eq. 13 (Hybrid Ping Pong-ordered EB 
mechanism - dotted lines).  
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When the dataset is fitted with the hybrid E*A2 model (eq.11), the fit improves (F = 17.8, p<0.01) compared 
to the fit with a Ping Pong mechanism (Table 6.4). From a visual inspection of the fits in Figure 6.12, it is 
obvious that the hybrid E*A2 model results in better fits at low tryptophan concentrations. This hybrid model 
is also able to account for the deviation from linearity observed in the 1/v0 versus 1/[BH4] plots at low 
tryptophan concentrations. The deviation from linearity is the result of the [B]
2
 terms becoming negligible at 
low BH4 concentrations, which results in eq. 11 being reduced to eq. 7 (Ping Pong). The kinetic parameters 
derived from this model are presented in Table 6.4. Fitting this hybrid model to the data results in a 
redundancy of K3 as it is zero. The hybrid EB model also results in an improved global fit (F = 6.1, p<0.01) 
compared to that of a Ping Pong mechanism, Table 6.4. Fitting this model to the data results in a 
redundancy of K4. 
Table 6.4. Kinetic parameters derived from global fits. Parameters are derived from fitting with a Ping Pong 
mechanism with dead-end EB (eq. 7), a sequential mechanism with a dead-end EB complex (Seq. EB - eq. 4), a 
sequential mechanism with a dead-end EA2 complex (Seq. EA2 - eq. 5), a rapid equilibrium random mechanism 
with dead-end EB and BEB formation (Rapid eq. EB – eq. 9), a hybrid Ping Pong-ordered mechanism with dead-
end EA2 formation (Hybrid EA2 – eq. 12), and a hybrid Ping Pong-ordered mechanism with dead-end EB 
formation (Hybrid EB – eq. 13) to all the data. The model error is given by the sum of squared residuals. *: F-test, 
p<0.01. 
Mechanism 
Vmax 
µM/min 
V2 
min
-1
 µM
-1
 
Km,Trp 
µM 
Km,BH4 
µM 
Ki 
µM 
KA 
µM 
K3 
K4 
µM
-1 
α Error 
Ping Pong EB 213 - 23 181 51 - - - - 551 
Seq. EB 213 - 23 181 51 0 - - - 551 
Seq. EA2 213 - 23 181 51 0 - - - 551 
Rapid eq. EB 213 - 23 181 51 0 - - 1 551 
Hybrid E*A2 117 0.2 18 46 17 - 0 7e10
-4
 - 325* 
Hybrid EB 210 0.3 24 135 52 - 2.8 0 - 445* 
6.3 Discussion of kinetic results 
The kinetic mechanism has not unambiguously been determined for the aromatic amino acid hydroxylases. 
Several studies of the mechanism have been conducted for PAH and TH but with conflicting conclusions. In 
the case of TPH, very little is known about the fundamental mechanism of both isoforms. In this study, 
elucidation of the catalytic mechanism of chTPH1 has been carried out by measuring the initial reaction 
velocity at different combinations of BH4 and tryptophan concentrations.  
Global fit of the conventional mechanisms to all the kinetic data obtained in this study yields the best fit with 
a Ping Pong mechanism in which BH4 binds before tryptophan and where tryptophan acts as an inhibitor 
upon binding prior to BH4. This order of substrate binding is in agreement with the majority of studies 
conducted on the AAAHs.[224,225,227,229,230,233] The same Ping Pong mechanisms has been proposed 
for TH [224,225], where a BH4 concentration-dependent substrate tryptophan inhibition constant was also 
observed [225]. However, other studies conducted on the AAAHs, including a study of rabbit TPH1, find the 
mechanism to be sequential.[227-231,233]  
A graphical analysis shows that the secondary plot of slope1/BH4 versus [Trp] gives a non-linear relationship, 
which suggests that the reaction follows a sequential mechanism. In the double reciprocal 1/v0 versus 
1/[BH4] plots, it is noteworthy that the plots are not linear at low concentrations of tryptophan. This unusual 
feature has also been observed for TH.[225] Oka et al.[225] found that at low tyrosine concentrations the 1/v0 
versus 1/BH4 plots were non-linear, and deviation from linearity occurred at ~0.2 mM BH4. The data was 
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therefore analyzed separately for velocity data obtained at respectively higher or lower than 0.2 mM BH4. 
Similar data has been recorded for i.e. pytuvate carboxylase, glutathione reductase, hypoxathine 
phosphoribosyltransferase, and glutathione S-transferase A.[217,237-239]  
When data obtained in this study is expressed in terms of a low and a high BH4 concentration ranges, two 
different kinetic mechanisms are obtained. At low concentrations of BH4, the reaction seems to follow a Ping 
Pong (dead-end EB) mechanism and at high concentrations a sequential mechanism. One sequential 
mechanism cannot be chosen over the other based on fitting with EB or EA2 dead-end models. Formation of 
a EA2 complex is less likely, as ITC experiments have shown that tryptophan only binds once (n = 1) in 
hTPH1.[240] In the kinetic study on rabbit cTPH1 [233], very high substrate concentrations ([6-MePH4] =1–
1.5 mM and [Trp]=0.5–1.0 mM) were used. The high substrate concentrations might explain the sequential 
mechanism they observed for rabbit cTPH1.  
A switch in mechanism, as a function of substrate concentration, has been observed for glutathione 
reductase and hypoxathine phosphoribosyltransferase.[217,238] Here, a mechanism that branches into 
either a Ping Pong or a sequential mechanism after binding of substrate A, were applied to account for the 
deviation of linearity in the double reciprocal plots. Such a mechanism has been denoted a hybrid Ping 
Pong-ordered mechanism.[208] 
A hybrid Ping Pong-ordered model where tryptophan binds as the first substrate (hybrid E*A2) fit the data 
obtained for chTPH1 very well. According to this model, at low BH4 concentrations the reaction occurs 
through a Ping Pong mechanism where tryptophan binds to TPH and induces an irreversible step. Such an 
irreversible change, which accounts for the Ping Pong kinetics, does not have to be a covalent modification 
of TPH, but can be a kinetically irreversible step that occurs before binding of BH4. Such a step can e.g. be a 
large conformational change which forward direction is much faster than the reverse direction, and where the 
reverse step is much slower than the kinetic steps of the mechanism.[213] Binding of tryptophan as the first 
substrate is supported by observations of Nielsen for isoform 2.[241] Here steady-state kinetic data for 
chTPH2 indicates a sequential mechanism with ordered binding of tryptophan followed by random binding of 
BH4 or O2. The data is, however, not statistically sufficient for a conclusive determination of the mechanism. 
In literature, a substantial amount of experimental evidence has been presented which documents that BH4 
binds before amino acid substrate.[224,225,227,229,230,233] ITC data for hTPH1 do not indicate that 
substrate tryptophan binds to multiple sites of the catalytic domain.[240] Furthermore, binding of two 
substrates has to the best of my knowledge never been observed for any for the AAAHs. Together, these 
observations render this mechanism unlikely despite the improved fit.  
A global fit with a hybrid Ping Pong-ordered model, in which BH4 binds first (hybrid EB), also results in a 
significantly improved fit compared to a Ping Pong mechanism. In this hybrid mechanism, the reaction can 
occur through a Ping Pong mechanism at low tryptophan concentrations. BH4 will bind first and undergo an 
irreversible reaction before binding of tryptophan. This correlates well with accepted reaction path catalyzed 
by TPH, where BH4 react with O2 and Fe(II) to form a reactive Fe
IV
O species which subsequently reacts with 
tryptophan.[242] Alternatively, at high tryptophan concentrations the reaction can occur through a sequential 
mechanism where both BH4 and tryptophan bind before a reaction with O2 takes place. This reaction path is 
in agreements with one observed in the study on rabbit TPH1 which was conducted at high tryptophan 
concentrations.[233]  
To truly understand the mechanism of chTPH1, initial velocities should be measured at different 
concentrations of O2. This is unfortunately a difficult task and could not be done within the timeframe of this 
project. Product inhibition studies with BH2 and 5-hydroxytryptophan are also needed to distinguish between 
the possible mechanisms. Product inhibition studies could especially be informative if KA << Km,A. Here it is 
very difficult to distinguish between an ordered sequential mechanism and a Ping Pong mechanism as they 
will yield very similar plots. The presented data should also be produced for chTPH2. chTPH2 is not subject 
to substrate tryptophan inhibition and analysis of this isoform will therefore be more straight forward. The 
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high sequence identity implies that the isoforms will follow the same mechanism; this is, however, not given 
as they display very different kinetic behaviors.   
6.4 Conclusion 
Knowledge about the steady-state kinetic mechanism of the TPH isoforms is very limited. In this chapter, two 
hybrid Ping Pong mechanisms resulted in improved fits to the experimental data compared to the reaction 
mechanisms by which the reaction has been described for TH and PAH. Based on observations from 
literature, one of the models is highly unlikely and can be discarded. The most plausible steady-state kinetic 
mechanism of chTPH1 is therefore a hybrid Ping Pong-ordered mechanism in which the reaction can either 
occur through a Ping Pong or a sequential mechanism depending on the concentration of tryptophan.  
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7  
A kinetic study of an active site loop 
This chapter concerns the steady-state kinetics of the catalytic domains of TPH1 and TPH2. In this chapter, 
the current knowledge about the catalytic domains and the substrate binding sites of the TPH isoforms will 
be presented. Structural information will be presented on a putatively important active site loop in the 
AAAHs.  
So far, the results obtained for the TPH isoforms have been very similar. In chapter 2 through 4 it was 
presented that the catalytic domains of the highly homologous TPH isoforms behave very similar in terms of 
purification yields, thermostability, and oligomeric state. In this chapter, different kinetic properties of the 
isoforms will be presented and discussed. As a result of sequence and structural analyses of the TPH 
isoforms, several mutations in the isoforms are conducted. Steady-state kinetic results obtained for these 
mutant variants will be presented and discussed. Some of the results presented in this chapter have been 
included in a submitted manuscript. (Appendix A.2)  
 
 
 
 
 
 
 
7.1 The catalytic domain 
The tertiary structures of the catalytic domains of both TPH isoforms are known. In total, eight crystal 
structures of the catalytic domain of TPH1 has been published.[243-247] The binding pockets of substrate 
and co-substrate are also well defined, as structures that include BH2 [243] or tryptophan [244] are available. 
The six remaining structures include bulky inhibitors in the active site. Only one structure of TPH2 has been 
uploaded to the protein data bank (PDB entry: 4V06) while an article based on this structure has not yet 
been published. This structure comprises the catalytic and tetramerization domains and has an imidazole 
bound to the active site iron.  
Because of the high sequence identity, the crystal structures of the catalytic domains of human TPH1 (PDB 
entry: 1MLW [243]) and human TPH2 (PDB entry: 4V06) display a root mean squared deviation of the Cα-
atoms (RMSDCα) of only 1.1 Å. The high sequence identity (81 %) and hence very similar ternary structures 
suggest that very similar substrate binding poses can be expected for the two isoforms. Similarly, the 
catalytic domain of chicken TPH1 has a sequence identity of 91 % and 83 % with TPH1 and TPH2, 
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respectively. In the following, the presented structural information will, therefore, be based on TPH1, but 
presumed to apply for both isoforms. 
The catalytic domains of the TPH isoforms have a basketlike structure with an active site consisting of a ~12 
Å long and ~7 Å wide channel, Figure 7.1.[243] The channel is intersected by the position of an iron atom, 
which separates the binding pockets of the substrate and co-substrate. 
 
Figure 7.1. The catalytic domain of human TPH1 (PDB entry: 1MLW) with bound BH2 and tryptophan. For 
illustrative purposes tryptophan has been superimposed from the structure of chicken TPH1 (PDB entry: 3E2T). 
Iron is shown as a pink sphere. Left: Cartoon representation of the catalytic domain illustrating the secondary 
and tertiary structure of the domain. Right: Surface representation of the catalytic domain illustrating the active 
site channel. 
In the crystal structures of chTPH1 which include inhibitors, the amino acid moiety of the inhibitors binds in 
the same pose as observed for tryptophan in chicken TPH1.[245] This confirms the binding pose of substrate 
tryptophan observed in chicken TPH1. 
7.1.1 The tryptophan binding pocket 
Based on the crystal structure of chicken TPH1, tryptophan binding is stabilized by several polar and 
hydrophobic interactions. The polar interactions occur through the carboxylate group of tryptophan which 
interacts with the side chains of Arg257 and Ser336 and the backbone of Thr265. Additionally, the indole 
nitrogen atom in the side chain of tryptophan interacts with the backbone of Ile366, Figure 7.2.[244] Deeper 
into the binding pocket, residues involved in hydrophobic interactions reside, these include; the side chains 
of Tyr235, Thr265, Pro268, His272, Phe313, Phe318, and Ile366. At the very bottom of the binding channel 
the active site iron atom resides at a distance of 4 Å to substrate tryptophan.  
All residues involved in tryptophan binding are conserved between human TPH1 and TPH2. In contrast, 
Tyr235, Phe313, and Ile366 are not conserved in PAH and TH, and Thr265 is not conserved in TH.[244]  
These residues have been found to have an important role in substrate selectivity. The corresponding 
identity of Tyr235 in PAH and TH is leucine, and mutations of Tyr235 to alanine or leucine in TPH1 result in 
reduced activity and increased Km for tryptophan.[248] This suggests that Tyr235 is important for substrate 
orientation and specificity.[248] Furthermore, it was found that these mutations eliminate the substrate 
inhibition of TPH1.[248] Phe313 corresponds to a tryptophan residue in both PAH and TH. Mutation of 
Phe313 to tryptophan results in a reduction of the preference of TPH1 for substrate tryptophan over 
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phenylalanine. This is caused by a reduction of the size of the hydrophobic binding pocket.[249] The residue 
Ile366 in TPH is a valine in PAH and an aspartic acid in TH. Mutation of the corresponding residue in PAH 
shows that this residue is important for substrate specificity. It is believed that it plays a role in controlling the 
shape of the hydrophobic pocket for the side chain of the substrate.[250] 
 
 
Figure 7.2. Cartoon representation (PDB entry: 3E2T) of the residues involved in tryptophan binding in chicken 
cTPH1. Residues involved in polar and hydrophobic interactions are colored green and blue, respectively. Iron 
is shown in pink and tryptophan in cyan. Dashed lines indicate hydrogen bonding distance. 
 
Km,Trp-values for TPH1 have been found to range from 8 to 48 µM [248,249,251-259], and for TPH2 from 15 
to 77 µM [252,254,258,260-264]. These values are very similar, as expected for highly conserved binding 
pockets. No difference is observed between Km,Trp-values obtained for full-length compared to variants 
comprising only the catalytic domain when they are directly compared.[256,259,260] 
7.1.2 The BH4 binding pocket 
The crystal structure of chTPH1 (PDB entry: 1MLW) [243] reveals the residues involved in co-substrate 
binding, Figure 7.3. Hydrogen bonds are formed between the backbone of Leu236 and Gly234 and the co-
substrate. The co-substrate also interacts with Glu273, via hydrogen bonding mediated by two water 
molecules. Figure 7.3 shows that the co-substrate is held in place by several water molecules which form a 
hydrogen bonding network in the active site. The co-substrate is furthermore held in place by π-π 
interactions with Tyr235 and Phe241. In hPAH, BH2 and BH4 are found to bind in the same orientation and 
position as observed for BH2 in chTPH1.[265,266]  
As is the case in the tryptophan binding pocket, all residues involved in BH4 binding are conserved between 
human TPH1 and TPH2 and similar Km,BH4-values are therefore expected. This is, however, not the case as 
Km,BH4-values for TPH1 have been found to range from 27 to 324 µM [248,251-257,259] and for TPH2 from 6 
to 80 µM [252,254,260-264]. There is a very broad range of Km,BH4-values especially for TPH1. This might 
indicate that the Km,BH4-value is sensitive to substrate concentrations, buffer solutions conditions, etc. It is 
therefore tough to compare different studies. Upon direct comparison in the same study, a 10-fold difference 
in the Km,BH4-values for the two isoforms was observed.[252] Studies that compare full-length TPH to variants 
containing only the catalytic domain find no differences in the observed Km,BH4-values.[256,259,260]  
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Figure 7.3. Residues in the active site of human cTPH1 (PDB entry: 1MLW) involved in BH2 binding. Iron is 
shown in pink, BH2 in cyan, and water molecules in red. Residues involved in hydrogen bonding are represented 
in green and residues with π-stacking interactions are shown in blue. Dashed lines indicate hydrogen bonding 
distance. 
7.1.3 Active site loop 
Common for the AAAHs is two intrinsically disordered loop regions lining the active site. These loops can 
either exist in an open or closed conformation dependent on active site occupancy. The role of these active 
site loops have been the subject of several studies, however, still remains unclear. In the following, 
information on these loop regions gathered from crystal structures and mutational studies of all the AAAHs is 
presented. 
7.1.3.1 Active site loops of TPH 
In hTPH1 the active site loop regions comprise Leu124-Asp139 and Ile367-Thr369. In total eight structures 
of cTPH1 are deposited in the PDB, Table 7.1. Four of these have insufficient electron density to solve the 
full structure of the active site Leu124-Asp139 loop [245,247] which indicates high mobility. Two recently 
published structures have density in the loops.[246,247] However, these structures include bulky inhibitors in 
the active site which perturbs the position of the loops. These structures will therefore not be considered in 
the discussion of the loop positions. The remaining two structures; chTPH1 (PDB entry: 1MLW) and chicken 
cTPH1 (PDB entry: 3E2T) have well resolved active site loops.  
When the crystal structures of chTPH1 with bound BH2 is compared to chicken cTPH1 with bound 
tryptophan and imidazole, a profound structural difference is observed within the loop regions lining the 
active site pocket.[244] The two structures reveal an open conformation and a closed conformation, 
respectively. In the closed conformation the loop regions close around the active site, Figure 7.4 a. This 
closure is observed upon L-tryptophan binding in the absence of BH4. However, imidazole is bound in the 
BH4 binding pocket, which might mimic binding of co-substrate.[244]  
The crystal structure of cthTPH2 (PDB entry: 4V06) has imidazole bound in the same position as in chicken 
cTPH1. cthTPH2 displays an open conformation very similar to the structure of chTPH1, suggesting that 
imidazole alone does cause loop closure. Whether the loop closure occurs solely upon binding of substrate 
or a combination of substrate and co-substrate is not known. 
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Table 7.1. Crystal structures of tryptophan hydroxylase isoform 1 and 2. In the header, substrate and co-
substrate refers to presence of a (co-)substrate/(co-)substrate analogue in their respective binding sites. 
Open/closed refers to an open or closed conformation of the active site loops. AA in/out refers to Tyr125/Tyr171 
pointing towards the active site or away from active site. *: part of the BH4 binding pocket is also occupied by 
the inhibitor. **: Inhibitor interacts with loop and perturbs the position of Tyr125. 
PDB 
entry 
AAAH Domain(s) Species Metal Substrate Co-substrate Open/closed 
AA 
in/out 
Ref 
1MLW TPH1 c Human Fe
3+
 - BH2 Open In [243] 
3E2T TPH1 c Chicken Fe
3+
 L-tryptophan imidazole Closed Out [244] 
3HF6 TPH1 c Human Fe
3+
 Inhibitor A * No density - [245] 
3HF8 TPH1 c Human Fe
3+
 Inhibitor B * No density - [245] 
3HFb TPH1 c Human Fe
3+
 Inhibitor C * No density - [245] 
5J6D TPH1 c Human Fe
3+
 Inhibitor D TRIS, * Closed In** [246] 
5I01 TPH1 c Human Fe
3+
 Inhibitor E * Open Out** [247] 
5TPG TPH1 c Human Fe
3+
 Inhibitor F TRIS, * No density - [247] 
4V06 TPH2 c/t Human Fe
3+
 - imidazole Open Out - 
BH2:  7,8-dihydrobiopterin, TRIS: 2-amino-2-hydroxymethyl-propane-1,3-diol, Inhibitor A: 4-(4-amino-6-{[(1R)-1-naphthalen-2-
ylethyl]amino}- 1,3,5-triazin-2-yl)-L-phenylalanine, Inhibitor B: 4-{2-amino-6-[(1R)-2,2,2-trifluoro-1-(3'- fluorobiphenyl-4-
yl)ethoxy]pyrimidin-4-yl}- L-phenylalanine, Inhibitor C: 4-(5-{[(2'-methylbiphenyl-2-yl)methyl]amino}pyrazin- 2-yl)-L-phenylalanine, 
Inhibitor D: 4-[(N-{[2-(3-methoxyphenoxy)-6-(piperidin- 1-yl)phenyl]methyl}carbamimidoyl)carbamoyl]- L-phenylalanine, Inhibitor E: 
(3~{S})-8-[2-azanyl-6-[(1~{R})-1-(4-chloranyl- 2-phenyl-phenyl)-2,2,2-tris(fluoranyl)ethoxy]pyrimidin- 4-yl]-2,8-diazaspiro[4.5]decane-3-
carboxylic acid, Inhibitor F: (3S)-8-(2-amino-6-{(1R)-1-[5-chloro-3'-(methylsulfonyl)[1,1'- biphenyl]-2-yl]-2,2,2-trifluoroethoxy}pyrimidin- 4-
yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid. 
 
Figure 7.4. Representations of closed and open structures of tryptophan hydroxylase and phenylalanine 
hydroxylase. (a) Relative positions of the active site loops Leu123-Asp138 and Ile366-Thr368 in chicken cTPH1 
(PDB entry: 3E2T) in which substrate tryptophan and imidazole are bound (green loops) and in chTPH1 (PDB 
entry: 1MLW) in which BH2 is bound (blue loops). (b) Relative positions of the active site loops Asn133-His146 
and Val379-Phe382 in chPAH (PDB entry: 1KW0) in which substrate analogue 3-(2-thienyl)-L-alanine and BH4 are 
bound (green loops) and in chPAH (PDB entry: 1J8U) in which BH4 is bound (blue loops). Iron is shown in pink, 
substrate and co-substrate in cyan. For illustration, the binding pockets include (co-)substrate/(co-)substrate 
analogue. 
84 
 
7.1.3.2 Active site loops of PAH 
In total, 41 crystal structures including the catalytic domain of PAH have been deposited in the PDB. Hence, 
more structural information has been gathered on the active site loop of PAH.  
In PAH, binding of BH4 causes only subtle structural changes in the BH4 binding pocket and no large 
structural changes are observed.[266] However, binding of BH4 and an L-phenylalanine analogue in PAH 
results in large structural changes, Figure 7.4 b.[267,268] The structural changes are primarily in the active 
site loop containing residue 133-141, which is found to close around the active site corresponding to the 
observation in TPH1.  
In all structures of PAH, this loop either exists in an open or closed conformation dependent upon active site 
occupancy, Table 7.2. In Table 7.2, only crystal structures from mammalian sources are presented. The 
remaining structures are of PAH from Chromobacterium violaceum, Colwellia psychrerythraea, Legionella 
pneumophila, or Dictyostelium discoideum. The active site loop regions of structures from these species are 
not conserved and will therefore not be considered. A table which includes these structures can be found in 
Appendix H.  
Table 7.2. Crystal structures of phenylalanine hydroxylase from mammalian species. In the header, substrate 
and co-substrate refers to presence of a (co-)substrate/(co-)substrate analogue in their respective binding sites. 
Open/closed refers to an open or closed conformation of the active site loops. AA in/out refers to Phe138 
pointing towards the active site or away from active site. *: lack residues 137-139. 
PDB 
entry 
Domain(s) Species Metal Substrate Co-substrate Open/closed 
AA 
in/out 
Ref 
1PAH c Human Fe
3+
 - - Open Out [271] 
3PAH c Human Fe
3+
 - D-adrenaline Open Out [272] 
4PAH c Human Fe
3+
 - L-norepinephrine Open Out [272] 
5PAH c Human Fe
3+
 - L-dopamine Open Out [272] 
6PAH c Human Fe
3+
 - L-DOPA Open Out [272] 
1PHZ r/c Rat Fe
3+
 - - No density - [273] 
2PHM r/c Rat Fe
3+
 - - No density - [273] 
2PAH c/t Human Fe
3+
 - - No density - [274] 
1DMW c Human Fe
3+
 - BH2 Open Out [265] 
1J8T c Human Fe
2+
 - - Open Out [266] 
1J8U c Human Fe
2+
 - BH4 Open Out [266] 
1LRM c Human Fe
3+
 - BH2 Open Out - 
1KW0 c Human Fe
2+
 3-(2-thienyl)-L-alanine BH4 Closed In [267] 
1MMK c Human Fe
2+
 3-(2-thienyl)-L-alanine BH4 Closed In [268] 
1MMT c Human Fe
2+
 L-norleucine BH4 Closed In [268] 
1TDW c Human Fe
3+
 - - Open Out [275] 
1TG2 c Human Fe
3+
 - BH2 Open Out [275] 
4ANP c Human Fe
3+
 - Compound 1 Open Out [276] 
5DEN r/c/t Rat Fe
3+
 - - No density - [277] 
5EGQ r/c/t Rat - - - No density - [278] 
5FGJ r/c/t Rat Fe
3+
 - - Open* - [278] 
BH2: 7,8-dihydrobiopterin, BH4: 5,6,7,8-tetrahydrobiopterin, Compound 1 (pharmacological chaperone): 5,6-dimethyl-3-(4-methyl-2-
pyridinyl)-2-thioxo-2,3-dihydrothieno[2,3-d]pyrimidin-4(1H)-one. 
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Table 7.2 shows that structures of mammalian PAH exist in an open conformation, unless iron, L-
phenylalanine analogue, and BH4 are present. In contrast to the catalytic domain, there is no crystal structure 
of full-length PAH which includes substrates. However, a similar functional importance of the loop has been 
found in the catalytic domain and the full-length tetramer.[269] This is further supported by a spectroscopic 
study on full-length hPAH.[270] 
7.1.3.3 Active site loops of TH 
The corresponding active site loop of TH comprises residues 178-193. Three crystal structures including the 
catalytic domain of TH reside in the PDB, Table 7.3. As was the case with PAH, no significant structural 
differences are detectable between rat TH with no substrates (PDB entry: 1TOH) [279] and with BH2 (PDB 
entry: 2TOH) [280]. However, TH with no substrates do not have density in the active side loop [279], while 
TH with BH2 has density in most of the loop but miss residue 183 to 185 [280]. The conformation of the part 
of the loop which is resolved, resembles the conformation of the loop observed in the PAH with BH4 bound 
(open conformation). The last crystal structure is from human and comprises the catalytic and tetrameric 
domains and include a Zn
2+
 atom in the active site (PDB entry: 2XSN). The active site loop in this structure 
neither adopts an open nor closed conformation, but something in between. No publication follows the 
structure. 
Table 7.3. Crystal structures of tyrosine hydroxylase. In the header, substrate and co-substrate refers to 
presence of a (co-)substrate/(co-)substrate analogue in their respective binding sites. Open/closed refers to an 
open or closed conformation of the active site loops. AA in/out refers to Tyr184 pointing towards the active site 
or away from active site. *No electron density for residue 183-185. **Not as open as observed in PAH (PDB entry: 
1J8U) or TPH (PDB entry: 1MLW). 
PDB 
entry 
Domain(s) Species Metal Substrate Co-substrate Open/closed AA in/out Ref 
1TOH c/t Rat Fe
3+
 - - No density - [279] 
2TPH c/t Rat Fe
3+
 - BH2 Open* - [280] 
2XSN c/t Human Zn
2+
 - - Open** In - 
BH2: 7,8-dihydrobiopterin. 
Tyrosine in the center of the active site loop 
It is well established that open and closed conformations of the AAAHs exist. However, information regarding 
the role of this loop TPH is very scarce. Again, more information has been gathered on the other two 
members of the enzyme family. 
In TH, the importance of this loop has been investigated by alanine-scanning. It was found that residues in 
the center of the loop, especially Phe184 (corresponding to Tyr125 in TPH1), have an effect on the kinetic 
parameters.[281] Phe184 was found to be important for substrate binding and catalysis, as a F184A 
mutation resulted in a 20-fold decrease in Vmax and a 4-fold decrease in Km,Tyr.[281] Further, the mutation 
resulted in a decrease from 37 ± 7 to 21 ± 3 in Km,6-MePH4, and increased unproductive breakdown of the 
hydroxylating intermediate.[281]. Fluorescence anisotropy experiments on TH, in which Phe184 was 
mutated to a tryptophan, showed that binding of a BH4 analogue resulted in decreased mobility of this 
residue.[282] This was interpreted as a closure of the active site loop, which contradicts observations from 
the crystal structures. 
 
The function of the corresponding residue Tyr138 in human PAH has very recently been investigated.[269] 
Mutation of this residue results in reduced Vmax and catalytic efficiency (kcat/[S]0.5) in both full-length and 
isolated catalytic domain of PAH.[269] Tyr138 is also found to play a role in the L-phenylalanine induced 
substrate activation for PAH. Furthermore, it is suggested that Gln134-Ile135 and Asp143-Ala144 act as 
hinge regions for the active site loop.[269]  
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7.2 Sequence and structural analysis of the active site loop of TPH 
From studies on TH and PAH, it has been deduced that the loop, and especially the aromatic amino acid in 
the center of the loop, is important for the kinetics of the enzymes. The corresponding residues in TPH1 and 
2 are Tyr125 and Tyr171, respectively. The significance of these residues has not previously been 
investigated. In the following sections, sequence and structural analyses are presented with the purpose of 
identifying possible explanations to the different kinetic properties of the two TPH isoforms.  
7.2.1 Structural differences of the TPH isoforms 
The TPH isoforms have a sequence identity of 81 % in the catalytic domains and their crystal structures 
show an RMSDCα of only 1.1 Å. Despite these similarities, the isoforms display very different kinetic 
properties.  
The kinetic differences might originate from non-conserved residues in the catalytic site. The sequences 
were therefore aligned to identify non-conserved residues, Figure 7.5. From the sequence alignment is 
seems that non-conserved residues are scattered over the entire sequence, but lower conservation is 
seemingly observed towards the terminals. The result of the alignment was depicted on the tertiary structure 
of chTPH1 to visualize if some of the non-conserved residues were located in the active site or confined to 
specific locations on the structure. Figure 7.6 illustrates the structural positions of the 19 % non-conserved 
residues (in orange) in the catalytic domains of the human TPH isoforms.   
 
Figure 7.5. Clustal Omega alignment of chTPH1 and chTPH2. Conserved residues are shown in gray and non-
conserved residues are shown in orange. 
It appears that the non-conserved residues are randomly distributed mainly on the surface of the protein. To 
determine the degree of conservation in the active site, residues within 10 Å of the active site iron were 
investigated. Figure 7.6 shows that the conservation of residues within the catalytic sites is very high. Within 
10 Å of the active site iron, only 2 (red residues) out of 37 residues are not conserved, and these residues 
are distant from the binding pockets of the substrate and co-substrate.  
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Figure 7.6. Crystal structure of human chTPH1 with BH2 and iron (PDB entry: 1MLW) and L-tryptophan 
(superimposed from chicken TPH1, PDB entry: 3E2T [244]). Orange secondary structure indicates the position 
of non-conserved residues and gray indicates conserved residue positions between the isoforms. Residues in 
red or green are non-conserved or conserved residues within 10 Å of active site iron, respectively. For 
illustration, the binding pockets include substrate and co-substrate analogue. 
Figure 7.6 shows that the kinetic differences are most likely not explained by non-conserved residues in the 
active site, as these are neither clustered in one area nor located close to the substrate or co-substrate 
binding sites. The alignment does, however, not reveal anything about the position and orientation of 
residues. Therefore, differences in the crystal structures of the isoforms determined by RMSDCα were 
analyzed in Figure 7.7. In Figure 7.7, high and low structural similarities are colored green and red, 
respectively. 
 
Figure 7.7. Sequence alignment of the catalytic domains of TPH1 and TPH2 (Clustal Omega 1.2.3 - * = identical, : 
= very similar, . = similar). The color scale (green is low and red is high) in the alignment shows the RMSD (unit 
Å) of the Cα-atoms calculated based on chTPH1 (PDB entry: 1MLW) and chTPH2 (PDB entry: 4V06). The black 
box indicates the sequence of the active site loop. The numbering of the sequence is based on TPH1. 
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Figure 7.7 shows that a stretch of sequence with high sequence identity displays relatively high RMSDCα-
values compared to the rest of the structure. This stretch corresponds to the loop lining the active site, Figure 
7.8. Especially tyrosine 125 in the center of the loop displays a high RMSDCα-value (5.2 Å) despite the fact 
that both structures are in open conformations. This loop spans residue 117-137 of TPH1 and 163-183 of 
TPH2.  
 
Figure 7.8. Crystal structure of chTPH1 (PDB entry: 1MLW) with gray surface. The active site loop of chTPH1 is 
shown in green with Tyr125 displayed as sticks and the loop of chTPH2 (superimposed from PDB entry: 4V06) is 
shown in blue with Tyr171 displayed as sticks. In the active site, L-tryptophan (superimposed from PDB entry: 
3E2T) and BH2 are shown as sticks, and iron is shown as a pink sphere. For illustrative purposes, the binding 
pockets include substrate and co-substrate analogue. 
Figure 7.8 shows that both isoforms are in an open conformation but the side chain of the tyrosine residue in 
the center of the loop is oriented towards the active site in chTPH1 and is pointing away from the active site 
in cthTPH2. To verify these different orientations, the structures of the loops and the orientation of the 
tyrosine residues, in the crystal structures, were assessed by B-factor and electron density in the loops.  
A high value of the B-factor is associated with high mobility and low crystallographic resolution.[283] Figure 
7.9 shows the B-factors obtained from the PDB-files of the crystal structures of chTPH1 (PDB entry: 1MLW, 
1.71 Å resolution) and cthTPH2 (PDB entry: 4V06, 2.63 Å resolution). The average B-factor of the Cα-atoms 
in chTPH1 is 23.0 Å
2
 while for the loop it is 30.0 Å
2
 (Tyr125 is 30.3 Å
2
). In cthTPH2, the average B-factor of 
the Cα-atoms is 64.1 Å
2
 while for the loop it is 54.8 Å
2
 (Tyr171 is 53.0 Å
2
). In chTPH1 the B-factor of the loop 
is slightly higher than the average value, while in cthTPH2 the value is lower than the average. Based on the 
B-factors, the orientations of the loops of the isoforms seem to be well ordered.  
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Figure 7.9. B-factor of the crystal structure of chTPH1 (PDB entry: 1MLW, 1.71 Å resolution) and cthTPH2 (PDB 
entry: 4V06, 2.63 Å resolution). The horizontal dashed lines represent the average B-factor of the structures and 
the vertical dashed lines represent the loop boarders. 
The electron densities were also investigated to further assess the structure in the loop regions, Figure 7.10. 
The 2Fo-Fc electron density maps of the crystal structures show that the structures of the loops in both 
isoforms are well resolved. 
 
Figure 7.10. Density in the active site loops of the TPH isoforms. (a) Crystal structure of TPH1 (PDB entry: 
1MLW) with 2Fo-Fc density map on the loop comprising residue 117 to 137. (b) Crystal structure of TPH2 (PDB 
entry: 4V06, chain A) with 2Fo-Fc density map on the loop comprising residue 163 to 183. The mesh map of the 
loop is contoured at 1.0 σ and within 1.6 Å of the selected atoms. 
Judged from the B-factors and the electron densities of the active site loops, the orientation of the loops and 
Tyr125/171 seem to be well defined.  
7.2.2 Mutations of tyrosine in the active site loop 
In the previous section, it was identified that a tyrosine residue in the center of the active site loop has 
different orientations in the open conformation of the two TPH isoforms. It is also known that the 
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corresponding residue in TH and PAH has a profound influence on the kinetic properties of the hydroxylases. 
It was investigated whether this residue might have different roles on the kinetic properties in the two TPH 
isoforms, as a consequence of their different orientations. To decipher the role of the tyrosine residue it was 
mutated in both TPH isoforms. The identification of suitable residues for mutation is presented in chapter 8.  
The tyrosine residues in both isoforms were mutated to alanine, leucine, or tryptophan. Each variant was 
expressed in E. coli and purified to homogeneity without complications (chapter 2). The variants are referred 
to as Y125A-chTPH1, Y125L-chTPH1, Y125W-chTPH1, Y171A-chTPH2, Y171L-chTPH2, and Y171W-
chTPH2 in the following. All these variants elute as mono-disperse monomers (chapter 4) and have identical 
thermostability (chapter 3).  
7.3 Substrate inhibition of TPH 
In chapter 4, it is described that the isoforms of TPH has a sequence identity in the catalytic domain of 81 % 
and shown that the catalytic domains of both isoforms prevail as monomers. Despite these similarities, the 
isoforms have been shown to display very different kinetic properties. Especially, one feature of the kinetic 
discrepancies is interesting; TPH1 exhibits significant substrate inhibition while TPH2 does not.  
Full-length human TPH1 has been found to be substrate tryptophan inhibited.[251] Direct comparison of the 
human TPH1 variants; full-length hTPH1, cthTPH1, and rchTPH1 shows that all variants exhibit comparable 
substrate inhibition.[259] Similar observations have been made in TH, where substrate inhibition was 
retained after deletion of the regulatory domain (NΔ132 or NΔ157) or deletion of both the regulatory and 
tetramerization domain (NΔ157/CΔ43).[284] This implies that the inhibition mechanism does not involve the 
tetramerization or regulatory domains. A study on the catalytic domains of both isoforms showed that only 
isoform 1 displays substrate tryptophan inhibition.[252] The substrate inhibition constant, Ki, was determined 
to 72 ± 7 µM.[252] Substrate inhibition has similarly been identified in the catalytic domain of rabbit TPH1, 
where a Ki-value of 146 ± 14 µM was obtained.[253]  
While it is clear that TPH1 is substrate inhibited it is less so for TPH2. Conflicting results have been reported 
for substrate tryptophan inhibition of human TPH2. Several studies have found that hTPH2 is not subjected 
to substrate inhibition [260,262,263], while others have found inhibition constants of 418 ± 107 µM [261] or 
970 ± 328 µM [254]. When the isoforms are directly compared in the same study, it was found that TPH1 
displays a ~2.5 fold lower Ki compared to hTPH2.[254] A variety of enzymes are substrate inhibited, but only 
at substrate concentrations much greater than what is observed in-vivo.[285] Judged from the very high Ki-
values, this is probably the case for TPH2. In contrast, the observed Ki-values of TPH1 are in a 
physiologically relevant range.[286]  
7.4 Steady-state kinetics results of chTPH variants 
Steady-state kinetic measurements were conducted on chTPH1, chTPH2, and the mutant variants in which 
the tyrosine residue in the center of the active site loop was mutated to alanine, leucine, or tryptophan. The 
experimental procedure and data analysis utilized to determine the kinetic parameters are described in 
chapter 6. To enable comparison, the non-varied substrate concentrations were chosen based on previous 
measurements performed by M. S. Nielsen.[287] The oxygen concentration was fixed at 500 µM, L-
tryptophan at 70 µM, and BH4 at 300 µM. In this section, apparent kinetic parameters are determined given 
that saturated concentrations of the non-varied substrates are not obtained. Saturated condition cannot be 
achieved because O2 has limited solubility, BH4 has a strong absorption at the excitation wavelength used in 
the assay, and L-tryptophan displays substrate inhibition.  
chTPH1 is purified at pH 8.0 and chTPH2 is purified at pH 7.0. To compare the isoforms, the kinetic 
measurements were conducted in the same buffer solution (pH 7.0) in the kinetic assay. It was found that 
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chTPH1 has a 50 % (n = 3) higher activity at pH 7.0 compared to at pH 8.0 (data not shown). At low BH4 
concentrations very high values of intensity/min were observed. It was tested if different results were 
obtained at a lower photomultiplier tube voltage. Within statistical error, the same kinetic parameters were 
determined at 650 V and 585 V (data not shown). In the following all measurements were therefore 
conducted at 650 V.    
The results of the steady-state kinetic measurements are presented in Figure 7.11 and Table 7.4. In 
agreement with results obtained by Windahl et al.[252], chTPH1 displays substrate inhibition while chTPH2 
does not. At these substrate concentrations, a substrate inhibition constant, Ki, of 165 ± 18 µM was obtained 
for chTPH1. Furthermore, it was also confirmed that chTPH1 displays a 10-fold higher Km,BH4 compared to 
chTPH2.  
 
 
Figure 7.11. Initial rates of chTPH1 variants (panel A and B) and chTPH2 variants (panel C and D) as function of 
L-tryptophan or BH4 concentration. Each measurement is reported as an average with standard deviation of 
three to five independent experiments. The TPH concentration was 0.8 µM in all measurements. 
Initial studies showed that the mutant variant Y125L-chTPH1 displayed the same kinetic parameters (data 
not shown) as Y125A-chTPH1, but resulted in lower purification yields (chapter 2). For this reason, Y125L-
chTPH1 will not be considered in the following.  
Panel A and B of Figure 7.11 show that the mutations of Tyr125 in chTPH1 to alanine or tryptophan have a 
big impact on the kinetic plots. The plots were fitted with either the Michaelis Menten (eq. 1, chapter 6) 
equation or a modified version which considers substrate inhibition (eq. 2, chapter 6). The derived kinetic 
parameters are summarized in Table 7.4. Mutation to alanine results in a ~35 % reduction of Km,BH4, while 
mutation to tryptophan results in a 5-fold reduction. The Y125W-chTPH1 also induce a change in Km,Trp.  
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The mutations also have an effect on the apparent tryptophan inhibition constant, Ki. Mutation to alanine 
increases the Ki-value by ~40 % while mutation to tryptophan results in a greater than 3-fold increase. 
Hence, mutations of Tyr125 in the active site loop significantly reduce the substrate inhibition observed in 
chTPH1. This reduced substrate inhibition is obvious from panel A in Figure 7.11.   
Beside the reduced Km,BH4 and increased Ki-values, kcat,Trp is also found to change with the mutations. kcat,Trp 
is increased by 50 % and 3-fold by mutation to alanine and tryptophan, respectively.  
Table 7.4. Kinetic parameters of chTPH1 and chTPH2 and mutation variants. Parameters are given as averages 
with standard deviations of at least three independent experiments from at least two purification batches. **: 
p<0.01, *: p<0.05 compared to wild-type. 
  L-tryptophan   BH4 
Variant kcat (µM min
-1
) Ki (µM) Km (µM) 
 
Km (µM) kcat (µM min
-1
) 
chTPH1 108 ± 10 165 ± 18 12.7 ± 1.4 
 
285 ± 15 145 ± 17 
Y125A-chTPH1 164 ± 10** 227 ± 21* 12.6 ± 0.5 
 
188 ± 19** 192 ± 13* 
Y125W-chTPH1 315 ± 55** 544 ± 126** 36.7 ± 4.6** 
 
57 ± 5** 203 ± 9* 
Loop-swap-chTPH1 178 ± 12** 189 ± 27 13.9 ± 2.7 
 
240 ± 42 191 ± 18* 
chTPH2 258 ± 20 - 13.1 ± 1.3 
 
26.7 ± 0.9 239 ± 12 
Y171A-chTPH2 220 ± 9 - 12.1 ± 1.3 
 
31.1 ± 6.0 201 ± 27 
Y171W-chTPH2 315 ± 34 - 21.7 ± 1.5** 
 
19.2 ± 3.4 274 ± 16 
Loop-swap-chTPH2 212 ± 4 497 ± 54 14.0 ± 0.7 
 
37.6 ± 8.1 145 ± 8** 
 
For chTPH2, mutations from tyrosine to alanine or tryptophan do not result in any significant changes in the 
kinetic parameters, apart from an increase in Km,Trp for Y171W-chTPH2. These observations correlate well 
with the different orientations of the tyrosine residue seen in the two crystal structures in Figure 7.8. In 
chTPH1, the tyrosine residue is in vicinity of the active site and influences the kinetics of the enzyme, whiles 
in chTPH2 the tyrosine residue point away from the active site which results in a less pronounced effect on 
the kinetics.  
7.4.1 Steady-state kinetics – Loop-swap mutations 
Mutations of the tyrosine residue in the center of the active site loop have different outcome on the kinetics of 
TPH1 and TPH2. This is most likely explained by the different orientations of the tyrosine residue, suggesting 
that the active site loops play different roles in the isoforms. It was therefore investigated how come this 
residue faces the active site in TPH1, while pointing away from the active site in TPH2.   
Figure 7.7 shows that of the 21 residues in the active site loops, only three residues are not conserved 
between isoform 1 and 2. These residues are positioned at the very beginning of the loop, Figure 7.12. To 
examine whether these residues contribute to the different orientations of the tyrosine residue, the three non-
conserved residues in chTPH1 were mutated to the corresponding residues of the chTPH2 sequence and 
vice versa. In chTPH1, His117, Ala119, and Asn120 were mutated to Lys, Ser, and His (variant referred to 
as loop-swap-chTPH1), respectively, while the opposite mutations were performed in position 163, 165, and 
166 of chTPH2 (variant referred to as loop-swap-chTPH2).  
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Figure 7.12. Loop-swap mutations in chTPH1 and chTPH2. Crystal structures of chTPH1 (dark gray – PDB entry: 
1MLW) and chTPH2 (light gray – PDB entry: 4V06). The active site loop of chTPH1 is shown in green with His117, 
Ala119, and Asn120 displayed as green sticks and the loop of chTPH2 is shown in blue with Lys163, Ser165, and 
His166 displayed as blue sticks. In the active site L-tryptophan (superimposed from PDB entry: 3E2T) and BH2 
are shown as sticks, and iron is shown as a pink sphere. For illustration, the binding pockets include substrate 
and co-substrate analogue. 
The kinetic results of the loop-swap mutation are presented in Figure 7.13 and the kinetic parameters are 
summarized in Table 7.4. In chTPH1, the loop-swap mutations result in only modest changes in the kinetic 
parameters. kcat,Trp is increased by 65 %, Ki is slightly increased, and Km,BH4 is slightly decreased. The 
changes in the latter two parameters are statistically insignificant but change in the same fashion as 
observed for the Tyr125 mutations; Km,BH4 decreases, Ki increases, and kcat increases. 
In chTPH2, the loop-swap mutations similarly only introduce subtle changes to the kinetic parameters. kcat,BH4 
is increased and Km,BH4 is slightly increased. However, the loop-swap mutations in chTPH2 result in 
introduction of substrate tryptophan inhibition with a Ki-value of 497 ± 54 µM (Figure 7.13, panel C). In 
chTPH1, Ki and Km,BH4 seem to be inversely related. This correlates with the observations in loop-swap-
chTPH2 where Km,BH4 is increased as substrate inhibition is observed.   
These results strongly suggest that the inhibition mechanism, which is only observed for chTPH1, can be 
traced to the loop lining the active site. The induced substrate inhibition suggests that the three mutations 
change the orientation of the loop. Its orientation might approach the orientation observed in chTPH1, which 
enables it to participate in the inhibition mechanism. 
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Figure 7.13. Initial rates of chTPH1, loop-swap-chTPH1 (panel A and B), chTPH2, and loop-swap-chTPH2 (panel 
C and D) as function of L-tryptophan or BH4 concentration. Each measurement is reported as an average with 
standard deviation of three independent experiments. The TPH concentration was 0.8 µM in all measurements. 
7.4.1.1 TPH active site loop conservation  
The kinetic results of the loop-swap variants suggest that the non-conserved residues are important for the 
function of the loop in the isoforms. The degree of conservation was therefore analyzed. The conservation 
was analyzed using a logo plot [288] with sequences of TPH1 and TPH2 from 61 and 63 vertebrate species, 
respectively. The sequences of the TPH isoforms were obtained from an NCBI protein search “tryptophan 5 
hydroxylase 1/2 AND vertebrates" accessed on 21.04.2017. The results are shown as a logo plot in Figure 
7.14. The logo plot shows that the sequence of the entire loop is highly conserved among species, 
suggesting that this loop has a specialized function.   
The sequence comparison across species shows that His117, Ala119, and Asn120 of TPH1 are 13, 100, 
and 97 % conserved, respectively (n = 61 vertebrates). In TPH2 Lys163, Ser165, and His166 are conserved 
75, 100, and 33 %, respectively (n = 63 vertebrates). Of the residues in TPH1, Ala119 and Asn120 show a 
high degree of conservation, while for TPH2, Ser165 is highly conserved. This implies that these residues 
are important for proper loop orientation and function. 
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Figure 7.14. Logo plots of the loops lining the active sites of TPH1 (top) and TPH2 (bottom). The overall height of 
a column indicates the sequence conservation at a given position and the height of a symbol within the column 
indicates the relative frequency of that amino acid in that position. 
7.5 Discussion 
The kinetic data presented in this chapter shed light on the different kinetic properties that are displayed by 
the TPH isoforms despite their high sequence identity and tertiary structure. For wild-type chTPH1 and 
chTPH2 identical Km,Trp-values and a 10-fold difference in Km,BH4-values were obtained. Furthermore, a ~2-
fold greater kcat was observed for chTPH2 compared to chTPH1. These kinetic parameters correspond well 
with previous observations.[252] The observed substrate inhibition constant for chTPH1 is also in agreement 
with previously determined values.[252,287] 
The sequence and structural analyses of the two isoforms revealed that the biggest difference between the 
crystal structures is in the tyrosine residue in the active site loop. Mutation of this residue results in significant 
changes in the kinetic parameters of only chTPH1. This implies that this residue has a functional importance 
in TPH1. This is supported by findings in PAH and TH where the corresponding residues Tyr138 and 
Phe184 have been found to be important for proper enzymatic function.[269,281]    
Crystal structures of TPH and PAH have clearly revealed the presence of an open and a closed 
conformation. In the crystal structure of chTPH1, the loop is in an open conformation and Tyr125 points 
towards the active site. From the crystal structures of PAH it is observed that the corresponding residue, 
Tyr138, is only oriented towards the active site in the closed conformation. Here, Tyr138 is only ~6 Å away 
from the iron atom resulting in a closed conformation [268] while the distance is ~10 Å in chTPH1 (open 
confirmation). A similar conformation is observed in TH (PDB entry: 2XSN) where Phe184 is positioned in 
the loop facing the active site. The role of the loop closing mechanism is poorly understood. For PAH, it has 
been suggested that the closing mechanism might protect the co-substrate to enable a high degree of 
coupling efficiency.[269]  Similarly, the loop in TH has been proposed to exclude water from the active site to 
avoid reaction between the hydroxylating intermediate and water molecules before hydroxylation of substrate 
takes place.[266,281,289] A similar functional importance is supported by the very high sequence 
conservation among vertebrate species observed for both TPH isoforms. The influence of the loop on the 
substrate inhibition mechanism is further investigated and discussed in chapter 8. 
 
For PAH, it was predicted that residue 134-135 constitute a hinge region which facilitates movement of the 
active site loop.[269] This region corresponds to residue 121-122 in TPH1 and 167-168 in TPH2.  This is 
very close to the non-conserved residues Ala119-Asn120 and Ser165-His166 which were mutated in this 
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study. This suggests that the loop-swap mutations were made in, or close to, one of the proposed hinge 
regions. It can be hypothesized that movement of the tyrosine residue in the loop requires a functional hinge 
region which is only observed in TPH1. The loop-swap mutations might have enhanced this hinge region, 
enabling loop movement, which might explain the induced substrate inhibition in loop-swap-chTPH2.  
  
Besides chTPH1, substrate inhibition is also observed in TH. For TH, substrate inhibition is observed at 
tyrosine concentrations higher than 50 µM [290]. The tyrosine concentration in the brain has been found to 
vary as much as a factor of two.[291] Substrate inhibition of TH has been proposed to explain the lack of L-
dopa concentration fluctuations as a consequence of increased tyrosine concentration upon food 
intake.[285] Tryptophan concentrations are around 60 µM in the blood [286] which is close to the tryptophan 
concentration at which the maximum velocity of TPH1 is achieved in this study. This suggests that substrate 
inhibition could play a role in the TPH1 regulation in vivo. It is possible that a corresponding mechanism 
observed for TH is ensuring that the production of 5-HT does not rise to high levels in the peripheral tissues, 
which is associated with several diseases.[292] The concentration of tryptophan in the brain is in the range 
of 25-35 µM [293] which is close to the observed Km,Trp of chTPH2. The velocities of 5-HTP production and in 
turn serotonin production are, therefore, very sensitive to changes in brain tryptophan 
concentration.[293,294] This might explain the lack of substrate inhibition observed in TPH2, as rapid 
responses are desirable in the brain. It could be speculated that different regulatory mechanisms of the two 
isoforms have evolved to accommodate the diverse need for serotonin biosynthesis in different tissues. 
7.6 Conclusion 
Despite high sequence identity and very similar tertiary structure of the chTPH isoforms, only chTPH1 is 
substrate inhibited. In this chapter, it was presented how the orientations of a tyrosine residue in the active 
site loop are different in the isoforms. Steady-state kinetic results demonstrated that mutation of this residue 
only significantly change the kinetic parameters of chTPH1, meaning that this residue have different 
properties in the two isoforms. The inhibition constant was significantly increased upon mutation of Tyr125, 
revealing that this residue, and hence the active site loop, plays a role in the inhibition mechanism. This was 
confirmed by the loop-swap mutations which introduced substrate inhibition in chTPH2.   
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8 In silico analysis - inhibition of hTPH1 
In chapter 7, it was determined that chTPH1 is substrate inhibited and that Tyr125 plays a significant role in 
the inhibition mechanism. In this chapter, molecular dynamics (MD) simulations are utilized in an attempt to 
understand the substrate inhibition mechanism on a structural level.   
In the following, homology modeling and molecular dynamics simulations are briefly introduced, and the 
experimental procedures for building the initial TPH structures and setting up the MD simulations are 
presented. The resulting MD trajectories are analyzed in pursuit of understanding the underlying mechanism 
of substrate inhibition.  Some of the results presented in this chapter have been included in a submitted 
manuscript. (Appendix A.2) 
 
 
 
 
 
 
 
8.1 Homology modeling 
To conduct a molecular dynamics simulation, a starting three-dimensional (3D) structure of the protein of 
interest is needed.  In the absence of an experimental structure, homology modeling can be used to predict a 
3D protein model, which will provide insight into the structure and function of the protein.[295]     
In homology modeling, the tertiary structure of a protein is predicted based on the general observation that 
proteins with homologous sequences have similar structures. The longer and the more identical the 
sequence is, to that of an experimentally determined protein structure (template), the better the model. A 
protein domain with sequence identity >30 % is considered a homologous template.[296]    
The process of homology modeling of a target protein consists of the following consecutive steps [297,298]; 
i) Identifying sequence homologues in the PDB utilizing a sequence search tool such as BLAST [299]. The 
most complete structure with the highest possible similarity score is chosen as a template. ii) Aligning the 
sequences of the target and template proteins using an alignment tool e.g. Clustal Omega [300]. iii) Building 
the model of the target protein based on the 3D structure of the template protein by transferring the position 
of every atom, which match in the sequence alignment. iv) Performing energy minimization to alleviate bad 
bond angles, atomic interactions, and to improve local geometries.  
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8.2 Molecular dynamics simulations 
To investigate the structure-function relationship and dynamics of proteins on an atomic level, molecular 
dynamic simulations can be a useful tool.  MD is a method based on classical mechanics which allows the 
description of large systems such as proteins or protein complexes on time scales typically of nano- to 
microseconds.[301] On this time scale e.g. atomic fluctuations, side-chain rearrangements, and loop 
movement can be observed.[302,303] 
In MD simulations, the positions and momenta of all atoms in a system are calculated as a function of time 
by integrating Newton’s equation of motion in discrete time steps. The equation of motion for a system 
consisting of N particles, which interact via a potential        , i = 1,…,N can be formulated as follows [304]: 
 
         
 
  
   
   
    (eq. 1) 
where the forces are given as  
 
                           
       
    
 (eq. 2) 
In eq. 1 and 2,       ,    and     are the pair potential, mass and position of i'th atoms, respectively. In three 
dimensions, eq. 1 results in 3 N second-order differential equations. To numerically solve these equations to 
give r(t), an integration algorithm is used which successively advances the system through discrete time 
steps.[305] Integration algorithms, such as the leap-frog [306] and velocity Verlet [307], are derived from 
Taylor expansions of the positions r(t) and velocities v(t). The different algorithms use different combinations 
of Taylor expansions of velocities v(t), v(t+δ ), v(t-δ ).  
In each integration cycle of e.g. the velocity Verlet algorithm, the first steps are to calculate the velocities one 
half time step ahead v(t+δ / ) and then calculate the positions one time step ahead r(t+δ ). Then the 
accelerations one time step ahead a(t+δ ) are derived from the interaction potential using r(t+δ ). In the end 
of a cycle, the velocities one time step ahead v(t+δ ) are calculated from v(t+δ / ) and a(t+δ ), and a new 
cycle can be initiated.[304]  
The integration algorithm needs initial position and velocities for each atom in the system. The initial 
positions of the atoms are provided by the coordinate file extracted from e.g. a 3D protein structure from the 
PDB. The initial velocities are usually assigned from the Maxwell-Boltzmann distribution at a given 
temperature.[305] The result of integrating eq. 1 is a trajectory that describes how positions and velocities of 
the atoms in the system vary with time. When initiating an MD calculation, a time interval, Δ , between 
updates of atomic positions is chosen. Furthermore, force field, solvent model, ions, pH, temperature, and 
pressure have to be defined. 
8.2.1 Force field 
In MD simulations, electrons are not treated explicitly. Instead, the nucleus and the electrons are combined 
in one particle resulting in atoms modeled as spheres with point charges.[308] The forces between the 
atoms are calculated using a force field. A force field is a collection of mathematical functions with 
associated parameters which describe the interaction between different types of atoms as a function of their 
coordinates. The parameters in a force field are typically determined from experimental data and from 
quantum mechanical calculations.[309] The majority of force fields include six potential energy terms which 
can be divided into bonded interactions and nonbonded interactions. The bonded interaction terms represent 
the intramolecular potential energies given by the molecular geometry i.e. variation in bond length, bond 
angle, torsion angle, and improper torsions. The nonbonded terms describe the electrostatic and van der 
Waals interactions between atoms that are separated by at least 3 bonds or between atoms in different 
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molecules.[301] The expression describing the potential energy of a molecular system can be formulated as 
eq.3 [297]: 
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(eq. 3) 
The first term in eq. 3 (harmonic potential) represents the potential energy of bond length variation. kl 
represents the force constant of the bond, l represents the bond length, and l0 represents the equilibrium 
bond length. The second term in eq. 3 represents the potential energy of bond angle deviating from an 
equilibrium angle,   . kb represents the force constant of the angle. The third term in eq. 3 represents the 
dihedral potential energy as a function of rotation about each dihedral angle, Χ. Vn is related to the height of 
the energy barrier, n is related to the number of minima in the energy function, and α is the phase factor that 
determines the position of the energy minima. The last bonded interaction term in eq. 3 represents improper 
torsion angles. This term is introduced to preserve planarity of groups with flat geometry. In the term,  
 
 
represents the equilibrium angle, and    represents the force constant. 
The last two terms represent nonbonded interactions. The fifth term in eq. 3 represents the potential energy 
of electrostatic interactions. All atoms have assigned partial charges which remain constant throughout the 
simulation. In the electrostatic term, rij represents the distance between atoms i and j which respectively have 
charges qi and qj. ε0 is a physical constant which describes the dielectric permittivity of vacuum. The sixth 
and final term describes the van der Waals component of the potential. This term is also known as the 
Lennard-Jones 12-6 potential and contains an attractive (powered by 6) and a repulsive term (powered by 
12). Here,  ij is the energy minimum of the interactions between i and j, and σij is the distance at which the 
potential energy is zero.  
8.2.2 NPT ensemble 
Experiments are often conducted at constant temperature and pressure. It is therefore desirable to perform 
MD simulations with constant number of atoms (N) in an isothermal (T)-isobaric (P) environment (NPT 
ensemble). Using Desmond for MD simulations, the temperature is by default kept constant with a Nosé-
Hoover thermostat.[310] This thermostat maintains the temperature constant by introducing an additional 
term to the equation of motion, which simulates a fictional heat bath mass from which temperature (energy) 
can be exchanged.[305] The pressure is by default held constant by the Martyna–Tobias–Klein 
barostat.[311] This method keeps the pressure constant by allowing the volume of the simulation box to 
change. 
8.2.3 Boundary conditions 
An MD simulation is set up in a simulation box with a confined size. To avoid interactions of the molecules 
with the boundaries of the box, periodic boundary conditions are applied. With periodic boundary conditions, 
the simulation box is replicated infinitely in all directions forming a lattice. The molecules in each box will 
move in exactly the same way, hence when a molecule leaves one box an identical molecule will enter 
through the opposite face of the box.  
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8.3 Experimental procedures 
In the following, procedures to build initial structures of the catalytic domains of the human TPH isoforms are 
presented. The procedures on how the to build the MD simulation systems are also described.  
8.3.1 Model structures 
Proper initial models are needed for MD simulations. Preliminary work was conducted on a homology model 
of chTPH2 which was build using the crystal structure of chTPH1 (PDB entry: 1MLW) as template. However, 
in October 2014 a crystal structure of cthTPH2 was uploaded to the PDB (PDB entry: 4V06), which made the 
homology model redundant. Instead, the crystal structure is used in the analysis of TPH2. In the following, 
the preparation of the input structures of chTPH1 and chTPH2 are presented.  
8.3.1.1 MD input structure of chTPH1 and system setup 
In the experiments, an NΔ99/CΔ31-hTPH1 variant was used (chTPH1). This variant is purified as a fusion 
protein with MBP which is cleaved during the purification leaving two residues in the N-terminus of chTPH1 
(chapter 2). These residues are a glycine and a proline from the protease recognition site. A chTPH1 
sequence including Gly and Pro was therefore used for preparation of the input structure.   
As described in chapter 7, there are seven structures of human cTPH1 in the PDB. Of these structures, 
1MLW (PDB entry) was chosen, as it has well resolved resolution in the loop of interest and compared to 
some of the other chTPH1 structures, 1MLW does not include a bulky inhibitor which perturbs the structure.  
The sequence used in the experiments was aligned using Clustal Omega with the primary structure of 
1MLW, Figure 8.1. The sequence alignment in Figure 8.1 shows that the sequence is not fully covered by 
the structure of 1MLW, especially in the C-terminus. Furthermore, two residues do not match, as 1MLW has 
serine in position 104 and arginine in position 179, which are threonine and glutamine in the chTPH1 
sequence, respectively.  
The missing C-terminal part is covered by the crystal structure of cthTPH2 (PDB entry: 4V06). Therefore, a 
prime energy based homology model was build based on the templates 1MLW and 4V06 (chain A), Figure 
8.1. Met102 and Glu103 were built on 4V06, Thr104 to Ile393 were built on 1MLW, and Lys394 to Asp413 
were built on 4V06. The missing residues Gly98 to Gly101 in the N-terminus were modeled by prime (energy 
based). Iron was included from 1MLW.   
In the graphical interface of Maestro, iron was reduced from +3 to +2, and the model was renumbered 
starting from Gly98. Resolved water molecules from 1MLW were retained (including the three water 
molecules coordinating to iron) by aligning the structures and superimposing the water molecules into the 
model structure. In the following, superimposing refers to aligning the structures, deleting everything other 
than e.g. the water molecules (or ligand), and then merging the files. This way the position of the water 
molecules (or ligand) have been adopted. The model was further prepared by using the Protein Preparation 
Wizard (PPW) software in the Maestro suite.[312] PPW was used to add hydrogen atoms and assign bond 
orders. Overlapping water molecules were deleted (six molecules). Refinement of the structure was 
performed by iterative restrained minimization (OPLS3, 0.3 Å) and PropKa optimization [313] at pH 8.0. No 
change in protonation state was observed as a result of the optimization (net charge of zero).  
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Figure 8.1. Homology model of chTPH1. Left: Alignment of the sequence of chTPH1 (used in experiments) and 
1MLW. Highlighted sequence represents parts of the sequence modeled by prime (pink), build with 1MLW as 
template (blue), and build with 4V06 as template (green). Pink letters represent parts of the 1MLW sequence 
which have no structure (insufficient density). Right: Cartoon illustration of the chTPH1 homology model with 
same color code as in the alignment.   
To setup the system for simulation, the model was placed in an orthorhombic box with boundaries exceeding 
10 Å in each direction from the protein using System Builder workflow in Desmond [314]. For the 
experiments, chTPH1 was prepared with 100 mM (NH4)2SO4. To mimic these conditions salt was also added 
to the simulations. NaCl was chosen as (NH4)2SO4 is not parameterized. The concentration of NaCl to 
achieve the same ionic strength was calculated using eq. 4 [315]: 
 
  
 
 
     
 
 
   
 (eq. 4) 
The same ionic strength is obtained by adding a concentration of 300 mM NaCl. 0.3 M NaCl (61 Na
+
 and 61 
Cl
-
) was added to the simulation box together with 10593 TIP3P (TIP3P water model [316]) water molecules. 
8.3.1.2 MD input structure of chTPH2 and system setup 
In the experiments, an NΔ145/CΔ31-hTPH2 variant was used (chTPH2). For the same reason as for 
chTPH1, the sequence of chTPH2 includes Gly and Pro in the N-terminus. As described in chapter 7, only 
one structure of TPH2 (PDB entry: 4V06) resides in the PDB. The sequence used in the experiments was 
aligned using Clustal Omega with the primary structure of 4V06, Figure 8.2. The sequence alignment in 
Figure 8.2 shows that the sequence is covered by the crystal structure. However, the first six residues in the 
N-terminus of the crystal structure do not match the sequence. These residues are probably part of a 
purification His-tag with a tobacco etch virus protease cleavage site, as the sequence 
“MHHHHHHSSGVDLGTENLYFQ↓SM” is often found in crystal structures utilizing this purification 
strategy.[317-319]      
To obtain a model structure with an N-terminus that matches the sequence used in the experiments, a 
homology model was build based on the template 4V06 (chain A), Figure 8.2. Chain A was chosen over 
chain B because it has well resolved side chains of all residues in the active site loop. The missing residues 
in the N-terminus were modeled by prime (energy based). Iron was included from 4V06.   
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Figure 8.2. Homology model of chTPH2. Left: Alignment of the sequence of chTPH2 (used in experiments) and 
4V06. Highlighted sequence represents parts of sequence modeled by prime (pink) and was built with 4V06 as 
template (blue). Right: Cartoon illustration of the chTPH2 homology model with same color code as in the 
alignment. 
In the graphical interface of Maestro, iron was reduced from +3 to +2 and the model was renumbered 
starting from Gly144. Resolved water molecules from 4V06 were retained by aligning the structures and 
superimposing the water molecules into the model structure. In chTPH1 (1MLW), three water molecules 
were found to coordinate iron. The position of these water molecules were transferred to the model structure 
of chTPH2 by superimposition. PPW was used to add hydrogen atoms and assign bond orders. Refinement 
of the structure was performed by iterative restrained minimization (OPLS3, 0.3 Å) and PropKa optimization 
at pH 7.0. No change in protonation state was observed as a result of the optimization (net charge of -6). 
To setup the system for simulation, the model was placed in a orthorhombic box with boundaries exceeding 
10 Å in each direction from the protein. 10176 TIP3P water molecules and 0.3 M NaCl (plus six sodium ions 
to neutralize the system) were added to the simulation box. 
MD simulations and RMSD verification 
After the system setups, 100 ns simulations were conducted with the chTPH1 and chTPH2 models as input 
structures. The MD simulations were performed with the Desmond package using the OPLS3 force-field 
[320] and periodic boundary conditions in all three Cartesian coordinates. Particle-mesh Ewald method [321] 
was applied to calculate long-range electrostatic interactions. Short-range electrostatic interactions and van 
der Waals were smoothly truncated at 9 Å. The simulations were run with NPT ensemble with constant 
temperature of 300 K maintained with Nosé–Hoover thermostat [310], and constant pressure maintained at 
1.01325 bar with the Martyna–Tobias–Klein barostat method [311]. RESPA integrator [322], with a 2.0-fs 
time step was utilized to solve the equations of motion for bonded and short-range interactions.  The RESPA 
integrator default setting for nonbonded interactions beyond the 0.9-nm cutoff was 6.0 fs time step. Before 
every 100 ns production simulation run, the model structure was relaxed using a default relaxation protocol 
in Desmond. Configurations and energies were saved at 5 ps intervals.  
The simulations were analyzed for convergences based on RMSD calculations.[323] Figure 8.3 shows that 
RMSD-plots of chTPH1 (A) and chTPH2 (B) seem to converge to a stable value after relatively short time 
(~10 ns). This suggests that the protein has reached a state of equilibrium.   
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Figure 8.3. RMSD plots from 100 ns simulations of chTPH1 (A) and chTPH2 (B). RMSD in each 10
th
 frame is 
calculated for all heavy atoms in the protein with the first frame as the reference structure.   
To examine the structural and dynamical influence of substrate and co-substrate binding, tryptophan and 
BH4 were introduced into the binding pockets of chTPH1. Substrate tryptophan was introduced into the 
binding pocket by superimposition from chicken cTPH1 (PDB entry: 3E2T) which has tryptophan bound. 
Substrate tryptophan was prepared by charging the amino group to +1 and the carboxyl group to -1 and 
adding hydrogen atoms using the Protein Preparation Wizard. The binding pose of BH4 was obtained from 
the crystal structure of human cTPH1 (PDB entry: 1MLW) which has BH2 bound. BH2 was superimposed into 
the model structure and changed to BH4 by creating the appropriate double bonds. Protein Preparation 
Wizard was used to assign bond orders and add hydrogen atoms. A series of 100 ns simulations were 
conducted on chTPH1•Trp, chTPH1•BH4, and chTPH1•Trp•BH4, Figure 8.4. RMSD-plots extracted from all 
simulations in Figure 8.4 were found to converge within the 100 ns simulations (Appendix I). 
 
Figure 8.4. Diagram visualizing the conducted MD simulations on the chTPH1 variants with or without 
substrates.  
Mutations of Tyr125 in the active site loop to alanine or tryptophan were performed utilizing Residue 
Scanning in the BioLuminate suite.[324] Simulations of the mutant variants were also conducted according to 
Figure 8.4. The exact same simulations conducted for the chTPH1 variants, were also conducted for chTPH2 
and mutant variants (Y171A-chTPH2 and Y171W-chTPH2). RMSD-plots extracted from all these simulations 
were found to converge within the 100 ns simulations (Appendix I).  
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8.4 Mutation stability prediction 
In chapter 7, it was found that a tyrosine residue in the center of the active site loop is orientated differently in 
the TPH isoforms. A mutational study was made to investigate if this residue had any effect on the properties 
of the isoforms. To identify amino acids that would not destabilize the structure of the TPH isoforms, the 
software I-Mutant3.0, Prediction of Protein Mutant Stability Changes (PoPMuSiC), and Residue Scanning 
were used. In all three software, the model structures of the TPH isoforms were given as input. 
I-Mutant3.0 [325] and PoPMuSiC [326] calculate protein stability changes (ΔΔG values) upon single-site 
mutations. The software is based on machine learning and has been trained on a large database of 
thermodynamic data of mutated proteins. In the calculations, e.g. spatial environment and relative solvent 
accessible area of the residue that undergoes mutation are considered.[327,328]  
Residue Scanning [324] calculates the change in stability (ΔΔG) upon mutation from a thermodynamic cycle 
in which the difference in free energy is calculated between the folded state and the unfolded state of the 
protein. In the calculation, the unfolded protein is represented as a tripeptide, Gly-X-Gly, where X is the 
residue that is mutated. The energy is calculated with the Prime energy function using an implicit solvation 
model.[329] 
 
Figure 8.5. Change in Gibbs free energy of single point mutation of Tyr125 in chTPH1 (top) or Tyr171 in chTPH2 
(bottom). I-Mutant3.0 and PoPMuSiC use the primary vertical axis (left) while Residue Scanning uses the 
secondary vertical axis (right).   
According to the results of the three stability prediction tools in Figure 8.5, almost every amino acid will result 
in reduced stability of the TPH isoforms. Leucine and tryptophan were chosen as all three software only 
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predict small destabilizing effects upon mutation to these amino acids in both TPH isoforms. Furthermore, 
they were chosen as tryptophan is more bulky and leucine is less bulky than tyrosine, respectively. As a 
safety precaution, Tyr125 was also mutated to alanine, in case the other mutations resulted in insoluble TPH 
variants.  
8.5 MD trajectory analysis 
In the following, efforts to illuminate the observed substrate inhibition mechanism on a molecular level are 
described. The conducted MD simulations (Figure 8.4) were used to study the influence of substrate binding 
in the active site of the TPH isoforms. Furthermore, the importance of the tyrosine residue in the center of the 
active site loop was investigated by the point mutations performed based on the analysis in Figure 8.5.  
As described in chapter 7, the Y125L-chTPH1 and Y125A-chTPH1 variants displayed identical kinetics, but 
the latter resulted in significantly greater purification yield (chapter 2). For these reasons only Y125A-
chTPH1 was characterized in silico.   
8.5.1 Active site blockage 
In chapter 6, it was described how substrate tryptophan causes inhibition of chTPH1 at elevated 
concentrations (~50 µM). The underlying molecular mechanism was investigated by comparing the 
simulations trajectories of chTPH1 without substrates and chTPH1 with bound tryptophan (chTPH1•Trp). 
Here, it was observed that in the simulation of chTPH1•Trp, the entrance to the BH4 binding pocket was 
blocked by Tyr235, Figure 8.6.  
 
Figure 8.6. Substrate Trp induced blocking of the BH4 binding pocket. BH2, shown in cyan licorice, is not 
included in the simulations but have been superimposed into the structures (from PDB entry: 1MLW) to 
illustrate its binding pose. Left: snapshot extracted from MD simulation of chTPH1 without substrates. Right: 
snapshot extracted from MD simulation of chTPH1 with bound substrate Trp. The snapshots represent the 
average position of Tyr235 based on the distance measurements over the 100 ns simulations. 
As described in chapter 7, Tyr235 constitutes part of the BH4 binding pocket. The crystal structure of chTPH1 
with bound BH2 (PDB entry: 1MLW), shows that Tyr235 interacts with BH2 through π-stacking interactions, 
Figure 8.7. In Figure 8.7, it can be seen that Tyr235 is in direct contact with the active site loop through 
Tyr125. This residue might therefore have an influence on the orientation of Tyr235. This is further 
investigated in the following sections.  
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Figure 8.7. The position and orientation of Tyr125, Tyr235, and BH2 in the crystal structure of chTPH1 (PDB 
entry: 1MLW). The active site loop is colored green and dashed lines represent distances. 
8.5.2 The orientation of Tyr235 
The initial model used as input structure for the MD simulations was build on the crystal structure of chTPH1 
which has BH2 bound (PDB entry: 1MLW). The presence of BH2 in the structure might have an influence on 
the orientation of Tyr235 as they are in direct contact, Figure 8.7. It was therefore investigated whether the 
orientation of Tyr235 changes during a 100 ns MD simulation in the absence of BH4 in the active site.  
This was analyzed by calculating the average RMSD of Tyr235 (all heavy atoms) between every 10
th
 frame 
in the trajectory and the crystal structure 1MLW. In the calculation, the model structure was aligned to 1MLW 
in all frames. The same calculation was made with the crystal structure of chicken cTPH1 (Trp bound, PDB 
entry: 3E2T) as the reference structure. In the absence of tryptophan, an average RMSDTyr235 of 1.1 ± 0.3 Å 
was obtained with 1MLW as the reference structure and 3.6 ± 0.2 Å with 3E2T as the reference structure. 
This is illustrated in Figure 8.8 (left), and this means that Tyr235 maintained the orientation observed in the 
crystal structure throughout the simulation.  
Figure 8.6 illustrates that Tyr235 changes orientation in the simulation of chTPH1•Trp compared to that of 
chTPH1 without Trp. The RMSDTyr235 was similarly calculated for the simulation of chTPH1•Trp. Here, an 
average RMSDTyr235 of 3.0 ± 0.6 Å was obtained with 1MLW as the reference structure and 1.8 ± 0.6 Å with 
3E2T as the reference structure. This means that Tyr235 has changed orientation upon substrate binding. 
This tryptophan induced change in orientation of Tyr235 is clearly visualized in Figure 8.8. The resulting 
movements of Tyr235 observed in MD simulations of chTPH1 and chTPH1•Trp correlate very well with the 
structural information obtained from the crystal structures.  
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Figure 8.8. Tyr235 movement upon substrate tryptophan binding. Left: Snapshot illustrating the average 
position (based on RMSDTyr235) of Tyr235 in the simulation of chTPH1 (green). Right: Snapshot illustrating the 
average position (based on RMSDTyr235) of Tyr235 in the simulation of chTPH1•Trp (blue). Gray structures 
represent the crystal structures of chTPH1 (PDB entry: 1MLW) and chicken cTPH1 (PDB entry: 3E2T). Substrate 
tryptophan is shown in pink.   
When the simulation trajectories of chTPH1 and chTPH1•Trp were compared, it was found that substrate 
tryptophan pulls the loop comprising Ile366 to Thr368 towards the active site, Figure 8.9. This in turn results 
in formation of hydrogen bonding interaction with Tyr125 in the active site loop (Leu123-Asp138) lining the 
opposite site of the BH4 binding pocket. As Tyr125 interacts with Tyr235 through π-stacking, these residues 
move consecutively, resulting in blocking of the BH4 binding pocket.  
 
Figure 8.9. Residue movements upon substrate tryptophan binding in chTPH1. Snapshots from MD simulations 
of chTPH1 (green) and chTPH1•Trp (blue). Substrate tryptophan is shown in pink and is from the simulation of 
chTPH1•Trp. The snapshots were chosen based on average RMSDTyr235 calculations. Arrows represent 
movements caused by tryptophan and dashed lines represent hydrogen bonding distance (both distances are 
2.8 Å). The double headed arrow represents the distance measured to quantify the blocking effect.  
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The interactions observed in Figure 8.9 were analyzed throughout the simulation trajectory of chTPH1•Trp by 
measuring the distances between the involved residues, Figure 8.10. Figure 8.10 A (closed circles) shows 
that initially the distance between substrate tryptophan and Thr367 in the loop over the active site is 
relatively large (~5 Å). As the hydrogen bonding interaction is formed, the loop is pulled towards tryptophan 
and the distance is reduced to ~2 Å. It takes around 5 ns to fully establish this interaction. To verify that the 
loop is pulled down and not just tryptophan being pulled towards the loop, the distance between tryptophan 
and iron (anchor point assumed not to move) was measured, Figure 8.10 B. This distance is not changed 
significantly which confirms that the loop moves towards the active site. Such a movement of the loop is also 
observed in the crystal structures of chPAH and chicken cTPH upon substrate/substrate analogue 
binding.[330,331] Following the established interaction between tryptophan and Thr367, formation of 
hydrogen bonding interactions between Thr367 and Tyr125 are formed, Figure 8.10 A (open circles). 
Hydrogen bonding distance (< 3 Å) between these residues is observed in 62 % (after 5 ns) of the frames. In 
the simulation of chTPH1 without tryptophan, hydrogen bonding distance is observed in 0 % (average 
distance of 5 Å) of the frames. The movement of Tyr125 ultimately causes Tyr235 to move closer to Ile366 
(Figure 8.10 C) which is positioned at the opposite side of the BH4 binding pocket resulting in blocking of the 
binding site. This is further discussed in the following section. 
 
Figure 8.10. Measured distances between the residues involved in the BH4 binding site blocking mechanism 
(Figure 8.9) extracted from the MD simulation trajectory of chTPH1•Trp. 
8.5.3 Influence of Tyr125 on active site blockage 
Results from the MD simulations suggest that tryptophan binding in the active site pocket induces a change 
in the orientation of Tyr235, which results in blockage of the BH4 binding pocket. This blocking mechanism 
might explain the substrate tryptophan inhibition observed in chapter 6. In chapter 7, it was found that 
mutation of Tyr125 in chTPH1 to alanine or tryptophan resulted in increased inhibition constants (Ki) 
(retardation of the inhibition).  
The structural origin of the changes in Ki was investigated by analyzing the blocking mechanism in the TPH 
variants. To quantify the blocking effect induced by tryptophan, the shortest distance from Tyr235 to the loop 
(residue 363 to 370) lining the opposite site of the BH4 binding pocket was measured, Figure 8.9. In all the 
simulations the shortest distance observed was to Ile366. Only distances to this residue will therefore be 
presented. 
The simulation results of chTPH1 show that tryptophan induces a reduction in the average distance from 6.8 
Å to 2.93 Å (Table 8.1). This reduced distance causes the blocking of the active site visualized in Figure 8.6. 
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In Y125A-chTPH1, tryptophan only induces a reduction in the average distance to 3.4 Å, while the average 
distance observed in Y125W-chTPH1 with tryptophan bound is 5.1 Å. These observations indicate that the 
BH4 binding pocket of Y125A-chTPH1 and especially Y125W-chTPH1 are not blocked to the same extent as 
observed in chTPH1 upon tryptophan binding.  
In chTPH2, the average distance is 8.1 ± 0.6 Å between Tyr281 (corresponding to Tyr235 in chTPH1) and 
the loop lining the opposite site of the BH4 binding pocket. This distance is larger than the one observed in 
chTPH1, Table 8.1. In chTPH1, Tyr125 π-stacks onto Tyr235 forming a T-shaped interaction (Figure 8.7), 
which presumably causes restricted movement of Tyr235. In chTPH2, Tyr281 does not interact with Tyr171 
(corresponding to Tyr125 in chTPH1) because this residue is orientated away from the active site, as 
discussed in chapter 7. The movement of Tyr281 is hence less restrained in chTPH2 compared to Tyr235 in 
chTPH1.  
In the presence of substrate tryptophan, the distance in chTPH2 is reduced to 5.7 Å, which is significantly 
larger than the observed distance of 2.9 Å in chTPH1. Hence, tryptophan binding in chTPH2 results in a 
more open structure which can presumably still accommodate binding of BH4. The same is true for Y171A-
chTPH1, in which tryptophan only induces a reduction in the average distance to 5.7 Å, and Y171W-chTPH1 
where the distance is increased to 9.7 Å.  
Table 8.1. Average distances measured between Tyr235 (chTPH1 variants) or Tyr281 (chTPH2 variants) and 
Ile366 (chTPH1 variants) or Ile412 (chTPH2 variants) extracted from MD simulations of the TPH variants with or 
without substrate tryptophan in the active site. Standard errors of means are based on the blocking method 
[332] based on five 20 ns fragments. Right panel illustrates the correlation between the measured distances and 
Ki-values (from chapter 7). 
 
The interpretation of the measured distances correlates well with the kinetic data presented in chapter 7, 
insert in Table 8.1. If tryptophan binding results in a short distance, which is interpret as low accessibility to 
the BH4 binding site, strong substrate inhibition (low Ki) is observed. Upon Trp binding, the distance in 
Y125A-chTPH1 is reduced to a value slightly greater than the one observed in chTPH1, which results in a 
small increase in Ki. The effect is more pronounced in Y125W-chTPH1, where tryptophan binding reduces 
the distance to a value only slightly lower than the one observed in chTPH2. This results in a retardation of 
the substrate inhibition mechanism. In the chTPH2 variants, tryptophan binding results in large distances that 
presumably reflect conformations of the chTPH2 variants, which can still accommodate binding of BH4. The 
chTPH2 variants are therefore not subjected to substrate inhibition.   
Figure 8.9 illustrates that the Tyr235 blocking mechanism upon tryptophan binding is mediated by Tyr125. 
The distance analysis summarized in Table 8.1, shows that Tyr235 in Y125A-chTPH1 and especially 
Y125W-chTPH1 do not block the active site to the same extend as in chTPH1. This is probably due to the 
missing hydrogen bonding interaction between position Tyr125 and Thr367. A more thorough analysis of the 
trajectories of all the TPH variants are, however, required to fully illuminate the complex interplay between 
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substrate tryptophan, Thr367, Tyr125, and Tyr235, which results in blocking of the BH4 binding pocket and 
ultimately lowers the enzymatic activity. 
8.6 Discussion 
In chapter 6, it was demonstrated that chTPH1 is subjected to competitive substrate inhibition. The inhibition 
by tryptophan was found to be competitive towards BH4, as increased BH4 concentrations increased the 
apparent substrate inhibition constant. In chapter 7, it was found that substrate inhibition only applies to TPH 
isoform 1. It was proposed that this originates from the different orientations of Tyr125 (chTPH1) and Tyr171 
(chTPH2) in the active site loops of the isoforms. To further support this hypothesis and to understand the 
underlying mechanism on a molecular level, the active site loop was analyzed in silico.  
Mutation stability prediction tools were utilized to predict which amino acids Tyr125/Tyr171 could be mutated 
to, without destabilizing the proteins. Here, it was found that mutations to leucine or tryptophan should not 
compromise the stability significantly. Purification results (chapter 2), however, revealed that Y125L-chTPH1 
resulted in low purification yields. In contrast, Y125A-chTPH1 resulted in similar purification yields. 
Thermostability measurements (DSF, chapter 3) revealed that mutation of Tyr125/Tyr171 to alanine or 
tryptophan did not cause changes in the transition temperature of the TPH variants. According to the 
prediction tools, mutation to alanine should cause decreased stability. The predicted stabilities do therefore 
not correlate well with the experimental observations.   
To analyze the substrate inhibition mechanism on a molecular level, models of chTPH1 and chTPH2 and 
their mutant variants were built, and MD simulations of all the variants were conducted. From the MD 
simulation trajectories, it is observed that tryptophan binding in chTPH1 caused a blocking of the BH4 binding 
pocket. The tryptophan-induced blocking mechanism occurs through a hydrogen bonding network including 
Thr367, Tyr125, and Tyr235. Residue movements are propagated from the tryptophan binding pocket to 
Tyr235, which moves to a position that presumably prevents BH4 binding. The residues in the network have 
previously been found to have important functions or reside in important loops. The loop containing Thr367 
in chTPH1 is known to participate in substrate binding and is part of the closing mechanism discussed in 
chapter 7.[330,331] The residue corresponding to Tyr125 in PAH (Phe184) and TH (Tyr138) has also been 
found to be important for proper enzymatic function. In TH, Phe184 has been found to be important for 
substrate binding and catalysis, as a F184A mutation resulted in a 20-fold decrease in Vmax and a 4-fold 
decrease in Km,Tyr.[333] In PAH, Tyr138 has similarly been found to be important for enzymatic 
efficiency.[334] The last residue in the network, Tyr235, has also been demonstrated to play a significant 
role. A mutagenesis study by Jiang et al.[335] has shown that Tyr235 is crucial for the substrate inhibition 
mechanism of hTPH1, as mutation of this residue to alanine or leucine resulted in elimination of substrate 
inhibition. 
The blocking mechanism observed in the MD simulations compliments the kinetic model in which a dead-end 
complex is formed when tryptophan binds before BH4. Collectively, the kinetic and MD results imply that the 
competitive substrate inhibition, which occurs at elevated tryptophan concentration, is caused by binding of 
tryptophan as the first substrate which results in blocking of the BH4 binding pocket and therefore prevents 
BH4 from binding. This substrate inhibition mechanism is further supported by the correlation between the 
Tyr235-Ile366 distances and the measured Ki-values. By combining results from the kinetic study with the 
results obtained from the MD simulations, the loop is conclusively found to have an important contribution to 
the inhibition mechanism of chTPH1.  
Unfortunately, due to time constraints not all MD simulation trajectories have been included in the exploration 
of the substrate inhibition mechanism. How the mutations hamper the blocking mechanism, therefore remain 
unresolved. 
113 
 
8.7 Conclusion 
Steady-state kinetic measurements revealed that chTPH1 is substrate inhibited and that mutation of Tyr125 
results in retardation of the inhibition mechanism. The MD simulation results presented in this chapter, 
demonstrate that the inhibition mechanism occurs through a tryptophan induced blocking of the BH4 binding 
pocket. Tyr125 is an important residue in the inhibition mechanism, as it mediates residue movements from 
the tryptophan binding pocket to the BH4 binding pocket. This mechanism only applies to isoform 1, as the 
corresponding tyrosine residue in chTPH2 is orientated away from the active site.  
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Overall conclusions 
 
The overall aim of this project was to shed light on the intriguing and important enzyme tryptophan 
hydroxylase. In the process of doing so, a variety of experimental techniques and computational tools have 
been utilized. In conjugation, the obtained results have revealed interesting properties of both isoforms of 
TPH.   
The initial goal was to increase the stability of hTPH2 variants containing the regulation domain, as such 
variants are inherently instable and tend to aggregate. This cause low purification yields and hampers 
characterization. An hTPH2 variant with deletion mutations in both terminals, NΔ47-rchTPH2, was produced. 
This variant was purified as an MBP-fusion protein utilizing a rapid two-step purification procedure with on-
column cleavage of MBP. This procedure was demonstrated efficient in purification of a variety of TPH1 and 
TPH2 variants. Compared to full-length hTPH2, the NΔ47-rchTPH2 variant showed improved properties 
which resulted in around 20-fold increase in purification yield.  
Utilizing differential scanning fluorimetry, it was found that phenylalanine stabilized hTPH2 variants 
comprising the regulatory and catalytic domains in a concentration-dependant fashion. Phenylalanine was 
subsequently demonstrated to cause a ~3-fold decrease in the rate of inactivation. Analytical gel filtration 
revealed that these variants reside in a monomer-dimer equilibrium which was significantly shifted towards 
dimer in the presence of phenylalanine. This observation explaines the observed increase in thermostability. 
With phenylalanine, the purification yields were further increased ~4-fold for NΔ47-rchTPH2 resulting in a 
total increase of ~80-fold compared to full-length hTPH2.  
Within the Metalloprotein Chemistry and Engineering Group at DTU, it has been discovered that chTPH1 
and chTPH2 display very different kinetic parameters and that only chTPH1 is substrate inhibited. This is 
puzzling, as the isoforms share high sequence identity and have very similar tertiary structures. Furthermore, 
results presented in this dissertation demonstrate that the isoforms display the same unfolding temperatures 
and both reside as mono-disperse monomers.  
In this current study, the origin of the different kinetic properties was sought. It was demonstrated that the 
steady-state mechanism of chTPH1 is a hybrid Ping Pong-ordered mechanism in which the reaction can 
occur through either a Ping Pong or a sequential mechanism depending on the concentration of tryptophan. 
In this mechanism, substrate inhibition occurs if tryptophan binds before BH4, resulting in competitive 
inhibition. It was found that this inhibition mechanism involves a loop lining the active site. Mutation of Tyr125 
in the center of the active site loop of chTPH1 resulted in retardation of the inhibition mechanism. Molecular 
dynamics simulations revealed that the substrate inhibition mechanism occurs via blocking of the BH4 
binding pocket upon tryptophan binding. Substrate tryptophan binding induces structural changes which 
propagate through Thr367, Tyr125, and Tyr235 resulting in a lowered accessibility of the BH4 binding pocket.  
The influence of the loop on the inhibition mechanism was confirmed by loop-swap mutations. In agreement 
with previous results, it was found that chTPH2 is not substrate inhibited. However, mutation of three non-
conserved residues in the hinge region of the loop resulted in profound substrate inhibition. Together, these 
results demonstrate that the different kinetic properties observed for the two TPH isoforms can be traced to 
the active site loops.      
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Perspectives and future work 
 
The results in the first chapters demonstrate that the purification yield was increased to quantities sufficient 
of enzymatic characterization of an hTPH2 variant which include the regulatory domain. This enables future 
studies of the structure and function of the regulatory domain, and even opens up the possibility of 
crystallization for structure determination. With addition of phenylalanine, even full-length hTPH2 can be 
purified in quantities sufficient for e.g. kinetic studies.    
Phenylalanine only had an influence on the thermostability, monomer-dimer equilibrium, and purification 
yields of hTPH2 variants comprising the regulatory domain. The dissociation constant of phenylalanine 
associated with these changes insinuate that they are induced by binding of phenylalanine in a site other 
than the active site. This suggests an allosteric site in the regulatory domain, as has been observed in PAH. 
The existence of such a site has to be confirmed by further experiments.  
To support the presence of an allosteric site in the regulatory domain, it should be investigated whether 
phenylalanine-induced changes in the monomer-dimer equilibrium and transition temperature occur in 
isolated regulatory domain of hTPH2. Alternatively, the dimerizing or stabilizating effects of phenylalanine 
could be analyzed for rchTPH2 variants in which key residues involved in substrate binding in the catalytic 
domain are mutated. 
The presence of phenylalanine in the purification buffers did not change the purification yield of hTPH1 
variants comprising the regulatory domain. This suggests that isoform 1 does not posses such an allosteric 
site. To confirm this hypothesis, DSF and analytical gel filtration experiments should be conducted on the 
hTPH1 variants.   
It is a possibility that phenylalanine is not the in vivo relevant ligand for the potential allosteric binding site. A 
more potent ligand could potentially be identified by utilizing DSF with a compound library or using 
computational docking software. Identification of such a ligand could likely increase the stability of hTPH2 
and maybe give insight into the complicated regulatory mechanism of TPH in vivo. If in fact, the allosteric site 
is isoform specific and potent ligands for this site can be identified, these ligands might have pharmaceutical 
applications.     
The steady-state kinetic mechanism of chTPH1 was determined in this dissertation by measuring the initial 
velocities at varied concentrations of tryptophan and BH4. The obtained mechanism can be further supported 
by conducting product inhibition experiments. A similar study should be carried out for chTPH2 to deduce its 
mechanism. This would reveal whether the two highly homologous enzymes follow the same mechanism or 
chTPH1 follows a more complicated mechanism induced by e.g. the different properties of the active site 
loops.  
The stopped-flow kinetic experiments conducted in Prof. Solomon’s group at Stanford University revealed 
that a relatively long-lived transient intermediate is formed with high yields during catalytic turn-over of 
chTPH2. These results open up the possibility of isolating and characterizing the so far only theoretical 
intermediate. Identification of this intermediate is one of the last pieces in the puzzle of the hydroxylation 
reaction mechanism of the aromatic amino acid hydroxylases.      
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Supplementary Material 
Sequences 
Color-code: 
XXXX = MBP 
XXXX = 3CP 
XXXX = Linker 
XXXX = 3CP recognition and cleavage site (shown as ↓)  
XXXX = Regulatory domain 
XXXX = Catalytic domain 
MBP-chTPH2: 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEI
TPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWP
LIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAA
TMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGLEVLFQ↓GPEELEDVPW
FPRKISELDKCSHRVLMYGSELDADHPGFKDNVYRQRRKYFVDVAMGYKYGQPIPRVEYTEEETKTWGVVFRELSKLYPT
HACREYLKNFPLLTKYCGYREDNVPQLEDVSMFLKERSGFTVRPVAGYLSPRDFLAGLAYRVFHCTQYIRHGSDPLYTPE
PDTCHELLGHVPLLADPKFAQFSQEIGLASLGASDEDVQKLATCYFFTIEFGLCKQEGQLRAYGAGLLSSIGELKHALSD
KACVKAFDPKTTCLQECLITTFQEAYFVSESFEEAKEKMRDFAKSITRPFSVYFNPYTQSIEILKD 
MBP-NΔ47-rchTPH2: 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEI
TPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWP
LIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAA
TMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGLEVLFQ↓GPGNKGSSKR
EAATESGKTAVVFSLKNEVGGLVKALRLFQEKRVNMVHIESRKSRRRSSEVEIFVDCECGKTEFNELIQLLKFQTTIVTL
NPPENIWTEEEELEDVPWFPRKISELDKCSHRVLMYGSELDADHPGFKDNVYRQRRKYFVDVAMGYKYGQPIPRVEYTEE
ETKTWGVVFRELSKLYPTHACREYLKNFPLLTKYCGYREDNVPQLEDVSMFLKERSGFTVRPVAGYLSPRDFLAGLAYRV
FHCTQYIRHGSDPLYTPEPDTCHELLGHVPLLADPKFAQFSQEIGLASLGASDEDVQKLATCYFFTIEFGLCKQEGQLRA
YGAGLLSSIGELKHALSDKACVKAFDPKTTCLQECLITTFQEAYFVSESFEEAKEKMRDFAKSITRPFSVYFNPYTQSIE
ILKD 
MBP-rchTPH2: 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEI
TPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWP
LIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAA
TMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGLEVLFQ↓GPQPAMMMFS
SKYWARRGFSLDSAVPEEHQLLGSSTLNKPNSGKNDDKGNKGSSKREAATESGKTAVVFSLKNEVGGLVKALRLFQEKRV
NMVHIESRKSRRRSSEVEIFVDCECGKTEFNELIQLLKFQTTIVTLNPPENIWTEEEELEDVPWFPRKISELDKCSHRVL
MYGSELDADHPGFKDNVYRQRRKYFVDVAMGYKYGQPIPRVEYTEEETKTWGVVFRELSKLYPTHACREYLKNFPLLTKY
CGYREDNVPQLEDVSMFLKERSGFTVRPVAGYLSPRDFLAGLAYRVFHCTQYIRHGSDPLYTPEPDTCHELLGHVPLLAD
PKFAQFSQEIGLASLGASDEDVQKLATCYFFTIEFGLCKQEGQLRAYGAGLLSSIGELKHALSDKACVKAFDPKTTCLQE
CLITTFQEAYFVSESFEEAKEKMRDFAKSITRPFSVYFNPYTQSIEILKD 
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MBP-3CP: 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEI
TPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWP
LIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAA
TMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGGIPGPEHEFLNALIRRN
CHIITTDKGEFNLLGIYSNCAVVPTHAEPGDVVDIDGRLVRVLKQQVLTDMNDVDTEVTVLWLDQNEKFRDIRRFIPEHQ
QDWHNIHLATNVTKFPMLNVEVGHTVPYGEINLSGNATCRLYKYDYPTQPGQCGAVLANTGNIIGIHVGGNGRVGYAAAL
LRKYFAEEQ 
Table S1. Primers utilized to construct the TPH2 variants. 
Variant Forward Primer Reverse Primer 
MBP-chTPH2 5’- aaaagggcccgaagagctggaagatgtgc – 3’ 5’- ttttctcgagttactaatctttcagaatttcaatgctct – 3’ 
MBP-rchTPH2 5’- aaaagggccccagccggcgat – 3’ 5’- ttttctcgagttactaatctttcagaatttcaatgctct – 3’ 
MBP-NΔ47-rchTPH2 5’- aaaagggcccggcaacaaaggcagc – 3’ 5’- ttttctcgagttactaatctttcagaatttcaatgctct – 3’ 
MBP-3C Protease 5’- aaaacatatgaaaatcgaagaaggtaaactggt – 3’   5’- aaaaggatcccaccgaggttgttgttattgtt – 3’  
 
 
 
Fig. S11. Alignment of the regulatory domains of hTPH2 and rnPAH using Clustal Omaga (1.2.1). "-" marks a gap in the 
primary structure. The grey background illustrates the highly mobile part of the N-terminal region, for which no crystal 
structure is available for rnPAH and the presumably equivalently mobile region of hTPH2. "*" marks conserved residues, 
":" marks conservation of residues with highly similar properties and "." marks conservation of residues with slightly 
similar properties. 
 
 
Fig. S12. Representative example of raw data from differential scanning fluorimetry of rchTPH2 (enzyme concentration of 1 
µM) with no ligand (blue line, reference) and with addition of 10 mM L-Trp (purple line). 
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rchTPH2: 
 
Fig. S13. SDS-PAGE results of collected peaks from purification of rchTPH2 using Phe buffer. M: Molecular weight 
standard. R: Resuspension of cell culture. P: Resuspended pellet. S: Supernatant. P2: Peak eluting after cleavage with MBP-
3CP. P3: Peak from elution of MBP-bound species. P4-P7: Peaks from size exclusion chromatography. P6: Collected fraction 
of rchTPH2. 
 
 
NΔ47-rchTPH2: 
 
Fig. S14. SDS-PAGE results of collected peaks from purification of NΔ47-rchTPH2 using Phe buffer. M: Molecular weight 
standard. R: Resuspension of cell culture. P: Resuspended pellet. S: Supernatant. P2: Peak eluting after cleavage with MBP-
3CP. P3: Peak from elution of MBP-bound species. P4 and P4a: Peak from size exclusion chromatography. P4: Collected 
fraction of NΔ47-rchTPH2.   
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chTPH2: 
 
Fig. S15. SDS-PAGE results of collected peaks from purification of chTPH2 using Phe buffer. M: Molecular weight standard. 
R: Resuspension of cell culture. P: Resuspended pellet. S: Supernatant. P1: Flow-through of unbound species. P2: Peak 
eluting after cleavage with MBP-3CP. P3: Peak from elution of MBP-bound species. P4 and P5: Peaks from size exclusion 
chromatography. P5: Collected fraction of chTPH2. The presence of target protein in P3 is indicative of incomplete cleavage 
of 3CP protease in the on-column purification step.  
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Abstract 
Tryptophan hydroxylase (TPH) catalyses the initial and rate-limiting step in the biosynthesis of serotonin, 
which is associated with a variety of disorders such as depression and irritable bowel syndrome. TPH exists 
in two isoforms; TPH1 and TPH2. TPH1 catalyses the initial step in the synthesis of serotonin in the 
peripheral tissues, while TPH2 catalyses this step in the brain. In this study, the steady-state kinetic 
mechanism for the catalytic domain of human TPH1 has been determined. Varying substrate tryptophan 
(Trp) and tetrahydrobiopterin (BH4) results in a hybrid Ping Pong-ordered mechanism in which the reaction 
can either occur through a Ping Pong or a sequential mechanism depending on the concentration of 
tryptophan. The catalytic domain of TPH1 shares a sequence identity of 81 % with TPH2. Despite the high 
sequence identity, differences in the kinetic parameters of the isoforms have been identified, i.e. only TPH1 
displays substrate tryptophan inhibition. This study demonstrates that the difference can be traced to an 
active site loop which displays different properties in the TPH isoforms. Steady-state kinetic results of the 
isoforms, and variants with point mutations in a loop lining the active site, show that the kinetic parameters 
of only TPH1 are significantly changed upon mutations. Mutations in the active site loop of TPH1 result in 
an increase in the substrate inhibition constant, Ki, and therefore turnover rate. Molecular dynamics 
simulations reveal that this substrate inhibition mechanism occurs through a closure of the co-substrate, BH4, 
binding pocket, which is induced by Trp binding.  
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Introduction 
Tryptophan hydroxylase (TPH) catalyses the first and rate-limiting reaction in the biosynthesis of the 
hormone and neurotransmitter serotonin (5-HT). TPH uses Fe
2+
, tetrahydrobiopterin (BH4), and O2 to 
generate 5-hydroxytryptophan (5-HTP) by hydroxylation of tryptophan (Trp).[1] 5-HTP is converted to 5-
HT by aromatic amino acid decarboxylase [2,3]. Together with phenylalanine hydroxylase (PAH) and 
tyrosine hydroxylase (TH), TPH is a member of the enzyme subfamily of iron(II)-containing mono-
oxygenases which are known as aromatic amino acid hydroxylases (AAAHs). The enzymes in the AAAH 
family form tetramers, in which each monomeric subunit consists of an N-terminal regulatory domain, a 
highly conserved catalytic domain, and a C-terminal tetramerization domain. [1,4]  
In human two isoforms of TPH exist, where isoform 1 (TPH1) mainly is responsible for catalyzing the initial 
step in the biosynthesis of peripheral serotonin, and isoform 2 (TPH2) is associated with biosynthesis of 
neuronal serotonin [1]. Dysregulation of serotonin levels is involved in various physiological and psychiatric 
disorders such as irritable bowel syndrome, depression, obsessive compulsive disorder, and schizophrenia 
[5]. Decreased levels of neuronal serotonin are associated with neurological disorders, whereas some 
gastrointestinal disorders are associated with increased peripheral serotonin levels [6-8].  
The kinetic mechanism has not unambiguously been determined for the aromatic amino acid hydroxylases. 
Despite great efforts to dissect the mechanism, ambiguities still exist. Of the AAAHs, PAH and TH have 
been more thoroughly studied. Steady-state kinetic studies have shown that bovine TH follows a Ping Pong 
mechanism.[9,10] This mechanism is supported by observation that in rat TH, where oxidation of BH4 can 
occur in the absence of substrate tyrosine at pH 8.2.[11] However, the oxidation occurs at slower rates at pH 
7.2 and not at all at pH 6.5.[11,12] In contrast, another steady-state kinetic study on rat TH finds an ordered 
sequential mechanism involving a quaternary complex with all three substrates bound.[12] The presence of a 
ternary complex which binds O2 during catalysis in rat TH, is supported by a spectroscopic study.[13] 
Furthermore, a sequential mechanism is supported by single turn-over kinetic studies on PAH from 
chromabacterium violaceum [14,15] and rat [16]. Similar results have been obtained for rabbit TPH1.[17] 
The substrate binding order in the AAAHs have been established to occur in an ordered fashion where pterin 
binds followed by substrate amino acid and then O2. [9,15,16] That pterin binds as the first substrate is 
consistent with finding in TPH1 where inhibitors display uncompetitive inhibition towards 6-MePH4, which 
indicates that pterin binds first.[18] Additionally, the crystal structure of chicken TPH (pdb: 3e2t) shows that 
binding of tryptophan and possibly imidazole results in a closed conformation, which indicates the formation 
of a dead-end complex.[19] 
Despite a sequence identity of 71 %, the two isoforms of TPH display differences in their kinetic 
properties.[20,21] Some of the differences are accounted for by the N-terminal regulatory domains. TPH2 
has an additional 46 residues in the regulatory domain compared to TPH1. This terminal extension has a 
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great impact on enzymatic activity, and serine 19 in the terminus of TPH2 has been identified as a 
phosphorylation site.[22] However, even in the absence of the regulatory domains, the isoforms display 
different kinetic properties.[21] Besides differences in kinetic parameters (Km and Vmax-values), TPH1 
displays a greater degree of substrate tryptophan inhibition compared to TPH2.[20,21] Human TPH1 variants 
without the regulatory or tetramerization domain exhibit substrate inhibition comparable to full-length 
TPH1.[23] The underlying molecular mechanism of this inhibition and the differences in the isoforms that 
govern these observations remains elusive.   
Here, we describe results that identify the steady-state kinetic mechanism for the catalytic domain of human 
TPH1. Furthermore, we describe results that identify the structural origin of the competitive substrate 
inhibition mechanism. The inhibition mechanism of TPH1 is governed by the orientation of Tyr125 which 
enables the active site loop to participate in the mechanism. Participation of Tyr125 occurs through the 
adjacent Tyr235 which is found to block the active site access upon substrate tryptophan binding.  
Results 
Enzymatic mechanism - To explore the kinetic mechanism of TPH1, the initial velocities of the catalytic 
domain of human TPH1 (chTPH1) was determined at various tryptophan and BH4 concentrations. The 
concentrations of the substrates were varied in a concentration matrix of 14 tryptophan concentrations and 
six BH4 concentrations. The O2 concentration was 500 µM in all measurements and apparent kinetic 
parameters were hence derived. This data are presented in Figure 16. For clarity, only the lowest seven 
concentrations of tryptophan are shown in Figure 16B. For all concentration see supporting information 
Figure S1.  
 
Figure 16. Global fits to initial velocity measurements for chTPH1. The oxygen concentration was 500 µM in all 
measurements. (A) Initial velocities versus Trp concentration at fixed concentration of BH4. (B) Initial velocities versus BH4 
concentration at fixed concentration of Trp. The plots are fitted with eq. 3 (Hybrid Ping Pong-ordered EB mechanism). 
143 
 
Figure 16A shows that the data deviate from the classical hyperbolic curve. The data can be fitted very well 
with the Michaelis-Menten equation with a substrate inhibition term (eq. 2 in experimental procedures – 
Figure S2), which describes linear substrate inhibition resulting from a dead-end complex formation between 
substrate and a non-productive enzyme form.[24] When the data in Figure 16A are replotted as v0 versus 
[BH4], the plots in Figure 16B are obtained. The data follow a classic hyperbolic shape, and the Michaelis-
Menten equation (eq. 1 in experimental procedures) fits well to the data (Figure S3).  
By fitting eq. 2 to the data for each fixed BH4 concentration, an apparent tryptophan substrate inhibition 
constants, Ki, can be determined. The secondary plot in Figure 17 shows that chTPH1 displays BH4 
concentration-dependent substrate inhibition. For instance, at low fixed concentrations of BH4 (20 µM), 
chTPH1 has an apparent Ki of 24 µM, while at high BH4 concentration (400 µM) the apparent Ki is increased 
to 206 µM. 
 
Figure 17. Secondary plot of apparent Ki-values obtained at different BH4 concentrations. Values obtained by fitting the v0 vs. 
Trp concentration data at fixed BH4 concentrations presented in Figure 16A with eq. 2 
To evaluate which mechanism the kinetic data represents, global fitting was conducted. The datasets were 
fitted to the velocity equations describing a i) Ping Pong mechanism with a dead-end EB complex formation, 
ii) sequential mechanism with a dead-end EB complex formation, iii) sequential mechanism with dead-end 
EA2 complex formation, and iv) hybrid Ping Pong-ordered mechanism with dead-end EB complex formation 
(hybrid EB).[25]  
The hybrid Ping Pong-ordered mechanism in Figure 6.10 was included in the analysis because both Ping 
Pong and sequential mechanisms have been observed in steady-state kinetic studies of the AAAHs.[9,10,12] 
In the hybrid model [26,27], the reaction can either occur through a Ping Pong or a sequential mechanism 
depending on the concentration of tryptophan. Substrate inhibition is caused by competitive formation of a 
dead-end EB (TPH•Trp) complex formed when tryptophan binds before BH4. Such hybrid mechanisms have 
also been observed in e.g. pyruvate carboxylase, glutathione reductase, hypoxanthine 
phosphoribosyltransferase, and glutathione S-transferase A.[28-31] 
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Table 2. Kinetic parameters derived from global fits. Parameters are derived by fitting the data with a Ping Pong mechanism 
with dead-end EB and a hybrid Ping Pong-ordered mechanism with dead-end EB formation (Hybrid EB – eq. 3) to all the 
data. The model error is given by the sum of squared residuals. *: F-test, p<0.01. 
Mechanism 
Vmax V2 Km,Trp Km,BH4 Ki 
K3 
K4 
Error 
µM min
-1
 min
-1
  µM µM µM µM
-1
 
Ping Pong EB 213 - 23 181 51 - - 551 
Hybrid EB 210 0.3 24 135 52 2.8 0 445* 
In the global fit, the sequential mechanisms (ii and iii) resulted in identical fits, as KA was reduced to zero 
resulting in a reduction of the equations to that of a Ping Pong mechanism (i). For this reason identical 
kinetic parameters were obtained for the three mechanisms, and the sequential mechanisms were discarded. 
Based on this analysis of the conventional non-branched mechanisms, a Ping Pong mechanism fit the total 
dataset best. The hybrid EB model, however, results in an improved global fit (p < 0.01) compared to that of 
a Ping Pong mechanism, Table 2. Fitting this model to the data results in a redundancy of K4. 
 
Figure 18. Basic scheme for a branching mechanism of chTPH1. The scheme corresponds to a hybrid Ping Pong-ordered 
mechanism with dead-end TPH•Trp complex (EB). TPH* indicates a TPH that has undergone an irreversible change (e.g. 
formation of Fe
IV
=O). Upper path represents a Ping Pong mechanism, and the lower path represents a sequential mechanism. 
In the proposed hybrid mechanism in Figure 6.10, the order of pterin and substrate binding is in agreement 
with the majority of studies conducted on the AAAHs.[9-11,15-17] Substrate inhibition occurs through 
competitive inhibition by tryptophan versus BH4. This yields a BH4 concentration-dependent substrate 
tryptophan inhibition constant which has similarly been observed for TH [10]. A hybrid Ping Pong-ordered 
model in which tryptophan binds before BH4 also resulted in an improved global fit (p < 0.01) compared to 
that of a Ping Pong EB mechanism. This model was, however, discarded because of the accumulated 
experimental data, that evidently find that BH4 binds as the first substrate.[9-11,15-17] Biphasic data was 
obtained by Oka et al.[10] who therefore analyzed the data separately for velocity data obtained at 
respectively higher or lower than 0.2 mM BH4. Such data might be explained by a hybrid Ping Pong-ordered 
model, which follows different mechanisms depending on substrate concentration.    
According to this proposed hybrid model, the reaction will occur through a sequential mechanism at high 
tryptophan concentrations. This correlates well with the fact that several of the AAAH studies which obtain a 
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sequential mechanism were conducted with relatively high substrate concentrations (typically >0.5 mM 
range).[13,14,16,17] 
Sequential and structural analysis of isoform differences – The human TPH isoforms display significantly 
different kinetic parameters, and only TPH1 is subjected to substrate inhibition.[21] In this study, it was 
investigated how inhibition only apply to chTPH1. The isoforms of TPH have a sequence identity of 81 % in 
the catalytic domain, which is reflected in their similar tertiary structures. The crystal structures of the 
catalytic domains of human TPH1 (chTPH1 - pdb: 1MLW [32]) and human TPH2 (chTPH2 - pdb: 4V06) 
display a root mean square deviation of the Cα-atoms (RMSDCα) of 1.1 Å. The TPH structures have BH2 and 
imidazole bound in the pterin binding pocket, respectively. Crystal structures of the homologous 
phenylalanine hydroxylase have shown that binding of BH2 or BH4 do not cause structural changes.[33,34] 
The two TPH structures are therefore comparable.  
It was found that the 19 % non-conserved residues are randomly distributed mainly on the surface of the 
protein. Within 10 Å of the active site iron, only 2 out of 37 residues are not conserved, and these residues 
are distant from the binding pockets of the substrate and co-substrate (Supporting information, Figure S4). 
As the non-conserved residues are not clustered in one area and are not close to the substrate or co-substrate 
binding sites, differences in the crystal structures determined by RMSDCα were analyzed. The alignment, 
with color-coded RMSDCα-values, in Figure 19 shows that a stretch of sequence, corresponding to a loop 
over the active site, displays relatively high RMSDCα-values compared to the rest of the structure despite a 
high sequence homology. The loops span residues 117-137 of TPH1 and 163-183 of TPH2 and are shown in 
Figure 20. Especially tyrosine 125/171 in the center of the loop displays a relatively high RMSDCα-value (5.2 
Å).  
 
 
Figure 19. Sequence alignment of the catalytic domains of TPH1 and TPH2 (Clustal Omega 1.2.3 - * = identical, : = very 
similar, . = similar). The color scale (green is low and red is high) in the alignment shows the RMSD of the Cα-atoms 
calculated between chTPH1 (pdb: 1MLW) and chTPH2 (pdb: 4V06). The black box indicates the sequence of the active site 
loop. The numbering of the sequence is based on TPH1. 
ch TPH1 E G M E S V P W F P K K I S D L D H C A N R V L M Y G S E L D A D H P G F K D N V Y R K R R K Y F A D S A
ch TPH2 E E L E D V P W F P R K I S E L D K C S H R V L M Y G S E L D A D H P G F K D N V Y R Q R R K Y F V D V A
* : * . * * * * * : * * * : * * : * : : * * * * * * * * * * * * * * * * * * * * * * : * * * * * . * *
ch TPH1 M S Y K Y G D P I P K V E F T E E E I K T W G T V F R E L N K L Y P T H A C R E Y L K N L P L L S K Y C G
ch TPH2 M G Y K Y G Q P I P R V E Y T E E E T K T W G V V F R E L S K L Y P T H A C R E Y L K N F P L L T K Y C G
* . * * * * : * * * : * * : * * * * * * * * . * * * * * . * * * * * * * * * * * * * * : * * * : * * * *
ch TPH1 Y Q E D N I P Q L E D I S N F L K E R T G F S I R P V A G Y L S P R D F L S G L A F R V F H C T Q Y V R H
ch TPH2 Y R E D N V P Q L E D V S M F L K E R S G F T V R P V A G Y L S P R D F L A G L A Y R V F H C T Q Y I R H
* : * * * : * * * * * : * * * * * * : * * : : * * * * * * * * * * * * * : * * * : * * * * * * * * : * *
ch TPH1 S S D P F Y T P E P D T C H E L L G H V P L L A E P S F A Q F S Q E I G L A S L G A S E E A V Q K L A T C
ch TPH2 G S D P L Y T P E P D T C H E L L G H V P L L A D P K F A Q F S Q E I G L A S L G A S D E D V Q K L A T C
. * * * : * * * * * * * * * * * * * * * * * * * : * . * * * * * * * * * * * * * * * * : * * * * * * * *
ch TPH1 Y F F T V E F G L C K Q D G Q L R V F G A G L L S S I S E L K H V L S G H A K V K P F D P K I T C K Q E C
ch TPH2 Y F F T I E F G L C K Q E G Q L R A Y G A G L L S S I G E L K H A L S D K A C V K A F D P K T T C L Q E C
* * * * : * * * * * * * : * * * * . : * * * * * * * * . * * * * . * * . : * * * * * * * * * * * *
ch TPH1 L I T T F Q D V Y F V S E S F E D A K E K M R E F T K T I K R P F G V K Y N P Y T R S I Q I L K D
ch TPH2 L I T T F Q E A Y F V S E S F E E A K E K M R D F A K S I T R P F S V Y F N P Y T Q S I E I L K D
* * * * * * : . * * * * * * * * : * * * * * * : * : * : * . * * * . * : * * * * : * * : * * * *
130 135 140 145 150125100 105 110 115 120
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The corresponding loop in PAH has been found to reside in either an open or closed conformation depending 
on the active site occupancy. A closed conformation has only been observed in the presence of both a pterin 
and a substrate analogue.[35,36]  However, a structure of PAH with only a substrate/substrate analogue has 
not been determined, and it is therefore unknown whether the loop closure occurs solely upon binding of 
substrate or a combination of substrate and co-substrate. Compared to the closed structures of PAH, both 
isoforms of human TPH exist in open conformations. For TPH, a closed conformation has been observed in a 
crystal structure of chicken TPH1 with bound substrate Trp and imidazole (pdb: 3E2T).[19] 
From Figure 20, it is noticed that the side chain of the tyrosine residue is oriented towards the active site in 
TPH1 but is pointing away from the active site in TPH2. The structures of the loops and the orientation of 
the tyrosine residues in the crystal structures are assessed by electron density in the loops. The 2Fo-Fc 
electron density maps of the crystal structures show that the structures of the loops in both isoforms are well 
resolved (Supporting information Figure S5 and S6).  
 
Figure 20. Crystal structure of chTPH1 (pdb: 1MLW – open conformation) with gray surface. The active site loop of chTPH1 
is shown in green with tyrosine 125 displayed as sticks and the loop of chTPH2 (superimposed from pdb: 4V06 – open 
conformation) is shown in orange with tyrosine 171 displayed as sticks. For illustration, Trp (superimposed from pdb: 3E2T) 
and BH2 have been placed in their respective binding pockets. Trp and BH2 are shown as cyan sticks and iron is shown as 
sphere. 
The effect of Tyr125/171 point mutations on TPH kinetics - In order to probe the importance of the loop in 
TPH, Tyr125 in chTPH1 and Tyr171 in chTPH2 were mutated to the smaller amino acid alanine or the more 
bulky amino acid tryptophan and characterized for changes. As the oligomeric state and the transition 
temperatures of the isoform mutant variants were not changed (Supporting information, Figure S7, Table S1, 
and Table S2), the kinetic parameters can be directly compared. Apparent kinetic parameters are determined 
given that saturated concentrations of the non-varied substrate could not be obtained due to substrate 
inhibition. 
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In agreement with Windahl et al. [21], chTPH1 displays substrate inhibition, with a substrate inhibition 
constant of 165 ± 18 µM, while chTPH2 does not display substrate inhibition (Table 3, Figure 21 panel A 
and C open circles). Additionally, chTPH1 displays a 10-fold higher Km,BH4 compared to chTPH2.  
The kinetic analysis shows that mutation of the tyrosine residue in the loop results in great changes in the 
kinetic parameters of chTPH1 (Table 3 and Figure 21). Mutation to alanine results in a small reduction of 
Km,BH4, while mutation to tryptophan results in a 5-fold reduction. A change in Km,Trp is only observed for 
Y125W-chTPH1. Notably, the mutations result in a significant increase in the substrate inhibition constant, 
Ki. Mutation to alanine increases the Ki-value slightly, while mutation to tryptophan results in a greater than 
3-fold increase. The decreased substrate inhibition is clearly visualized in Figure 21 panel A.  
Beside the reduced Km,BH4 and increased Ki-values, kcat,Trp is also found to change with the mutations. Similar 
to the other kinetic parameters, kcat,Trp is slightly increased with mutation to alanine and increased 3-fold by 
mutation to tryptophan.  
Table 3. Kinetic parameters of chTPH1 and chTPH2 variants derived from data presented in Figure 21. Parameters are 
given with standard deviations of at least three independent experiments from at least two purification batches. *: p < 0.05, 
**: p < 0.01. 
  Tryptophan   BH4 
Variant kcat (µM min
-1) Ki (µM) Km (µM) 
 
Km (µM) kcat (µM min
-1) 
chTPH1 108 ± 10 165 ± 18 12.7 ± 1.4 
 
285 ± 15 145 ± 17 
Y125A-chTPH1 164 ± 10** 227 ± 21* 12.6 ± 0.5 
 
188 ± 19** 192 ± 13* 
Y125W-chTPH1 315 ± 55** 544 ± 126** 36.7 ± 4.6** 
 
57 ± 5** 203 ± 9* 
Loop-swap-chTPH1 178 ± 12** 189 ± 27 13.9 ± 2.7 
 
240 ± 42 191 ± 18* 
chTPH2 258 ± 20 - 13.1 ± 1.3 
 
26.7 ± 0.9 239 ± 12 
Y171A-chTPH2 220 ± 9 - 12.1 ± 1.3 
 
31.1 ± 6.0 201 ± 27 
Y171W-chTPH2 315 ± 34 - 21.7 ± 1.5** 
 
19.2 ± 3.4 274 ± 16 
Loop-swap-chTPH2 212 ± 4 497 ± 54 14.0 ± 0.7 
 
37.6 ± 8.1 145 ± 8** 
For chTPH2, mutation from tyrosine to alanine or tryptophan results in no significant changes in the kinetic 
parameters, apart from a change in the Km,Trp. These observations correlate well with the different 
orientations of the tyrosine residue seen in the two crystal structures. In chTPH1, the tyrosine residue is in 
vicinity of the active site and influences the kinetics of the enzyme, while in chTPH2, the tyrosine residue 
point away from the active site which results in a less pronounced effect on the kinetics.  
Loop-swap mutations of non-conserved residues - Of the 21 residues located in the loop, only three residues 
are not conserved between the isoforms (Figure 19). To examine whether these residues contribute to the 
different orientations of the tyrosine residue, the three non-conserved residues in chTPH1 were mutated to 
the corresponding residues of the sequence of chTPH2 and vice versa. In chTPH1, His117, Ala119, and 
Asn120 were mutated to Lys, Ser, and His, respectively (referred to as loop-swap-chTPH1), while the 
148 
 
opposite mutations were performed in position 163, 165, and 166 of chTPH2 (referred to as loop-swap-
chTPH2).  
The kinetic results of the loop-swap mutations are presented in Figure 21, and the kinetic parameters are 
summarized in Table 3. In chTPH1, the loop-swap mutations result in only modest changes in the kinetic 
parameters. Although statistically insignificant, the kinetic parameters change in the same fashion as 
observed for the Tyr125 mutations; Km,BH4 decreases, Ki increases, and kcat,Trp increases. 
In chTPH2, the loop-swap mutations similarly only introduce modest changes to the kinetic parameters. 
However, the loop-swap mutations in chTPH2 result in introduction of substrate tryptophan inhibition with a 
Ki-value of 497 ± 54 µM (Figure 21, panel C black circles). In chTPH1, Ki and Km,BH4 seem to be inversely 
related. This correlates with the observations in loop-swap-chTPH2 where Km,BH4 is increased with the 
introduced substrate inhibition.   
 
Figure 21. The initial rates of the chTPH1 variants (panel A and B) and of the chTPH2 variants (panel C and D) as a function 
of Trp or BH4 concentration. The oxygen concentration was 500 µM in all measurements. Each measurement is reported as 
an average with standard deviation of at least three independent experiments from at least two purification batches. The 
TPH concentration was 0.8 µM in all measurements. 
The conservation of the loops was analyzed (logo plot [37] in Supporting information Figure S8) with 
sequences of TPH1 and TPH2 from 61 and 63 vertebrate species, respectively. It was found that His117, 
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Ala119 and Asn120 of TPH1 are 13, 100, and 97 % conserved, respectively. In TPH2, Lys163, Ser165, and 
His166 are conserved 75, 100, and 33 %, respectively. Of the residues in TPH1, Ala119 and Asn120 show a 
high degree of conservation, while for TPH2, Ser165 is highly conserved. This implies that these residues are 
important for proper loop orientation and function. 
Molecular Dynamics (MD) Simulations - MD simulations were employed to investigate the underlying 
mechanism that governs the observed substrate inhibition in TPH1. 100 ns MD simulations of chTPH1 with 
and without substrate Trp were conducted. From comparison of the trajectories, it is observed that in the 
presence of Trp, the entrance to the BH4 binding pocket becomes blocked, Figure 22. The blocking of the 
entrance is caused mainly by Tyr235. Tyr235 is in direct contact with the active site loop through Tyr125, 
which is under investigation, Figure 23A.[32]   
 
Figure 22. Substrate Trp induced closure of the BH4 binding pocket. BH2, shown in cyan licorice, is not included in the 
simulations but have been superimposed into the structures (from pdb: 1MLW) to illustrate its binding pose. Left: snapshot 
extracted from MD simulation of chTPH1 without substrates. Right: snapshot extracted from MD simulation of chTPH1 
with bound substrate Trp. The snapshots represent the average position of Tyr235 based on the distance measurements over 
the 100 ns simulations  
Throughout the simulation of chTPH1, Tyr235 resides in a position very similar to the one observed in the 
crystal structure (average RMSDTyr235 of 1.1 Å compared to 1MLW and 3.6 Å compared to 3E2T), Figure 
23B. In the simulation of chTPH1 with Trp in the active site, Tyr235 moves to the position which blocks the 
BH4 entrance. This new position of Tyr235 is very similar to the one observed for the equivalent Tyr236 in 
the crystal structure of chicken TPH1 [19] which has Trp bound (average RMSDTyr235 of 1.8 Å from 3E2T 
and 3.0 Å from 1MLW), Figure 23. The movement of Tyr235 observed in the simulation of chTPH1 
correlates very well with the structural information obtained from the crystal structures. The importance of 
Tyr235 for the inhibition mechanism of TPH1 is supported by a mutational study, in which it was found that 
substrate inhibition was removed upon mutation of Tyr235 to alanine or leucine.[38]  
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In chTPH1, Tyr235 constitutes part of the BH4 binding pocket and is in direct contact with the pterin.[32] 
Tyr125 which is under investigation in this study, π-stacks onto Tyr235 forming a T-shaped interaction.[32] 
It is therefore reasonable to believe that mutation of Tyr125 has an influence on the orientation of Tyr235 
and thereby explain the influence on the kinetic parameters, especially the substrate inhibition.  
 
Figure 23. (A) The position and orientation of Tyr125, Tyr235, and BH2 in the crystal structure of chTPH1 (pdb: 1MLW). 
The active site loop is colored green and dotted lines represent distances. (B) Superposition of the crystal structure of human 
TPH1 (pdb: 1MLW), chicken TPH1 (pdb: 3E2T), snapshot from MD simulation of chTPH1 without substrate (green 
Tyr235), and snapshot from MD simulation of chTPH1 with bound Trp (orange Tyr235). The snapshots represent the 
average position of the tyrosine residues based on the distance measurements over the 100 ns simulations. 
Discussion 
The data presented here shed light on the kinetic mechanism of TPH1 and on the different kinetic properties 
which are displayed by the TPH isoforms. The kinetic mechanism of TPH has not previously been 
determined and both Ping Pong and sequential mechanisms have been observed in steady-state kinetic 
studies of the AAAHs.[9-11] In this study, a hybrid Ping Pong-ordered mechanism in which the reaction can 
either occur through a Ping Pong or a sequential mechanism depending on the concentration of tryptophan is 
observed. The substrate binding order is BH4 followed by tryptophan and substrate inhibition occurs through 
competitive inhibition of tryptophan versus BH4. This order of substrate binding is in agreement with the 
majority of studies conducted on the AAAHs. [9-12,15-17] This model might explain the contradicting 
results obtained for the AAAHs because very different substrate concentrations are used in these studies.  
In this study, wild-type chTPH1 and chTPH2 displayed identical Km,Trp-values but a 10-fold difference in 
Km,BH4-values. Furthermore, a ~2-fold greater kcat,Trp was observed for chTPH2 compared to chTPH1 and 
only chTPH1 displayed substrate inhibition. These kinetic parameters correlate well with previous 
observation.[21,39] TPH2 has similarly been reported not to be subject of substrate inhibition [1,22,40] but 
has also been found to display inhibition, however, with relatively high inhibition constants (418 - 970 µM) 
[20,41]. Substrate inhibition is an important regulatory mechanism observed in a variety of enzymes.[42] 
Amino acid substrate inhibition has been observed in both full-length human TPH1 and rat TH.[43,44] 
Deletion mutagenesis has shown that substrate inhibition is retained to upon deletion of either the regulatory 
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or tetramerization domain of TPH and TH.[23,44] This suggests that the observed substrate inhibition in full-
length TPH and TH only involves the catalytic domain, which implies that the results obtained in this study 
can be applied to the full-length enzyme.  
The sequential and structural analyses of the two isoforms revealed that the biggest difference between the 
crystal structures is the tyrosine residue in the active site loop. Mutation of this residue resulted in significant 
changes in the kinetic parameters of only chTPH1. This implies that this residue has a functional importance 
in TPH1. The importance of this loop and in particular this residue is supported by findings in PAH and TH 
where the corresponding residues Tyr138 and Phe184 have been found to be important for proper enzymatic 
function.[45,46]  
Crystal structures of TPH and PAH have clearly revealed the presence of an open and a closed conformation. 
For PAH, closed conformations have only been observed when both a pterin and a substrate analogue are 
bound.[35,36]  A closed conformation has also been observed for chicken TPH1 with bound tryptophan and 
imidazole.[19] Imidazole is bound in the BH4 binding pocket, which might mimic binding of co-substrate.  
However, a structure of TPH or PAH with only a substrate/substrate analogue has not been determined, and 
it is therefore unknown whether the loop closure occurs solely upon binding of substrate or a combination of 
substrate and co-substrate. The role of the loop closing mechanism is poorly understood. For PAH, it has 
been suggested that the closing mechanism might protect the co-substrate to enable a high degree of coupling 
efficiency.[45]  Similarly, the loop in TH has been proposed to exclude water from the active site to avoid 
reaction of the water with the hydroxylating intermediate before hydroxylation of substrate can 
occur.[34,46,47] A similar functional importance of the loop in TPH is supported by the very high sequence 
conservation among vertebrate species observed for both TPH isoforms. 
From the MD simulations, it is observed that Trp binding in chTPH1 results in a blocking of the BH4 binding 
pocket. The Trp-induced blocking mechanism occurs through Tyr235 which moves from a BH4 binding 
position to a position in the opening of the BH4 binding pocket. This observation compliments the kinetic 
model in which a dead-end complex is formed when Trp binds before BH4. The influence of Tyr235 on the 
substrate inhibition mechanism is also supported by the results of Jiang et al. where mutations of Tyr235 to 
alanine or leucine were found to remove substrate inhibition.[38]. Tyr235 is in direct contact with the active 
site loop through Tyr125.[32] The mutations of Tyr125 will therefore most likely have an influence on the 
orientation of Tyr235, and thereby explain the influence on the kinetic parameters, especially the substrate 
inhibition. These results strongly suggest that the inhibition mechanism, which is only observed for chTPH1, 
can be traced to the loop lining the active site. The induced substrate inhibition observed in loop-swap-
chTPH2 suggests that the three mutations change the orientation of the loop to an orientation approaching 
the one observed in chTPH1.  
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Besides chTPH1, substrate inhibition is also observed in TH. For TH, substrate inhibition is observed at 
tyrosine concentrations higher than 50 µM [48]. The tyrosine concentration in the brain has been found to 
vary as much as a factor of two. [49] Substrate inhibition of TH has been proposed to explain the lack of L-
DOPA concentration fluctuations as a consequence of increase Tyr concentration upon food intake.[42] Trp 
concentrations are around 60 µM in the blood [50] which is close to the Trp concentration at which the 
maximum velocity of TPH1 is achieved in this study. This suggests that substrate inhibition could play a role 
in the TPH1 regulation in vivo. It is possible that a corresponding mechanism observed for TH is ensuring 
that the production of 5-HT does not rise to high levels in the peripheral tissues, which is associated with 
several diseases.[51] The concentration of tryptophan in the brain is in the range of 25-35 µM [52] which is 
close to the observed Km,Trp of chTPH2. The velocities of 5-HTP production and in turn serotonin production 
are, therefore, very sensitive to changes in brain Trp concentration.[52,53] This might explain the lack of 
substrate inhibition observed in TPH2, as rapid responses are desirable in the brain. It could be speculated 
that different regulatory mechanisms of the two isoforms have evolved to accommodate the diverse need for 
serotonin biosynthesis in different tissues. 
Experimental Procedures 
Materials. All used chemicals were of analytical grade, and all solutions were prepared using water from an 
18.2 MΩ·cm Milli-Q synthesis A10 Q-Gard system which was filtered through a 0.22 µm filter. Protein 
purification was performed on an ÄKTA purifier 100 from GE Healthcare. Utilized GE Healthcare column 
are: HiLoad Superdex 200 26/60 pg, Superdex 200 10/300 GL, and a XK 16/20 column packed with 25 mL 
Dextrin Sepharose High Performance media. During purifications, all TPH containing solutions were kept in 
ice water, except during the chromatographic steps, which were performed at room temperature. Protein 
solutions were concentrated using an Amicon ultrafiltration cell with an Ultracell PL-3 membrane. Protein 
concentrations were determined by measuring the absorbance at 280 nm on an ND-1000 NanoDrop 
Spectrophotometer from Saveen Werner.  
Cloning and Expression. Full-length human TPH2 cDNA optimized for expression in E. coli was obtained 
from GenScript. The construct encoding the different protein variants was obtained by PCR. All DNA 
sequences were verified by sequencing (Eurofins). All proteins were expressed as maltose binding protein 
fusion proteins from the pET26 expression vector in E. coli BL21(DE3) (Novagen) cells. All TPH1 and 
TPH2 variants were expressed as NΔ99/CΔ31 and NΔ145/CΔ31, respectively, lacking the N-terminal 
regulatory domain and the C-terminal tetramerization domain. The sequences of the proteins expressed are 
given in Supporting information. The recombinant fusion proteins contain a cleavage recognition site for 
human rhinovirus 3C protease (3CP) [54]. Proteins were expressed at 20°C for 14 h as previously described 
[55]. MBP-3CP was cloned, expressed, and purified in-house. 
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Purification. The purification procedure comprises an affinity chromatography step utilizing a column 
packed with dextrin sepharose and a size exclusion step using a HiLoad Superdex 200 prep grade column, as 
previously described [56]. All variants were cleaved from the MBP fusion protein utilizing an on-column 
cleavage procedure with MBP-3CP during the first purification step. Human TPH1 variants were purified in 
buffer containing 20 mM TRIS/H2SO4, 100 mM (NH4)2SO4, pH 8.0 and human TPH2 variants in 20 mM 
HEPES/NH4OH, 100 mM (NH4)2SO4, pH 7.0. 
Activity Assay. The activity assay was performed as described by Moran et al. [57] and Nielsen et al.[55], 
and the sample preparation was conducted as previously described [56]. The activity measurements were 
performed using a Varian Cary Eclipse Fluorescence Spectrophotometer. For activity measurements, the 
TPH variants were thawed under running water, filtered, and the concentrations were determined by UV-Vis 
absorption at 280 nm. The TPH samples were diluted with the buffer in which they were purified. TPH 
activity was assayed in a reaction mixture (10x10 mm QS quartz cuvette from Hellma - 2500 µL total 
volume) containing 50 mM HEPES/NH4OH, 200 mM (NH4)2SO4, pH 7.0, 0.025 g/L catalase, 25 µM  
(NH4)2Fe(II)(SO4)2
.
6H2O, 7 mM dithiothreitol (DTT) with stirring at 15 °C. The standard substrate 
concentrations were 70 µM L-Trp, 300 µM BH4, and 500 µM O2. The O2 concentration was achieved by 
equilibrating the solution with a mixture of O2 and N2. Excitation and emission wavelengths were 300 and 
330 nm, respectively. Initial velocity was determined from linear regression through the first 0.04 min after 
BH4 addition. Apparent kinetic parameters were calculated by curve fitting using non-linear least-squares 
approach. When only one substrate was varied, the initial velocity data were fitted using eq. 1 or eq. 2 in case 
of substrate inhibition. When two substrates were varied, the initial velocity data were fitted using eq. 
3.[26,27,29] 
   
       
      
                                                                                                                       
   
       
       
    
  
                                                                                                          
   
                   
 
         
   
  
                                
                    
Kinetic parameters were determined from three independent experiments from at least two different 
purifications batches for each variant. 
Molecular Dynamic Simulations. The x-ray structures of TPH1 (pdb: 1MLW, open loop conformation) and 
TPH2 (pdb: 4V06, open loop conformation) were used as initial models for MD simulations. The crystal 
structure of human TPH1 lacks interpretable electron density in the C-terminus (residue 394 to 413). 
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Homology modeling was utilized to build the terminus with 4V06 as template. The position and orientation 
of substrate Trp were obtained from the crystal structure of chicken TPH (pdb: 3E2T [19]) and superimposed 
into the structures of human TPH isoforms.  
In the Schrödinger suite, mutations were performed by Residue Scanning in the BioLuminate suite.[58] The 
proteins were prepared for simulation with the default parameters of the Protein Preparation Workflow in 
Maestro [59]. Protonation states at pH 8.0 were assigned with the PropKa module [60]. The system was built 
by adding 0.3 M NaCl and water molecules (TIP3P model [61]) in an orthorhombic box exceeding 10 Å in 
each direction from the protein using System Builder workflow in Desmond [62]. The MD simulations were 
performed with the Desmond package using the OPLS3 force-field [63], and periodic boundary conditions in 
all three Cartesian coordinates were applied. Particle-mesh Ewald method [64] was applied to calculate long-
range electrostatic interactions. Short-range electrostatic and van der Waals interactions were smoothly 
truncated at 9 Å. The simulations were run with constant number of atoms, with constant temperature of 300 
K maintained with Nosé–Hoover thermostats [65], and constant pressure maintained at 1.01325 bar with the 
Martyna–Tobias–Klein barostat method [66]. RESPA integrator [67], with a 2.0-fs time step was utilized to 
solve the equations of motion for bonded and short-range interactions.  The RESPA integrator default setting 
for nonbonded interactions beyond the 0.9-nm cutoff was 6.0-fs time step. Before every 100-ns production 
simulation run, a relaxation with the default parameters in Desmond was performed. Configurations and 
energies were saved at 5-ps intervals. Convergences of the MD simulations were based on RMSD 
calculations. 
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Supporting information 
 
Sequences of TPH variants and MBP-3CP 
Color-code: 
XXXX = MBP 
XXXX = 3CP 
XXXX = Linker 
XXXX = 3CP recognition and cleavage site (shown as ↓)  
XXXX = Catalytic domain 
 
MBP-chTPH2: 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEI
TPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWP
LIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAA
TMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGLEVLFQ↓GPEELEDVPW
FPRKISELDKCSHRVLMYGSELDADHPGFKDNVYRQRRKYFVDVAMGYKYGQPIPRVEYTEEETKTWGVVFRELSKLYPT
HACREYLKNFPLLTKYCGYREDNVPQLEDVSMFLKERSGFTVRPVAGYLSPRDFLAGLAYRVFHCTQYIRHGSDPLYTPE
PDTCHELLGHVPLLADPKFAQFSQEIGLASLGASDEDVQKLATCYFFTIEFGLCKQEGQLRAYGAGLLSSIGELKHALSD
KACVKAFDPKTTCLQECLITTFQEAYFVSESFEEAKEKMRDFAKSITRPFSVYFNPYTQSIEILKD 
 
MBP-Y171A-chTPH2: 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEI
TPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWP
LIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAA
TMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGLEVLFQ↓GPEELEDVPW
FPRKISELDKCSHRVLMAGSELDADHPGFKDNVYRQRRKYFVDVAMGYKYGQPIPRVEYTEEETKTWGVVFRELSKLYPT
HACREYLKNFPLLTKYCGYREDNVPQLEDVSMFLKERSGFTVRPVAGYLSPRDFLAGLAYRVFHCTQYIRHGSDPLYTPE
PDTCHELLGHVPLLADPKFAQFSQEIGLASLGASDEDVQKLATCYFFTIEFGLCKQEGQLRAYGAGLLSSIGELKHALSD
KACVKAFDPKTTCLQECLITTFQEAYFVSESFEEAKEKMRDFAKSITRPFSVYFNPYTQSIEILKD 
 
MBP-Y171W-chTPH2: 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEI
TPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWP
LIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAA
TMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGLEVLFQ↓GPEELEDVPW
FPRKISELDKCSHRVLMWGSELDADHPGFKDNVYRQRRKYFVDVAMGYKYGQPIPRVEYTEEETKTWGVVFRELSKLYPT
HACREYLKNFPLLTKYCGYREDNVPQLEDVSMFLKERSGFTVRPVAGYLSPRDFLAGLAYRVFHCTQYIRHGSDPLYTPE
PDTCHELLGHVPLLADPKFAQFSQEIGLASLGASDEDVQKLATCYFFTIEFGLCKQEGQLRAYGAGLLSSIGELKHALSD
KACVKAFDPKTTCLQECLITTFQEAYFVSESFEEAKEKMRDFAKSITRPFSVYFNPYTQSIEILKD 
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MBP-loop-swap-chTPH2: 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEI
TPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWP
LIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAA
TMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGLEVLFQ↓GPEELEDVPW
FPRKISELDHCANRVLMYGSELDADHPGFKDNVYRQRRKYFVDVAMGYKYGQPIPRVEYTEEETKTWGVVFRELSKLYPT
HACREYLKNFPLLTKYCGYREDNVPQLEDVSMFLKERSGFTVRPVAGYLSPRDFLAGLAYRVFHCTQYIRHGSDPLYTPE
PDTCHELLGHVPLLADPKFAQFSQEIGLASLGASDEDVQKLATCYFFTIEFGLCKQEGQLRAYGAGLLSSIGELKHALSD
KACVKAFDPKTTCLQECLITTFQEAYFVSESFEEAKEKMRDFAKSITRPFSVYFNPYTQSIEILKD 
 
MBP-chTPH1: 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEI
TPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWP
LIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAA
TMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGLEVLFQ↓GPDGMETVPW
FPKKISDLDHCANRVLMYGSELDADHPGFKDNVYRKRRKYFADLAMNYKHGDPIPKVEFTEEEIKTWGTVFQELNKLYPT
HACREYLKNLPLLSKYCGYREDNIPQLEDVSNFLKERTGFSIRPVAGYLSPRDFLSGLAFRVFHCTQYVRHSSDPFYTPE
PDTCHELLGHVPLLAEPSFAQFSQEIGLASLGASEEAVQKLATCYFFTVEFGLCKQDGQLRVFGAGLLSSISELKHALSG
HAKVKPFDPKITCKQECLITTFQDVYFVSESFEDAKEKMREFTKTIKRPFGVKYNPYTRSIQILKD 
 
MBP-Y125A-chTPH1: 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEI
TPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWP
LIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAA
TMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGLEVLFQ↓GPDGMETVPW
FPKKISDLDHCANRVLMAGSELDADHPGFKDNVYRKRRKYFADLAMNYKHGDPIPKVEFTEEEIKTWGTVFQELNKLYPT
HACREYLKNLPLLSKYCGYREDNIPQLEDVSNFLKERTGFSIRPVAGYLSPRDFLSGLAFRVFHCTQYVRHSSDPFYTPE
PDTCHELLGHVPLLAEPSFAQFSQEIGLASLGASEEAVQKLATCYFFTVEFGLCKQDGQLRVFGAGLLSSISELKHALSG
HAKVKPFDPKITCKQECLITTFQDVYFVSESFEDAKEKMREFTKTIKRPFGVKYNPYTRSIQILKD 
 
MBP-Y125W-chTPH1: 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEI
TPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWP
LIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAA
TMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGLEVLFQ↓GPDGMETVPW
FPKKISDLDHCANRVLMWGSELDADHPGFKDNVYRKRRKYFADLAMNYKHGDPIPKVEFTEEEIKTWGTVFQELNKLYPT
HACREYLKNLPLLSKYCGYREDNIPQLEDVSNFLKERTGFSIRPVAGYLSPRDFLSGLAFRVFHCTQYVRHSSDPFYTPE
PDTCHELLGHVPLLAEPSFAQFSQEIGLASLGASEEAVQKLATCYFFTVEFGLCKQDGQLRVFGAGLLSSISELKHALSG
HAKVKPFDPKITCKQECLITTFQDVYFVSESFEDAKEKMREFTKTIKRPFGVKYNPYTRSIQILKD 
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MBP-loop-swap-chTPH1: 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEI
TPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWP
LIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAA
TMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGLEVLFQ↓GPDGMETVPW
FPKKISDLDKCSHRVLMYGSELDADHPGFKDNVYRKRRKYFADLAMNYKHGDPIPKVEFTEEEIKTWGTVFQELNKLYPT
HACREYLKNLPLLSKYCGYREDNIPQLEDVSNFLKERTGFSIRPVAGYLSPRDFLSGLAFRVFHCTQYVRHSSDPFYTPE
PDTCHELLGHVPLLAEPSFAQFSQEIGLASLGASEEAVQKLATCYFFTVEFGLCKQDGQLRVFGAGLLSSISELKHALSG
HAKVKPFDPKITCKQECLITTFQDVYFVSESFEDAKEKMREFTKTIKRPFGVKYNPYTRSIQILKD 
 
MBP-3CP: 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEI
TPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWP
LIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAA
TMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGGIPGPEHEFLNALIRRN
CHIITTDKGEFNLLGIYSNCAVVPTHAEPGDVVDIDGRLVRVLKQQVLTDMNDVDTEVTVLWLDQNEKFRDIRRFIPEHQ
QDWHNIHLATNVTKFPMLNVEVGHTVPYGEINLSGNATCRLYKYDYPTQPGQCGAVLANTGNIIGIHVGGNGRVGYAAAL
LRKYFAEEQ 
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Steady-state kinetics 
 
Figure S24. Initial velocity of chTPH1 against BH4 concentration at fixed concentrations of tryptophan. The oxygen 
concentration was 500 µM in all measurements. The plots are fitted with the a hybrid Ping Pong-ordered mechanism (eq. 3, 
experimental procedure). 
 
 
Figure S25. Initial velocity of chTPH1 against Trp concentration at fixed concentrations of BH4. The oxygen concentration 
was 500 µM in all measurements. The plots are fitted with the Michaelis-Menten equation with substrate inhibition (eq. 2, 
experimental procedure). 
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Figure S26. Initial velocity of chTPH1 against BH4 concentration at fixed concentrations of tryptophan. The oxygen 
concentration was 500 µM in all measurements. The plots are fitted with the Michaelis-Menten equation (eq. 1, experimental 
procedure). 
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Structural analysis of isoform sequence differences 
 
 
Figure S27. Crystal structure of human chTPH1 with BH2 and iron (pdb: 1MLW) and Trp (superimposed from chicken 
TPH1, pdb: 3E2T). Orange secondary structure indicates the position of non-conserved residues and gray indicates 
conserved residue positions between the isoforms. Residues in red (Val316 and Phe330) or green are non-conserved or 
conserved residues within 10 Å of active site iron, respectively. 
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 Active site loop density 
 
Figure S28. Crystal structure of TPH1 (pdb: 1MLW) with 2Fo-Fc density map on the loop comprising residue 117 to 137. The 
mesh map of the loop is contoured at 1.0 σ and within 1.6 Å of the selected atoms. 
Tyr125 
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Figure S29. Crystal structure of TPH2 (pdb: 4V06, chain A) with 2Fo-Fc density map on the loop comprising residue 163 to 
183. The mesh map of the loop is contoured at 1.0 σ and within 1.6 Å of the selected atoms. 
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Analytical gel filtration 
Expermental procedure - Determination of the oligomeric state of the TPH variants was performed on a 
Superdex 200 10/300 GL column. Samples were injected with a 500 µL loop and analyzed at a flow rate of 
0.5 mL/min.  
Results – The oligomeric states of the eight TPH variants were determined using size exclusion 
chromatography. The chromatograms display that all TPH variants of the two isoforms are monodisperse 
(Figure S7). The chTPH1 variants elute at volumes from 15.505 ± 0.004 to 15.64 ± 0.05 mL while the 
chTPH2 variants elute from 15.70 ± 0.05 to 15.78 ± 0.03 mL (Table S1). These results show that all the TPH 
variants reside as monomers [1] and that no significant changes within each variant occur as a consequence 
of mutation. Despite the slightly higher molecular weights of the chTPH2 variants (36274 to 36362 Da) 
compared to chTPH1 counterparts (36128 to 36250 Da), they elute at a slightly greater elution volume, 
which indicate that the chTPH2 variants are more compact.  
 
 
Figure S30. Normalized size exclusion chromatography results of the chTPH variants. 
Table S4. Elution volumes (mL) at maximum intensity with standard deviations (n=3). 
 
 
 
 
 
 
 
 
                                                   
[1] Tidemand, K. D., Christensen, H. E. M., Hoeck, N., Harris, P., Boesen, J., and Peters, G. H. (2016) Stabilization of 
tryptophan hydroxylase 2 by L-phenylalanine-induced dimerization, FEBS Open Bio 6, 987–999. 
Variant 
Volume ± SD 
(mL) 
chTPH1 15.64 ± 0.05 
Y125A-chTPH1 15.505 ± 0.004 
Y125W-chTPH1 15.60 ± 0.04 
Loop-swap-chTPH1 15.53 ± 0.03 
chTPH2 15.72 ± 0.06 
Y171A-chTPH2 15.70 ± 0.05 
Y171W-chTPH2 15.74 ± 0.05 
Loop-swap-chTPH2 15.78 ± 0.03 
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Differential scanning fluorimetry 
Experimental procedure - The unfolding of the TPH variants was recorded with an Agilent Technologies 
Stratagene MX3005 P RT-PCR machine. Each measurement was performed with total volume of 25 µL in 
96-well plates (polypropylene plates from Agilent Technologies). Each well was composed of protein at a 
concentration of 2 µM and SYPRO orange at a concentration of 4X (diluted from SYPRO
® 
5000X stock 
from Sigma). Scans were carried out using a scan-rate of 1 °C/min, going from 20 °C to 95 °C. The 
thermograms were baseline corrected with MxPro QPCR Software and analyzed for transition temperatures 
with GraphPad Prism 6 utilizing a Boltzmann sigmoid fit:  
     
     
      
    
 
 
 
 where LL and UL are the values of minimum and maximum intensities, respectively, and a denotes the 
slope of the curve at Tm.[2] 
Results – The thermal stability of the TPH variants was determined utilizing differential scanning fluorimetry 
(DSF). The results are summarized in Table S2. The transition temperature of chTPH1 is determined to 41.4 
± 0.2 ºC. Mutations of Tyr125 to alanine or tryptophan or the three loop-swap mutations did not induce a 
significant change in the transition temperature. The transition temperature of chTPH2 is determined to 42.1 
± 0.3 ºC which corresponds well with previous results.[1] As it was the case of chTPH1, the substitution of 
tyrosine to alanine or tryptophan in position 171 or the three loop-swap mutations did not significantly 
change the transition temperature of the TPH2 variants. Overall, the mutations do not result in major changes 
in the thermal stability of the TPH variants. 
 
Table S5. Transition temperatures (Tm) obtained from differential scanning fluorimetry experiments (n=4-6). 
 
 
 
 
 
 
                                                   
[1] Tidemand, K. D., Christensen, H. E. M., Hoeck, N., Harris, P., Boesen, J., and Peters, G. H. (2016) Stabilization of 
tryptophan hydroxylase 2 by L-phenylalanine-induced dimerization, FEBS Open Bio 6, 987–999. 
[2] Niesen, F.H., Berglund, H., and Vedadi, M. (2007) The use of differential scanning fluorimetry to detect ligand 
interactions that promote protein stability, Nat. Protoc. 2, 2212–2221. 
Variant 
Tm ± SD 
(ºC) 
chTPH1 41.4 ± 0.2 
Y125A-chTPH1 40.1 ± 0.2 
Y125W-chTPH1 43.3 ± 0.1 
Loop-swap-chTPH1 42.1 ± 0.2 
chTPH2 42.1 ± 0.3 
Y171A-chTPH2 40.5 ± 0.3 
Y171W-chTPH2 41.3 ± 0.5 
Loop-swap-chTPH2 42.4 ± 0.1 
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Sequence conservation in the active site loop 
 
 
Figure S31. Logo plots of the loops lining the active sites of TPH1 (top) and TPH2 (bottom). Sequences of TPH1 were 
obtained from an NCBI protein search: (tryptophan 5 hydroxylase 1) AND "vertebrates" accessed 04.21.2017. Sequences of 
TPH1 were obtained from an NCBI protein search: (tryptophan 5 hydroxylase 2) AND "vertebrates" accessed 04.21.2017. 
The overall height of a column indicates the sequence conservation at a given position, and the height of a symbol within the 
column indicates the relative frequency of that amino acid in that position. 
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Appendix B – TPH sequences 
TPH sequences 
 
 
Color-code: 
XXXX = MBP 
XXXX = 3CP 
XXXX = Linker 
XXXX = 3CP recognition and cleavage site (shown as ↓)  
XXXX = Regulatory domain 
XXXX = Catalytic domain 
XXXX = Tetramerization domain 
 
MBP-chTPH1: 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEI
TPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWP
LIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAA
TMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGLEVLFQ↓GPDGMETVPW
FPKKISDLDHCANRVLMYGSELDADHPGFKDNVYRKRRKYFADLAMNYKHGDPIPKVEFTEEEIKTWGTVFQELNKLYPT
HACREYLKNLPLLSKYCGYREDNIPQLEDVSNFLKERTGFSIRPVAGYLSPRDFLSGLAFRVFHCTQYVRHSSDPFYTPE
PDTCHELLGHVPLLAEPSFAQFSQEIGLASLGASEEAVQKLATCYFFTVEFGLCKQDGQLRVFGAGLLSSISELKHALSG
HAKVKPFDPKITCKQECLITTFQDVYFVSESFEDAKEKMREFTKTIKRPFGVKYNPYTRSIQILKD 
MBP-Y125A-chTPH1: 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEI
TPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWP
LIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAA
TMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGLEVLFQ↓GPDGMETVPW
FPKKISDLDHCANRVLMAGSELDADHPGFKDNVYRKRRKYFADLAMNYKHGDPIPKVEFTEEEIKTWGTVFQELNKLYPT
HACREYLKNLPLLSKYCGYREDNIPQLEDVSNFLKERTGFSIRPVAGYLSPRDFLSGLAFRVFHCTQYVRHSSDPFYTPE
PDTCHELLGHVPLLAEPSFAQFSQEIGLASLGASEEAVQKLATCYFFTVEFGLCKQDGQLRVFGAGLLSSISELKHALSG
HAKVKPFDPKITCKQECLITTFQDVYFVSESFEDAKEKMREFTKTIKRPFGVKYNPYTRSIQILKD 
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MBP-Y125L-chTPH1: 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEI
TPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWP
LIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAA
TMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGLEVLFQ↓GPDGMETVPW
FPKKISDLDHCANRVLMLGSELDADHPGFKDNVYRKRRKYFADLAMNYKHGDPIPKVEFTEEEIKTWGTVFQELNKLYPT
HACREYLKNLPLLSKYCGYREDNIPQLEDVSNFLKERTGFSIRPVAGYLSPRDFLSGLAFRVFHCTQYVRHSSDPFYTPE
PDTCHELLGHVPLLAEPSFAQFSQEIGLASLGASEEAVQKLATCYFFTVEFGLCKQDGQLRVFGAGLLSSISELKHALSG
HAKVKPFDPKITCKQECLITTFQDVYFVSESFEDAKEKMREFTKTIKRPFGVKYNPYTRSIQILKD 
MBP-Y125W-chTPH1: 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEI
TPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWP
LIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAA
TMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGLEVLFQ↓GPDGMETVPW
FPKKISDLDHCANRVLMWGSELDADHPGFKDNVYRKRRKYFADLAMNYKHGDPIPKVEFTEEEIKTWGTVFQELNKLYPT
HACREYLKNLPLLSKYCGYREDNIPQLEDVSNFLKERTGFSIRPVAGYLSPRDFLSGLAFRVFHCTQYVRHSSDPFYTPE
PDTCHELLGHVPLLAEPSFAQFSQEIGLASLGASEEAVQKLATCYFFTVEFGLCKQDGQLRVFGAGLLSSISELKHALSG
HAKVKPFDPKITCKQECLITTFQDVYFVSESFEDAKEKMREFTKTIKRPFGVKYNPYTRSIQILKD 
MBP-loop-swap-chTPH1: 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEI
TPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWP
LIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAA
TMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGLEVLFQ↓GPDGMETVPW
FPKKISDLDKCSHRVLMYGSELDADHPGFKDNVYRKRRKYFADLAMNYKHGDPIPKVEFTEEEIKTWGTVFQELNKLYPT
HACREYLKNLPLLSKYCGYREDNIPQLEDVSNFLKERTGFSIRPVAGYLSPRDFLSGLAFRVFHCTQYVRHSSDPFYTPE
PDTCHELLGHVPLLAEPSFAQFSQEIGLASLGASEEAVQKLATCYFFTVEFGLCKQDGQLRVFGAGLLSSISELKHALSG
HAKVKPFDPKITCKQECLITTFQDVYFVSESFEDAKEKMREFTKTIKRPFGVKYNPYTRSIQILKD 
MBP-rchTPH1 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEI
TPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWP
LIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAA
TMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGLEVLFQ↓GPIEDNKENK
DHSLERGRASLIFSLKNEVGGLIKALKIFQEKHVNLLHIESRKSKRRNSEFEIFVDCDINREQLNDIFHLLKSHTNVLSV
NLPDNFTLKEDGMETVPWFPKKISDLDHCANRVLMYGSELDADHPGFKDNVYRKRRKYFADLAMNYKHGDPIPKVEFTEE
EIKTWGTVFQELNKLYPTHACREYLKNLPLLSKYCGYREDNIPQLEDVSNFLKERTGFSIRPVAGYLSPRDFLSGLAFRV
FHCTQYVRHSSDPFYTPEPDTCHELLGHVPLLAEPSFAQFSQEIGLASLGASEEAVQKLATCYFFTVEFGLCKQDGQLRV
FGAGLLSSISELKHALSGHAKVKPFDPKITCKQECLITTFQDVYFVSESFEDAKEKMREFTKTIKRPFGVKYNPYTRSIQ
ILKD 
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MBP-hTPH1 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEI
TPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWP
LIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAA
TMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGLEVLFQ↓GPIEDNKENK
DHSLERGRASLIFSLKNEVGGLIKALKIFQEKHVNLLHIESRKSKRRNSEFEIFVDCDINREQLNDIFHLLKSHTNVLSV
NLPDNFTLKEDGMETVPWFPKKISDLDHCANRVLMYGSELDADHPGFKDNVYRKRRKYFADLAMNYKHGDPIPKVEFTEE
EIKTWGTVFQELNKLYPTHACREYLKNLPLLSKYCGYREDNIPQLEDVSNFLKERTGFSIRPVAGYLSPRDFLSGLAFRV
FHCTQYVRHSSDPFYTPEPDTCHELLGHVPLLAEPSFAQFSQEIGLASLGASEEAVQKLATCYFFTVEFGLCKQDGQLRV
FGAGLLSSISELKHALSGHAKVKPFDPKITCKQECLITTFQDVYFVSESFEDAKEKMREFTKTIKRPFGVKYNPYTRSIQ
ILKDTKSITSAMNELQHDLDVVSDALAKVSRKPSI 
MBP-chTPH2: 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEI
TPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWP
LIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAA
TMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGLEVLFQ↓GPEELEDVPW
FPRKISELDKCSHRVLMYGSELDADHPGFKDNVYRQRRKYFVDVAMGYKYGQPIPRVEYTEEETKTWGVVFRELSKLYPT
HACREYLKNFPLLTKYCGYREDNVPQLEDVSMFLKERSGFTVRPVAGYLSPRDFLAGLAYRVFHCTQYIRHGSDPLYTPE
PDTCHELLGHVPLLADPKFAQFSQEIGLASLGASDEDVQKLATCYFFTIEFGLCKQEGQLRAYGAGLLSSIGELKHALSD
KACVKAFDPKTTCLQECLITTFQEAYFVSESFEEAKEKMRDFAKSITRPFSVYFNPYTQSIEILKD 
MBP-Y171A-chTPH2: 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEI
TPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWP
LIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAA
TMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGLEVLFQ↓GPEELEDVPW
FPRKISELDKCSHRVLMAGSELDADHPGFKDNVYRQRRKYFVDVAMGYKYGQPIPRVEYTEEETKTWGVVFRELSKLYPT
HACREYLKNFPLLTKYCGYREDNVPQLEDVSMFLKERSGFTVRPVAGYLSPRDFLAGLAYRVFHCTQYIRHGSDPLYTPE
PDTCHELLGHVPLLADPKFAQFSQEIGLASLGASDEDVQKLATCYFFTIEFGLCKQEGQLRAYGAGLLSSIGELKHALSD
KACVKAFDPKTTCLQECLITTFQEAYFVSESFEEAKEKMRDFAKSITRPFSVYFNPYTQSIEILKD 
MBP-Y171W-chTPH2: 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEI
TPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWP
LIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAA
TMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGLEVLFQ↓GPEELEDVPW
FPRKISELDKCSHRVLMWGSELDADHPGFKDNVYRQRRKYFVDVAMGYKYGQPIPRVEYTEEETKTWGVVFRELSKLYPT
HACREYLKNFPLLTKYCGYREDNVPQLEDVSMFLKERSGFTVRPVAGYLSPRDFLAGLAYRVFHCTQYIRHGSDPLYTPE
PDTCHELLGHVPLLADPKFAQFSQEIGLASLGASDEDVQKLATCYFFTIEFGLCKQEGQLRAYGAGLLSSIGELKHALSD
KACVKAFDPKTTCLQECLITTFQEAYFVSESFEEAKEKMRDFAKSITRPFSVYFNPYTQSIEILKD 
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MBP-loop-swap-chTPH2: 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEI
TPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWP
LIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAA
TMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGLEVLFQ↓GPEELEDVPW
FPRKISELDHCANRVLMYGSELDADHPGFKDNVYRQRRKYFVDVAMGYKYGQPIPRVEYTEEETKTWGVVFRELSKLYPT
HACREYLKNFPLLTKYCGYREDNVPQLEDVSMFLKERSGFTVRPVAGYLSPRDFLAGLAYRVFHCTQYIRHGSDPLYTPE
PDTCHELLGHVPLLADPKFAQFSQEIGLASLGASDEDVQKLATCYFFTIEFGLCKQEGQLRAYGAGLLSSIGELKHALSD
KACVKAFDPKTTCLQECLITTFQEAYFVSESFEEAKEKMRDFAKSITRPFSVYFNPYTQSIEILKD 
MBP-NΔ47-rchTPH2: 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEI
TPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWP
LIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAA
TMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGLEVLFQ↓GPGNKGSSKR
EAATESGKTAVVFSLKNEVGGLVKALRLFQEKRVNMVHIESRKSRRRSSEVEIFVDCECGKTEFNELIQLLKFQTTIVTL
NPPENIWTEEEELEDVPWFPRKISELDKCSHRVLMYGSELDADHPGFKDNVYRQRRKYFVDVAMGYKYGQPIPRVEYTEE
ETKTWGVVFRELSKLYPTHACREYLKNFPLLTKYCGYREDNVPQLEDVSMFLKERSGFTVRPVAGYLSPRDFLAGLAYRV
FHCTQYIRHGSDPLYTPEPDTCHELLGHVPLLADPKFAQFSQEIGLASLGASDEDVQKLATCYFFTIEFGLCKQEGQLRA
YGAGLLSSIGELKHALSDKACVKAFDPKTTCLQECLITTFQEAYFVSESFEEAKEKMRDFAKSITRPFSVYFNPYTQSIE
ILKD 
MBP-rchTPH2: 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEI
TPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWP
LIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAA
TMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGLEVLFQ↓GPQPAMMMFS
SKYWARRGFSLDSAVPEEHQLLGSSTLNKPNSGKNDDKGNKGSSKREAATESGKTAVVFSLKNEVGGLVKALRLFQEKRV
NMVHIESRKSRRRSSEVEIFVDCECGKTEFNELIQLLKFQTTIVTLNPPENIWTEEEELEDVPWFPRKISELDKCSHRVL
MYGSELDADHPGFKDNVYRQRRKYFVDVAMGYKYGQPIPRVEYTEEETKTWGVVFRELSKLYPTHACREYLKNFPLLTKY
CGYREDNVPQLEDVSMFLKERSGFTVRPVAGYLSPRDFLAGLAYRVFHCTQYIRHGSDPLYTPEPDTCHELLGHVPLLAD
PKFAQFSQEIGLASLGASDEDVQKLATCYFFTIEFGLCKQEGQLRAYGAGLLSSIGELKHALSDKACVKAFDPKTTCLQE
CLITTFQEAYFVSESFEEAKEKMRDFAKSITRPFSVYFNPYTQSIEILKD 
MBP-hTPH2 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEI
TPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWP
LIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAA
TMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGLEVLFQ↓GPQPAMMMFS
SKYWARRGFSLDSAVPEEHQLLGSSTLNKPNSGKNDDKGNKGSSKREAATESGKTAVVFSLKNEVGGLVKALRLFQEKRV
NMVHIESRKSRRRSSEVEIFVDCECGKTEFNELIQLLKFQTTIVTLNPPENIWTEEEELEDVPWFPRKISELDKCSHRVL
MYGSELDADHPGFKDNVYRQRRKYFVDVAMGYKYGQPIPRVEYTEEETKTWGVVFRELSKLYPTHACREYLKNFPLLTKY
CGYREDNVPQLEDVSMFLKERSGFTVRPVAGYLSPRDFLAGLAYRVFHCTQYIRHGSDPLYTPEPDTCHELLGHVPLLAD
PKFAQFSQEIGLASLGASDEDVQKLATCYFFTIEFGLCKQEGQLRAYGAGLLSSIGELKHALSDKACVKAFDPKTTCLQE
CLITTFQEAYFVSESFEEAKEKMRDFAKSITRPFSVYFNPYTQSIEILKDTRSIENVVQDLRSDLNTVCDALNKMNQYLG
I 
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MBP-3CP: 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEI
TPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWP
LIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAA
TMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGGIPGPEHEFLNALIRRN
CHIITTDKGEFNLLGIYSNCAVVPTHAEPGDVVDIDGRLVRVLKQQVLTDMNDVDTEVTVLWLDQNEKFRDIRRFIPEHQ
QDWHNIHLATNVTKFPMLNVEVGHTVPYGEINLSGNATCRLYKYDYPTQPGQCGAVLANTGNIIGIHVGGNGRVGYAAAL
LRKYFAEEQ 
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Appendix C – Purification chromatograms 
Purification chromatograms of chTPH variants 
 
In this appendix, the chromatograms are presented for purifications of hTPH2, chTPH1, loop-swap-chTPH1, 
Y125A-chTPH1, Y125L-chTPH1, Y125W-chTPH1, chTPH2, loop-swap-chTPH2, Y171A-chTPH2, and 
Y171W-chTPH2.  
C. 1   Purification of hTPH2 
 
Figure C. 1. Chromatogram from affinity chromatography of chTPH2 using 20 mM HEPES/NH4OH, 300 mM 
(NH4)2SO4, pH 7.0 as mobile phase on a Dextrin Sepharose 16/12 column. 
 
 
Figure C. 2. Chromatogram from gel filtration on a Hiload 26/600 Superdex 200 column of the collected protein 
from affinity chromatography in the purification of hTPH2 using 20 mM HEPES/NH4OH, 300 mM (NH4)2SO4, pH 
7.0. 
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C. 2   Purification of chTPH1 
 
 
Figure C. 3. Chromatogram from affinity chromatography of chTPH1 using 20 mM TRIS/H2SO4, 100 mM 
(NH4)2SO4, pH 8.0 as mobile phase on a Dextrin Sepharose 16/12 column.  
 
 
 
 
Figure C. 4. Chromatogram from gel filtration on a Hiload 26/600 Superdex 75 column of the collected protein 
from affinity chromatography in the purification of chTPH1 using 20 mM TRIS/H2SO4, 100 mM (NH4)2SO4, pH 8.0. 
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C. 3   Purification of Loop-swap-chTPH1 
 
 
Figure C. 5. Chromatogram from affinity chromatography of loop-swap-chTPH1 using 20 mM TRIS/H2SO4, 100 
mM (NH4)2SO4, pH 8.0 as mobile phase on a Dextrin Sepharose 16/12 column. 
 
 
 
Figure C. 6. Chromatogram from gel filtration on a Hiload 26/600 Superdex 75 column of the collected protein 
from affinity chromatography in the purification of loop-swap-chTPH1 using 20 mM TRIS/H2SO4, 100 mM 
(NH4)2SO4, pH 8.0. 
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C. 4   Purification of Y125A-chTPH1 
 
 
Figure C. 7. Chromatogram from affinity chromatography of Y125A-chTPH1 using 20 mM TRIS/H2SO4, 100 mM 
(NH4)2SO4, pH 8.0 as mobile phase on a Dextrin Sepharose 16/12 column. 
 
 
 
Figure C. 8. Chromatogram from gel filtration on a Hiload 26/600 Superdex 75 column of the collected protein 
from affinity chromatography in the purification of Y125A-chTPH1 using 20 mM TRIS/H2SO4, 100 mM (NH4)2SO4, 
pH 8.0. 
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C. 5   Purification of Y125L-chTPH1 
 
 
Figure C. 9. Chromatogram from affinity chromatography of Y125L-chTPH1 using 20 mM TRIS/H2SO4, 100 mM 
(NH4)2SO4, pH 8.0 as mobile phase on a Dextrin Sepharose 16/12 column. 
 
 
 
Figure C. 10. Chromatogram from gel filtration on a Hiload 26/600 Superdex 75 column of the collected protein 
from affinity chromatography in the purification of Y125L-chTPH1 using 20 mM TRIS/H2SO4, 100 mM (NH4)2SO4, 
pH 8.0. 
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C. 6   Purification of Y125W-chTPH 
 
 
Figure C. 11. Chromatogram from affinity chromatography of Y125W-chTPH1 using 20 mM TRIS/H2SO4, 100 mM 
(NH4)2SO4, pH 8.0 as mobile phase on a Dextrin Sepharose 16/12 column. 
 
 
 
Figure C. 12. Chromatogram from gel filtration on a Hiload 26/600 Superdex 75 column of the collected protein 
from affinity chromatography in the purification of Y125W-chTPH1 using 20 mM TRIS/H2SO4, 100 mM (NH4)2SO4, 
pH 8.0. 
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C. 7   Purification of chTPH2 
 
 
Figure C. 13. Chromatogram from affinity chromatography of chTPH2 using 20 mM HEPES/NH4OH, 100 mM 
(NH4)2SO4, pH 7.0 as mobile phase on a Dextrin Sepharose 16/12 column. 
 
 
 
Figure C. 14. Chromatogram from gel filtration on a Hiload 26/600 Superdex 75 column of the collected protein 
from affinity chromatography in the purification of chTPH2 using 20 mM HEPES/NH4OH, 100 mM (NH4)2SO4, pH 
7.0. 
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C. 8   Purification of Loop-swap-chTPH2 
 
 
Figure C. 15. Chromatogram from affinity chromatography of loop-swap-chTPH2 using 20 mM HEPES/NH4OH, 
100 mM (NH4)2SO4, pH 7.0 as mobile phase on a Dextrin Sepharose 16/12 column. 
 
 
 
Figure C. 16. Chromatogram from gel filtration on a Hiload 26/600 Superdex 75 column of the collected protein 
from affinity chromatography in the purification of loop-swap-chTPH2 using 20 mM HEPES/NH4OH, 100 mM 
(NH4)2SO4, pH 7.0. 
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C. 9   Purification of Y171A-chTPH2 
 
 
Figure C. 17. Chromatogram from affinity chromatography of Y171A-chTPH2 using 20 mM HEPES/NH4OH, 100 
mM (NH4)2SO4, pH 7.0 as mobile phase on a Dextrin Sepharose 16/12 column. 
 
 
 
Figure C. 18. Chromatogram from gel filtration on a Hiload 26/600 Superdex 75 column of the collected protein 
from affinity chromatography in the purification of Y171A-chTPH2 using 20 mM HEPES/NH4OH, 100 mM 
(NH4)2SO4, pH 7.0. 
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C. 10   Purification of Y171W-chTPH2 
 
 
Figure C. 19. Chromatogram from affinity chromatography of Y171W-chTPH2 using 20 mM HEPES/NH4OH, 100 
mM (NH4)2SO4, pH 7.0 as mobile phase on a Dextrin Sepharose 16/12 column. 
 
 
 
Figure C. 20. Chromatogram from gel filtration on a Hiload 26/600 Superdex 75 column of the collected protein 
from affinity chromatography in the purification of Y171W-chTPH2 using 20 mM HEPES/NH4OH, 100 mM 
(NH4)2SO4, pH 7.0. 
 
 
 
 
 
0 
500 
1000 
1500 
2000 
2500 
3000 
3500 
4000 
0 50 100 150 200 
A
b
s
o
rb
a
n
c
e
 a
t 
2
8
0
 n
m
 (
m
A
U
) 
Volume (mL) 
0 
50 
100 
150 
200 
250 
300 
0 50 100 150 200 250 300 
A
b
s
o
rb
a
n
c
e
 a
t 
2
8
0
 n
m
 (
m
A
U
) 
Volume (mL) 
184 
 
Appendix D – Pufification yields 
Purification yields of TPH variants 
 
This appendix presents purification yields obtained for purifications of different TPH variants. All purifications 
are conducted with the two-step purification procedure presented in chapter 2. In chapter 2, the purification 
buffer solutions for the individual TPH variants are specified.  
 
Table D. 1. Purification yields (average ± standard deviation of n purifications) obtained for the TPH variants. In 
the table header, Std and Phe refer to purification in the absence of phenylalanine or presence of 3 mM 
phenylalanine, respectively. 
 
Std Phe 
 
Average n Average n 
hTPH2 0.4  1 1.9 1 
rchTPH2 0.8 ± 0.2 6 4.8 ± 2.2 5 
NΔ47-rchTPH2 8.7 ± 4.2 10 32.5 ± 5.5 3 
chTPH2 15.8 ± 3.2 7 10.8 ± 3.8 3 
Y171A-chTPH2 15.1 ± 1.8 2 
  
Y171W-chTPH2 12.5 ± 2.3 3 
  
Loop-swap-chTPH2 9.8 ± 2.3 2 
  
hTPH1 20.4 ± 3.3 2 16.0 1 
rchTPH1 25.5 1 26.4 1 
chTPH1 21.8 ± 4.3 4 
  
Y125A-chTPH1 19.3 ± 4.3 2 
  
Y125L-chTPH1 5.9 1 
  
Y125W-chTPH1 21.8 ± 9.0 4 
  
Loop-swap-chTPH1 22.7 ± 3.1 2 
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Appendix E - Differential scanning fluorimetry 
Differential scanning fluorimetry 
 
E. 1   DSF results obtained for NΔ47-rchTPH2. 
 
Figure E. 1. Baseline corrected differential scanning fluorimetry of NΔ47-rchTPH2 (enzyme concentration of 1 
µM) in absence of ligand, presence of 10 mM L-Phe, or presence of 10 mM L-Trp. 
 
E. 2   DSF results obtained for rchTPH2 illustrated the day-to-day variation.  
 
Figure E. 2. DSF results of rchTPH2. Transition temperature as a function of L-Trp concentration obtained from 
two different days.   
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Appendix F – Analytical gel filtration 
Analytical gel filtration 
 
In this appendix, the correlation between maximum UV-absorbance (Amax) and protein loading concentration 
from analytical gel filtrations are presented for chTPH2 and NΔ47-rchTPH2. The exact elution volumes 
observed for chTPH1, chTPH2, and their mutant variants are also presented.  
F. 1   Amax versus loading concentration - chTPH2 
 
Figure F. 1. Maximum absorbance obtained for chTPH2 at different loading concentrations. The correlation is 
obtained using a buffer solution containing 20 mM HEPES/NH4OH, 300 mM (NH4)2SO4, pH 7.0. 
 
F. 2   Amax versus loading concentration - NΔ47-rchTPH2 
 
Figure F. 2. Maximum absorbance obtained for NΔ47-rchTPH2 at different loading concentrations. The 
correlation is obtained using a buffer solution containing 20 mM HEPES/NH4OH, 300 mM (NH4)2SO4, 3 mM 
phenylalanine, pH 7.0. 
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F. 3   Elution volumes of chTPH variants 
 
Table F. 1. Elution volumes (mL) at maximum intensity with standard deviations (n=3). The elution volumes are 
obtained from analytical gel filtration on a superdex 200 10/300 GL column. 
Variant Volume ± SD (mL) 
chTPH1 15.64 ± 0.05 
Y125A-chTPH1 15.505 ± 0.004 
Y125W-chTPH1 15.60 ± 0.04 
Loop-swap-chTPH1 15.53 ± 0.03 
chTPH2 15.72 ± 0.06 
Y171A-chTPH2 15.70 ± 0.05 
Y171W-chTPH2 15.74 ± 0.05 
Loop-swap-chTPH2 15.78 ± 0.03 
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Appendix G – Steady-state kinetics 
Steady-state kinetics 
 
In this appendix, standard curves produced for 5-hydroxytryptophan (5-HTP) at different concentrations of 
BH4 are presented. The standard curves are produced to convert intensity/min to µM 5-HTP/min. Additional 
steady-state kinetic results obtained for chTPH1 are also presented.   
 
G. 1   5-HTP standard curve for Varian Cary Eclipse fluorescence spectrophotometer 
 
Figure G. 1. Standard curves of 5-HTP at different concentrations of BH4 (µM). The measurements are conducted 
with a PMT of 650 V. The insert presents the slopes (intensity/µM 5-HTP) at the different concentrations of BH4. 
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G. 2   Initial velocities measured for chTPH1 
 
Figure G. 2. Double reciprocal v0 versus [BH4] plots of the seven lowest concentrations of tryptophan. 
 
 
Figure G. 3. Double reciprocal v0 versus [BH4] plots of the seven highest concentrations of tryptophan. 
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G. 3   Apparent kinetic parameters of chTPH1 determined at high and low 
concentrations of BH4 – dataset split 
 
Table G. 1. Apparent kinetic parameters for chTPH1 determined from fitting the kinetic data obtained at low BH4 
concentrations (20, 50, and 100 µM) with eq. 1 (chapter 6). 
  Trp (uM) 
  1.5 2.5 5 10 15 20 30 40 50 70 100 150 200 300 
Vmax 10.2 17.6 30.3 55.9 76.5 106.9 140.6 186.6 349.6 675.4 17650 14066.4 11757.8 9278.6 
Km,BH4 4.2 11.6 19.5 40.6 68.7 116 191.7 300.9 689 1664.6 55439 56577.9 57151 57660.3 
1/Vmax 0.0980 0.0568 0.0330 0.0179 0.0131 0.0094 0.0071 0.0054 0.0029 0.0015 0.0001 0.0001 0.0001 0.0001 
1/Trp 0.66667 0.4 0.2 0.1 0.06667 0.05 0.03333 0.025 0.02 0.01429 0.01 0.00667 0.005 0.00333 
Km/Vmax 0.41176 0.65909 0.64356 0.7263 0.89804 1.08513 1.36344 1.61254 1.97082 2.46461 3.14102 4.0222 4.86069 6.21433 
 
  
Table G. 2. Apparent kinetic parameters for chTPH1 determined from fitting the kinetic data obtained at low BH4 
concentrations (200, 300, and 400 µM) with eq. 1 (chapter 6). 
  Trp (uM) 
  1.5 2.5 5 10 15 20 30 40 50 70 100 150 200 300 
Vmax 37.5 62.1 47.4 90.8 97.4 130.1 128.4 203.2 166 180.7 211.1 229.3 270.3 12513.2 
Km,BH4 520.9 601.9 121.1 237.1 158.9 231.3 197.1 464.2 332.2 437.6 591.9 868.1 1242.9 85583.1 
1/Vmax 0.0267 0.0161 0.0211 0.0110 0.0103 0.0077 0.0078 0.0049 0.0060 0.0055 0.0047 0.0044 0.0037 0.0001 
1/Trp 0.66667 0.4 0.2 0.1 0.06667 0.05 0.03333 0.025 0.02 0.01429 0.01 0.00667 0.005 0.00333 
Km/Vmax 13.8907 9.69243 2.55485 2.61123 1.63142 1.77786 1.53505 2.28445 2.0012 2.42169 2.80388 3.78587 4.59822 6.83943 
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Appendix H – Crystal structures of PAH 
Available crystal structures of phenylalanine hydroxylase 
 
Table H. 1. Crystal structures of phenylalanine hydroxylase from all available species. In the header, substrate 
and co-substrate refers to presence of a (co-)substrate/(co-)substrate analogue in their respective binding sites. 
Open/closed refers to an open or closed conformation of the active site loops. AA in/out refers to Phe138 
pointing towards active site or away from active site. *: different orientation compared to mammalian variants, 
**: lack residues 137-139. 
PDB 
entry Domain(s) species Metal Substrate Co-substrate Open/closed AA in/out 
1PAH c Human Fe
3+
 - - Open Out 
3PAH c Human Fe
3+
 - D-adrenaline Open Out 
4PAH c Human Fe
3+
 - L-norepinephrine Open Out 
5PAH c Human Fe
3+
 - L-dopamine Open Out 
6PAH c Human Fe
3+
 - L-DOPA Open Out 
1PHZ r/c Rat Fe
3+
 - - No density - 
2PHM r/c Rat Fe
3+
 - - No density - 
2PAH c/t Human Fe
3+
 - - No density - 
1DMW c Human Fe
3+
 - BH2 Open Out 
1J8T c Human Fe
2+
 - - Open Out 
1J8U c Human Fe
2+
 - BH4 Open Out 
1LRM c Human Fe
3+
 - BH2 Open Out 
1LTU c Cv - - - Open* Out 
1LTV c Cv Fe
3+
 - - Open* Out 
1LTZ c Cv Fe
3+
 - BH2 Open* Out 
1KW0 c Human Fe
2+
 3-(2-thienyl)-L-alanine  BH4 Closed In 
1MMK c Human Fe
2+
 3-(2-thienyl)-L-alanine  BH4 Closed In 
1MMT c Human Fe
2+
 L-norleucine BH4 Closed In 
1TDW c Human Fe
3+
 - - Open Out 
1TG2 c Human Fe
3+
 - BH4 Open Out 
2V27 c Cp Fe
3+
 - - No density - 
2V28 c Cp - - - No density - 
4ANP c Human Fe
3+
 - Compound 1 Open Out 
3TCY c Cv Co
2+
 - - Open* Out 
3TK2 c Cv Co
2+
 - - Open* Out 
3TK4 c Cv Co
2+
 - - Open* Out 
4ESM c Cv Co
2+
 - - Open* Out 
4ETL c Cv Co
2+
 - - Open* Out 
4JPX c Cv Co
2+
 - - Open* Out 
4JPY c Cv Fe
3+
 - - Open* Out 
4BPT c Lp - - - Open* Out 
4Q3W c Cv Co
2+
 - - Open* Out 
4Q3X c Cv Co
2+
 - - Open* Out 
4Q3Y c Cv Co
2+
 - - Open* Out 
4Q3Z c Cv Co
2+
 - - Open* Out 
5DEN r/c/t Rat Fe
3+
 - - No density - 
5EGQ r/c/t Rat - - - No density - 
5FGJ r/c/t Rat Fe
3+
 - - Open** - 
5JK5 r/c 
 
Fe
3+
 - BH2 Open In/Not conserved 
5JK6 r/c Dd Fe
3+
 - - Open In/Not conserved 
5JK8 r/c Dd Fe
3+
 L-norleucine BH2 No density - 
Cv: Chromobacterium violaceum, Dd: Dictyostelium discoideum, Lp: Legionella pneumophila, Cp: Colwellia psychrerythraea, BH2: 7,8-
dihydrobiopterin, BH4: 5,6,7,8-tetrahydrobiopterin, Compound 1 (pharmacological chaperone): 5,6-dimethyl-3-(4-methyl-2-pyridinyl)-2-
thioxo-2,3-dihydrothieno[2,3-d]pyrimidin-4(1H)-one. 
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Appendix I – RMSD plots 
RMSD plots from MD simulations of chTPH variants 
 
This appendix presents RMSD (heavy atoms) plots of the TPH variants calculated from MD simulation 
trajectories. In the figures, Trp, BH4, and Trp+BH4 refer to the presence of tryptophan, BH4, or both in the 
binding pockets of the catalytic domain.  
I. 1   RMSD plots – chTPH1 
 
Figure I. 1. RMSD plots from 100 ns simulations of chTPH1 without ligands, with Trp bound, with BH4 bound, and 
with both Trp and BH4 bound. RMSD in each 10
th
 frame is calculated for all heavy atoms in the protein with the 
first frame as the reference structure. 
I. 2   RMSD plots – Y125A-chTPH1 
 
Figure I. 2. RMSD plots from 100 ns simulations of Y125A-chTPH1 without ligands, with Trp bound, with BH4 
bound, and with both Trp and BH4 bound. RMSD in each 10
th
 frame is calculated for all heavy atoms in the 
protein with the first frame as the reference structure. 
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I. 3   RMSD plots – Y125W-chTPH1 
 
Figure I. 3. RMSD plots from 100 ns simulations of Y125W-chTPH1 without ligands, with Trp bound, with BH4 
bound, and with both Trp and BH4 bound. RMSD in each 10
th
 frame is calculated for all heavy atoms in the 
protein with the first frame as the reference structure. 
 
I. 4   RMSD plots –chTPH2 
 
Figure I. 4. RMSD plots from 100 ns simulations of chTPH2 without ligands, with Trp bound, with BH4 bound, and 
with both Trp and BH4 bound. RMSD in each 10
th
 frame is calculated for all heavy atoms in the protein with the 
first frame as the reference structure. 
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I. 5   RMSD plots – Y171A-chTPH2 
 
Figure I. 5. RMSD plots from 100 ns simulations of Y171A-chTPH2 without ligands, with Trp bound, with BH4 
bound, and with both Trp and BH4 bound. RMSD in each 10
th
 frame is calculated for all heavy atoms in the 
protein with the first frame as the reference structure. 
 
I. 6   RMSD plots – Y171W-chTPH2 
 
Figure I. 6. RMSD plots from 100 ns simulations of Y171W-chTPH2 without ligands, with Trp bound, with BH4 
bound, and with both Trp and BH4 bound. RMSD in each 10
th
 frame is calculated for all heavy atoms in the 
protein with the first frame as the reference structure. 
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